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Abstract
Randomised controlled trial of Tumour necrosis factor
inhibitors Against Combination Intensive Therapy with
conventional disease-modifying antirheumatic drugs in
established rheumatoid arthritis: the TACIT trial and
associated systematic reviews
David L Scott,1* Fowzia Ibrahim,1 Vern Farewell,2 Aidan G O’Keeffe,2
Margaret Ma,1 David Walker,3 Margaret Heslin,4 Anita Patel4
and Gabrielle Kingsley1
1Department of Rheumatology, King’s College London School of Medicine, London, UK
2MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
3Musculoskeletal Unit, Freeman Hospital, Newcastle upon Tyne, UK
4Centre for the Economics of Mental and Physical Health, Institute of Psychiatry, King’s College
London, London, UK
*Corresponding author d.scott1@nhs.net
Background: Rheumatoid arthritis (RA) is initially treated with methotrexate and other disease-modifying
antirheumatic drugs (DMARDs). Active RA patients who fail such treatments can receive tumour necrosis
factor inhibitors (TNFis), which are effective but expensive.
Objective: We assessed whether or not combination DMARDs (cDMARDs) give equivalent clinical benefits
at lower costs in RA patients eligible for TNFis.
Design: An open-label, 12-month, pragmatic, randomised, multicentre, two-arm trial [Tumour necrosis
factor inhibitors Against Combination Intensive Therapy (TACIT)] compared these treatment strategies.
We then systematically reviewed all comparable published trials.
Setting: The TACIT trial involved 24 English rheumatology clinics.
Participants: Active RA patients eligible for TNFis.
Interventions: The TACIT trial compared cDMARDs with TNFis plus methotrexate or another DMARD;
6-month non-responders received (a) TNFis if in the cDMARD group; and (b) a second TNFi if in the TNFi group.
Main outcome measures: The Heath Assessment Questionnaire (HAQ) was the primary outcome
measure. The European Quality of Life-5 Dimensions (EQ-5D), joint damage, Disease Activity Score for
28 Joints (DAS28), withdrawals and adverse effects were secondary outcome measures. Economic
evaluation linked costs, HAQ changes and quality-adjusted life-years (QALYs).
Results: In total, 432 patients were screened; 104 started on cDMARDs and 101 started on TNFis.
The initial demographic and disease assessments were similar between the groups. In total, 16 patients
were lost to follow-up (nine in the cDMARD group, seven in the TNFi group) and 42 discontinued their
intervention but were followed up (23 in the cDMARD group and 19 in the TNFi group). Intention-to-treat
analysis with multiple imputation methods used for missing data showed greater 12-month HAQ score
reductions with initial cDMARDs than with initial TNFis [adjusted linear regression coefficient 0.15,
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v
95% confidence interval (CI) −0.003 to 0.31; p= 0.046]. Increases in 12-month EQ-5D scores were greater
with initial cDMARDs (adjusted linear regression coefficient −0.11, 95% CI −0.18 to −0.03; p= 0.009)
whereas 6-month changes in HAQ and EQ-5D scores and 6- and 12-month changes in joint damage
were similar between the initial cDMARD group and the initial TNFi group. Longitudinal analyses
(adjusted general estimating equations) showed that the DAS28 was lower in the initial TNFi group in
the first 6 months (coefficient −0.63, 95% CI −0.93 to −0.34; p< 0.001) but there were no differences
between the groups in months 6–12. In total, 36 patients in the initial cDMARD group and 44 in the
initial TNFi group achieved DAS28 remission. The onset of remission did not differ between groups
(p= 0.085 on log-rank test). In total, 10 patients in the initial cDMARD group and 18 in the initial TNFi
group experienced serious adverse events; stopping therapy because of toxicity occurred in 10 and
six patients respectively. Economic evaluation showed that the cDMARD group had similar or better QALY
outcomes than TNFi with significantly lower costs at 6 and 12 months. In the systematic reviews we
identified 32 trials (including 20–1049 patients) on early RA and 19 trials (including 40–982 patients) on
established RA that compared (1) cDMARDs with DMARD monotherapy; (2) TNFis/methotrexate with
methotrexate monotherapy; and (3) cDMARDs with TNFis/methotrexate. They showed that cDMARDs and
TNFis had similar efficacies and toxicities.
Conclusions: Active RA patients who have failed methotrexate and another DMARD achieve equivalent
clinical benefits at a lower cost from starting cDMARDs or from starting TNFis (reserving TNFis for
non-responders). Only a minority of patients achieve sustained remission with cDMARDs or TNFis;
new strategies are needed to maximise the frequency of remission.
Trial registration: Current Control Trials ISRCTN37438295.
Funding: This project was funded by the National Institute for Health Research Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 18, No. 66.
See the NIHR Journals Library website for further project information.
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Plain English summary
Patients with rheumatoid arthritis (RA) usually take methotrexate or similar conventional drugs tomodify the course of their disease. These treatments are called disease-modifying antirheumatic
drugs (DMARDs). If conventional DMARDs are insufficient patients try high-cost biological treatments.
The main biologics are tumour necrosis factor inhibitors (TNFis).
As conventional DMARDs can be given in combination, it is possible that combination DMARDs
(cDMARDs) may be equally as effective as but less expensive than TNFis.
We compared these approaches in a trial [Tumour necrosis factor inhibitors Against Combination Intensive
Therapy (TACIT)]. We studied patients at 24 specialist centres to ensure that the findings apply throughout
England. The trial lasted 12 months. Patients not helped by cDMARDs switched to TNFis after 6 months.
The trial showed that patients starting cDMARDs and patients starting TNFis do equally well. Disability
decreased in both groups and quality of life improved over 1 year. Disease activity also fell in both groups.
Joint damage stayed much the same. The chance of having side effects and the severity of side effects
were similar in both groups. However, cDMARDs cost much less.
When the TACIT trial was completed we looked at all of the other trials published in the field. We did
this systematically to make sure that we did not miss any out. These trials also showed that the two
approaches give similar improvements over periods ranging from 6 months to 2 years.
We think that cDMARDs and TNFis are equally good in active RA. However, cDMARDs cost much less.
As only a few patients underwent long-term remission neither treatment approach seemed ideal.
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Scientific summary
Background
Rheumatoid arthritis (RA) affects nearly 1% of adults in the UK. It causes joint inflammation, joint damage
and extra-articular disease, and leads to disability and a reduction in quality of life. Core treatments are
methotrexate and other disease-modifying antirheumatic drugs (DMARDs). Treating active RA can involve
combination DMARDs (cDMARDs). Active RA patients in the UK who have failed methotrexate and another
DMARD can receive tumour necrosis factor inhibitors (TNFis), which are both effective and expensive.
Objectives
Overall
We assessed whether or not RA patients eligible to receive TNFis achieve similar outcomes with cDMARDs
in a head-to-head trial that compared both approaches [Tumour necrosis factor inhibitors Against
Combination Intensive Therapy (TACIT)]. We also systematically reviewed published trials that assessed the
efficacy of cDMARDs, TNFis with methotrexate and both approaches in patients with active RA.
The Tumour necrosis factor inhibitors Against Combination Intensive
Therapy trial
The TACIT trial tested the hypothesis that patients with active RA meeting UK criteria for receiving
TNFis gain equivalent benefit over 12 months at less expense and without increased toxicity if they
start cDMARDs.
Systematic reviews
The systematic reviews assessed the efficacy and toxicity of cDMARDs and TNFis with methotrexate.
They evaluated published randomised controlled trials that compared (1) cDMARDs with DMARD
monotherapy; (2) TNFis plus methotrexate with methotrexate monotherapy; and (3) cDMARDs with TNFis
plus methotrexate (head-to-head trials). The trials that enrolled patients with early RA were analysed
separately from the trials that enrolled patients with established RA.
Methods
The Tumour necrosis factor inhibitors Against Combination Intensive
Therapy trial
The TACIT trial was an open-label, 12-month, pragmatic, randomised, multicentre, two-arm trial. It compared
cDMARDs with TNFis given with methotrexate or another DMARD in active, established RA. The 6-month
non-responders in the cDMARDs arm could start TNFis and the 6-month non-responders in the TNFis arm
could have a second TNFi. The Heath Assessment Questionnaire (HAQ), a patient-completed disability
assessment, was the primary outcome measure. Secondary outcome measures included quality of life,
joint damage, disease activity, withdrawals and adverse effects. An intention-to-treat (ITT) analysis used
multiple imputation methods for missing data. The primary outcome was evaluated by linear regression with
treatment, sex, ethnicity, age, region and disease duration as explanatory variables. The trial included an
economic evaluation from both health and social care, and societal perspectives, linking costs with the HAQ
and quality-adjusted life-years (QALYs) based on both the Short Form questionnaire-36 items (SF-36) and
European Quality of Life-5 Dimensions (EQ-5D) at 6 and 12 months.
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Systematic reviews
Ovid MEDLINE and EMBASE were searched from 1946 to 2012 for trials in English using the search term
‘rheumatoid arthritis’ with the search term ‘DMARDs’, ‘TNFis’ or ‘combination therapy’. Treatment arms
included cDMARDs or TNFi/methotrexate and control arms included DMARD monotherapy. Early RA trials
enrolled patients with a duration of disease of < 3 years. Established RA trials enrolled treatment-resistant
patients to at least one DMARD. The results were analysed using Review Manager 5.1.6 (The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). A random-effects model estimated
pooled effect sizes. Cochran’s chi-squared test and I2-statistics were used to assess heterogeneity.
Results
The Tumour necrosis factor inhibitors Against Combination Intensive
Therapy trial
The TACIT trial screened 432 patients from 2008 to 2010 at 24 rheumatology clinics. Of these, 218 patients
were excluded (196 did not consent) and 214 were randomised. Nine randomised patients withdrew before
being treated (six decided not to participate); therefore, 104 patients started cDMARDs and 101 started
TNFis. The initial demographic and disease assessments were similar between the groups. Over 12 months,
16 out of 205 were lost to follow-up (nine in the cDMARDs arm and seven in the TNFi arm). In total, 42 out
of 205 discontinued their intervention but remained under follow-up (23 in the cDMARDs arm and 19 in
the TNFi arm). ITT analysis evaluated all 205 patients. A secondary completer analysis evaluated 147 patients
(72 in the cDMARDs arm and 75 in the TNFi arm). After 6 months, 42 out of 104 cDMARDs non-responders
switched to TNFis.
Intention-to-treat analysis showed that reductions in HAQ score between baseline and 12 months were
greater in the cDMARDs group [mean 0.45; 95% confidence interval (CI) 0.34 to 0.55] than in the TNFi
group (mean 0.30, 95% CI 0.19 to 0.42). Adjusted linear regression showed that this was significant
(coefficient 0.15, 95% CI −0.003 to 0.31; p= 0.046). Increases in EQ-5D score between baseline and
12 months were greater in the cDMARDs group (mean 0.20, 95% CI 0.13 to 0.27) than in the TNFi group
(mean 0.14, 95% CI 0.08 to 0.21). Adjusted linear regression analysis showed that this difference was
also significant (coefficient −0.11, 95% CI −0.18 to −0.03; p= 0.009). Changes between baseline and
6 months in HAQ and EQ-5D scores and between 6 and 12 months in radiological progression were
similar between the groups.
Longitudinal analysis showed an overall difference between treatment groups in Disease Activity Score for
28 Joints (DAS28) over the whole 12 months. Patients randomised to the TNFi group had greater overall
reductions in DAS28 than those randomised to cDMARDs; the adjusted general estimating equation
showed a difference of −0.40 (95% CI −0.69 to −0.10, p= 0.009). Comparing the initial and final
treatment periods showed different patterns of change. In the first 6 months DAS28 was lower in patients
randomised to TNFis (coefficient −0.63, 95% CI −0.93 to −0.34; p< 0.001) whereas in the second period
there was no difference between the groups (coefficient −0.19, 95% CI −0.55 to 0.18; p= 0.317).
In total, 36 out of 104 patients in the cDMARDs group and 44 out of 101 in the TNFi group achieved
DAS28 remission. The onset of remission did not differ between groups (p= 0.085 on log-rank test).
Remissions did not always persist; however, the number of patients in remission gradually increased over
time. Fewer than 5% of patients in the cDMARDs group were in remission by 3 months; this rose to
20% by 12 months. In the TNFi group, 16% of patients were in remission by 3 months; this increased
to 32% by 11 months.
Ten patients in the cDMARDs group had a serious adverse event, compared with 18 in the TNFi group
(one died from pneumonia). In total, 10 patients in the cDMARDs group and six in the TNFi group stopped
treatment because of toxicity. The cDMARDs group reported 635 different adverse events, compared with
465 in the TNFi group.
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The economic evaluation, which was within the trial and did not include an extension to a longer-term
disease model, showed that the cDMARDs group had the same or better HAQ, SF-36 QALY and EQ-5D
QALY outcomes at 6 and 12 months and significantly lower costs at both time points. From a health-care
perspective, focusing on EQ-5D-based QALYs at 12 months using imputed data, the mean adjusted cost
difference was −£1937 (95% CI −£2612 to −£1353) and the mean adjusted outcome difference was
0.02 (95% CI −0.00 to 0.05). Combination DMARDs had a higher probability of cost-effectiveness than
TNFis at both time points and on all cost–outcome combinations (although based on the HAQ at 6 months,
the probability of cost-effectiveness decreased with increased willingness-to-pay thresholds). These
conclusions apply from both a health and social care perspective and a societal perspective.
Systematic reviews
The early RA review identified 32 trials (including 20–1049 patients), which enrolled over 8400 patients;
19 trials compared cDMARDs with DMARD monotherapy, 10 trials compared TNFi/methotrexate with
methotrexate and three were head-to-head trials. Indirect comparisons showed that (1) more patients
achieved American College of Rheumatology (ACR)20–ACR70 responses [odds ratio (OR) 1.76–2.81)
with cDMARDs than with DMARD monotherapy and fewer withdrew for lack of effect (OR 0.47) and
(2) more patients achieved ACR20–ACR70 responses (OR 1.88–2.22) with TNFi/methotrexate than with
methotrexate and fewer withdrew for lack of effect (OR 1.42, 95% CI 0.87 to 2.34). Head-to-head trials
showed no differences in ACR20 responses or inefficacy withdrawals but fewer ACR50 and ACR70
responses with cDMARDs (ORs 0.53 and 0.54 respectively). Indirect comparisons showed greater HAQ
improvements with both combination regimens.
The established RA review identified 19 trials (including 40–982 patients), which enrolled over 5500 patients:
10 trials compared cDMARDs with monotherapy (six involving methotrexate), eight trials compared
TNFi/methotrexate with methotrexate and there was also a single head-to-head trial. Indirect comparisons
showed that (1) more patients achieved ACR20–ACR70 responses with cDMARDs than with monotherapy
(OR 2.75–5.07) and fewer withdrew for inefficacy (OR 0.38) and (2) more patients achieved ACR20–ACR70
responses with TNFi/methotrexate than with methotrexate (OR 5.32–8.13) and fewer withdrew for inefficacy
(OR 0.12). The head-to-head trial showed no difference in ACR20–70 responses between the two treatment
arms. Indirect comparisons showed greater HAQ improvements with both combination regimens.
Conclusions
The TACIT trial showed that RA patients who have failed to respond to methotrexate and another DMARD
show clinically important improvements over 12 months if initially treated with cDMARDs, reserving TNFis
for non-responders to these combinations. These improvements were equivalent to those achieved by
starting all patients on TNFis in line with current National Institute for Health and Care Excellence (NICE)
guidance. The equivalence of cDMARDs with TNFis was confirmed in systematic reviews of published trials
in both early RA and established RA.
Implications for health care
In patients with active RA who have failed to respond to initial DMARDs:
1. This study indicates that giving all patients intensive cDMARD therapy and reserving TNFis for 6-month
non-responders may be effective and cost-effective.
2. Only a minority of patients achieve sustained remission with cDMARDs or TNFis, indicating that neither
represents an ideal long-term treatment for all RA patients.
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Recommendations for research
1. Identifying predictors of response to cDMARDs and TNFis will enable a move towards individualised
treatment. This is of crucial importance as some patients respond well to cDMARDs whereas others
respond well to TNFis, and prospectively identifying potential good responders should optimise
treatment outcomes.
2. We need to define the most effective ways of using current treatments in strategy trials to examine
novel ways of using high-cost treatments. Examples include identifying the benefits of short courses of
biologics in early RA, in which the rapid effects of biologics may be very beneficial, and redefining the
optimal duration of TNFi treatment in established RA.
3. There should be a greater emphasis on head-to-head trials of cDMARDs and TNFis compared with
effective low-cost comparators when defining the overall benefits of high-cost treatments in RA.
Placing excessive reliance on short-term placebo-controlled trials in conjunction with modelling of future
benefits based on data from historical observational studies has limitations when defining optimal
treatment pathways.
Trial registration
This trial is registered as ISRCTN37438295.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Rheumatoid arthritis
Key impacts
Rheumatoid arthritis (RA), one of the commonest disabling diseases in the UK, remains a major health-care
problem.1–3 It affects almost 1% of UK adults and is more common in women. There are two peak ages of
onset, early adulthood (mainly women) and later life (equal sex distribution). There are internationally
accepted classification criteria for RA; from time to time these been revised and modernised.3–6
Its main impacts are increasing disability and reduced quality of life.7 Both are substantial and persistent and
reflect the combined effects of persisting joint inflammation, progressive joint damage and extra-articular
features of RA.8 Another significant impact of RA is reduced life expectancy, which is mainly due to
associated comorbidities such as coronary artery disease.9 The final major impact of RA is the substantial
costs in terms of medical and social care and lost employment.10
Disease course and outcomes
The primary clinical feature of RA is chronic, usually persistent, inflammatory synovitis, initially mainly
affecting the small joints of the hands and feet but subsequently spreading to involve multiple other
joints.7 Without adequate treatment many patients will develop joint damage, classically erosions, but also
joint space loss and secondary osteoarthritis.11 In addition, RA may be associated with extra-articular
features, such as nodules and interstitial lung disease,8 and with comorbidities, such as the increased risk
of cardiovascular disease and infection.12
Diagnosis combines clinical features with laboratory tests such as acute phase markers [erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP)],13 rheumatoid factor, anticyclic citrullinated peptide
(anti-CCP) antibodies14–16 and imaging [ultrasound, magnetic resonance imaging (MRI) and/or
radiography].17–19 Definitive differentiation from other forms of inflammatory arthritis is difficult in early
arthritis but usually uncontroversial in established disease.
The outcome of RA is highly variable, ranging from mild disease with limited impact on a patient’s life
to severe unremitting disease unresponsive to treatment. Some features are known genetically and
epidemiologically to be associated with a poorer outcome, including specific human leucocyte antigen
genotypes, smoking and the presence of anti-CCP antibodies.20–22 However, it has proved difficult to
develop an outcome predictor at the level of the individual patient, which would be required to develop
tailor-made individual treatment regimens.
Disease costs
Rheumatoid arthritis results in high medical and social costs,23 with drug costs a significant part of the
economic cost. Conventional drugs are relatively inexpensive whereas newer biological agents are very
expensive; over time, drug costs have risen substantially. A second cost component is other medical care.
These costs are modest in the short term but rise substantially when surgical treatment or supportive
long-term medical treatment is needed for disabling severe RA or for comorbid disease. The final costs are
societal costs. These include loss of work, support from family and carers and costs of care within the
community. These societal costs usually exceed medical expenses and rise with disease duration and severity.
Historically, in the period before biological treatments were available, the direct and indirect costs were
estimated to be in the region of £55–70M per million of the population,24 with a total disease cost of £4B
for the UK as a whole.25 Since the introduction of biological treatments, drug costs have increased
substantially. A report by the National Audit Office in 2009 estimated that RA costs the NHS around
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£560M a year in health-care costs, with the majority of this in the acute sector.26 This report estimated that
the costs to the NHS of biologics for treating RA were around £160M annually. As biologics prescribing
for RA has continued to increase, the current costs are likely to be substantially higher but may be
balanced by reductions in other medical costs, such as orthopaedic interventions for RA, if high-cost drug
treatments improve medical outcomes. The National Audit Office report also estimated that the additional
cost to the UK economy of sick leave and work-related disability for RA is £1.8B a year.
Assessments
Assessments in RA mainly look at joint inflammation. Clinical-based assessments include swollen and
tender joint counts and global assessment, which estimates overall disease activity and health status.
Standard joint counts focus on 28 joints in the hands, upper limbs, and knees. Some experts prefer
extended 66 and 68 joint counts; these include the feet. Laboratory measures include the ESR, CRP or
both. Patient-based measures span pain, global assessment and disability.27–29 The Health Assessment
Questionnaire (HAQ) measures disability.30 Other areas, such as fatigue and depression,31,32 are very
relevant to patients but are not always formally assessed. Patient-based measures are especially important
because they measure an individual’s perspective of the burden of their RA.
A number of combined indices amalgamate individual assessments. A widely used combined index is the
Disease Activity Score for 28 Joints (DAS28), which combines the numbers of swollen and tender joints
(hands, arms and knees) out of a total of 28, a patient’s global assessment and the ESR to indicate a
patient’s current status.33 As calculating the DAS28 involves a complex mathematical formula, simplified
variants have been devised.34 The Simplified Disease Activity Index uses the number of tender and swollen
joints (out of a total of 28), doctors’ and patients’ global assessments and CRP level. The Clinical Disease
Activity Index is similar but omits CRP level. The American College of Rheumatology (ACR) improvement
criteria, which gauge change in status in clinical trials, include falls in joint counts and several other
measures (patients’ and doctors’ global assessments, ESR, pain and HAQ). They record 20% (ACR20),
50% (ACR50) and 70% (ACR70) improvements in five of the seven measures.35
Juxta-articular erosions characterise progressive, established RA and are usually irreversible. They can
be readily identified on radiographic images of the hands and feet. Two typical erosions are sufficient
for diagnosis.36 Extensive damage seen on radiographs suggests that RA is inadequately controlled.
Rapid progression of joint damage needs intensive treatment.37 Several scoring systems are used to
quantify damage seen on radiographs in research studies. Although new imaging modalities such as
ultrasound and MRI can assess structural changes, they are not yet widely used except in research.38
Treatment goals
The overall treatment goal is making patients feel better and minimising the impact of RA on their lives.39
The main immediate treatment goal over the last two decades has been to reduce disease activity.
Reducing joint and systemic inflammation is beneficial in itself. Crucially, it is also associated with other
benefits including decreased disability, improved quality of life and reduced progression of joint damage.
A dominant theme has been to treat patients with active RA; in the main, current treatments mean that
few patients now have persisting active disease.
More recently there has been a shift towards making remission the main goal. An ideal treatment would
result in the majority of patients achieving remission with no active joint inflammation and no functional
deterioration or erosive progression.40 Although 10–50% of patients with early RA can achieve remission,41
only a small minority of established RA patients achieve sustained remission. An associated difficulty in
determining the frequency of remission depends on how it is defined and the intensity of treatment.42
Relatively cheap, readily available disease-modifying antirheumatic drugs (DMARDs) such as methotrexate
have made major inroads into managing active RA. DMARDs were initially given as monotherapies but
in recent years there has been greater emphasis on using combinations of two or more DMARDs as this
has been shown to be more effective in disease control.43
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Since the mid-1990s a new treatment approach has been developed – the use of targeted biological
treatments. They are usually given in combination with methotrexate or other DMARDs. Biologics have
revolutionised the treatment of severe RA, for which they appear highly effective. A major limiting factor is
their high cost.44
Reducing disease activity appears a clear-cut well-defined goal. However, the degree of reduction required
for a good ultimate outcome is not yet known. Intensive treatment aimed at inducing remission45 appears
an inevitable next step. However, it is not clear whether or not this is appropriate for every patient.
Furthermore, there remains uncertainty about the appropriate definition of remission in RA.46
Synopsis of specific drug treatment
Conventional disease-modifying antirheumatic drugs
Disease-modifying antirheumatic drugs are a diverse range of drugs.47 They form a single group because
they both improve symptoms and also, to a greater or lesser extent, modify the course of the disease.
This means that they reduce the progression of erosive joint damage and decrease disability.48,49
Many drugs have some features of DMARDs but only a few have been accepted into clinical practice.
The use of DMARDs varies, with a small number being particularly favoured. The current situation is
summarised in Table 1. At present, methotrexate is the dominant DMARD because of its greater efficacy
and retention compared with other DMARDs.50 As the most widely used DMARD, methotrexate is now
considered by regulatory agencies as a benchmark against which new agents must be tested. The majority
of RA patients treated with DMARDs in most UK specialist units either are currently taking or have
previously received methotrexate. Sulfasalazine, leflunomide and hydroxychloroquine (the last largely as
part of a combination regime) are the only other DMARDs used to any appreciable extent in the UK.51
TABLE 1 Disease-modifying antirheumatic drugs
Theme DMARDs
Range of DMARDs
Commonly used Methotrexate, leflunomide, sulfasalazine
Infrequently used Hydroxychloroquine/chloroquine, injectable gold, azathioprine
Rarely used Ciclosporin, auranofin, cyclophosphamide
Combinations of DMARDs
Methotrexate-based Methotrexate, sulfasalazine, hydroxychloroquine
Methotrexate, leflunomide
Methotrexate, ciclosporin
Methotrexate, gold
Methotrexate, sulfasalazine
Methotrexate, azathioprine
Other DMARDs Leflunomide, sulfasalazine
Gold, hydroxychloroquine
Steroid based Steroids, methotrexate, sulfasalazine
Steroids, methotrexate, ciclosporin
Steroids, methotrexate
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The efficacy of DMARDs involves reduced features of joint inflammation, such as fewer swollen joints and
a lower ESR, a reduction in the progression of joint damage, particularly erosive damage, decreased levels
of disability and improved quality of life. The harms, or adverse events, related to DMARDs include
common problems seen with most DMARDs such as low white cell or platelet counts and unique toxicities
with specific DMARDs. There is a reasonable evidence base for their use as monotherapies.52–58
Steroids
The commonest use of steroids in RA is as adjunctive agents to control disease flares; they may be given
intra-articularly, intramuscularly or orally. Because in early disease it has been suggested that steroids
exert a disease-modifying effect, they form an initial but temporary component of several early arthritis
combination regimens. They are also widely used as part of intensive DMARD combination therapy
regimes in patients with uncontrolled established disease. There is a reasonably strong evidence base for
their use.59–61
Disease-modifying antirheumatic drug combinations with and
without steroids
Disease-modifying antirheumatic drugs can be used in combination (see Table 1). This approach,
initially advocated by McCarty,62 has been examined in many clinical trials. Initial studies evaluated
combinations that turned out to have excessive toxicity (gold–hydroxychloroquine)63 or limited efficacy
(methotrexate–azathioprine).64 This toxicity led early reviews to suggest that risk/benefit ratios were
unfavourable compared with monotherapy.65
However, the situation changed when randomised controlled trials (RCTs) of methotrexate–ciclosporin,66
methotrexate–sulfasalazine–hydroxychloroquine67 and methotrexate–sulfasalazine–steroids68 reported
improved disease control in active RA with mild or no excess toxicity; similar results were obtained in
subsequent combination therapy studies. Combination DMARDs (cDMARDs) may not be required for all
RA patients. In the only RCT of mild, early RA patients on stable DMARD monotherapy, they did not
add benefit.69
Overall, from our 2005 systematic review,70 and as suggested by a gradual expansion of its use in routine
practice,71 the benefits of combination therapy are now thought to outweigh the risks in patients with
active disease not controlled by monotherapy. They are recommended in UK national guidelines72 for early
RA patients with active disease to avoid delay in bringing the disease under control, which is known to be
associated with a poor outcome.
The RCT evidence for using DMARD combinations is of crucial importance to the Tumour necrosis factor
inhibitors Against Combination Intensive Therapy (TACIT) trial. It is summarised in detail for both early and
established RA in two systematic reviews (see Chapter 3).
Tumour necrosis factor inhibitors
These agents were developed in the late 1980s to target tumour necrosis factor (TNF)-α, a cytokine of
central importance in the pathogenesis of RA, which exerts its effects by binding to type 1 and 2 receptors
on immune, inflammatory and endothelial cells in the lymphoid system and joints and in less well-studied
systems such as the central nervous system.73
The proof of principle for inhibiting this cytokine came from an open-label clinical study in which patients
with RA received a single infusion of a tumour necrosis factor inhibitor (TNFi). Patients showed a rapid
response, including an early fall in CRP level. However, the anti-inflammatory effect lasted only 6−12 weeks
and was followed by a return of active disease.74 As a result, patients were retreated with further infusions;
these showed responses of similar magnitude and duration.75 The scene was set for a major clinical
development programme.
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There are currently five TNFis available to treat inflammatory arthropathies, summarised in Table 2. All have
been shown to be effective in large clinical trials, which have been collated in systematic reviews.76–80
These TNFis can be subdivided into first-generation agents (comprising etanercept, infliximab and
adalimumab) and second-generation agents (comprising certolizumab and golimumab). In RA, all of these
agents are licensed for use in routine clinical care; they are also approved by National Institute for Health
and Care Excellence (NICE) for use in the NHS although in some cases this has required a financial
risk-sharing agreement.81–83
There is no clear-cut evidence that any one of these agents is superior to any other, and practical issues,
including cost, determine which is chosen. There have been network meta-analyses of the efficacy
and toxicity of different TNFis and these suggest potential minor differences in efficacy and adverse
event risks.84–86
Infliximab must be given concurrently with methotrexate (or another DMARD in methotrexate-intolerant
patients) to prevent the formation of human antichimeric antibodies.87 The licence for adalimumab also
requires concomitant methotrexate unless the patient is intolerant. Although concomitant treatment is
not required for etanercept, substantial data suggest that combination treatment is more effective,
especially in terms of the effect on bone erosion. Therefore, all three drugs are almost always given with
methotrexate or another DMARD.88
The RCT evidence for using TNFis in combination with methotrexate and other DMARDs is also of
crucial importance to the TACIT trial. This evidence is also summarised in detail in the systematic
reviews in Chapter 3.
The question of what to do when a TNFi failed was a crucial question, particularly in the early 2000s when
other biologics were not available. There is only limited information about the relative merits of switching
from one TNFi to another. The only RCT studied golimumab in patients who had failed another TNFi;
this showed some benefit from the switch.89 The relative benefits of switching TNFis in patients who,
for one reason or another, have not responded to their first biologic has also been addressed using
observational data from registries and similar studies. Again, these studies provided some evidence that
switching TNFis can give clinically useful improvements although response rates for second and subsequent
TNFis are lower than for first-time use.90
More recently, several trials evaluating non-TNF-targeted biologics, including abatacept, rituximab and
tocilizumab, have provided convincing evidence that non-TNF-targeted biologics are effective in patients
who have failed with TNFis, and this is increasingly the preferred approach.91,92
TABLE 2 Tumour necrosis factor inhibitors
TNFi Site of action Dosing Methotrexate
Infliximab Binds soluble/transmembrane TNF-α and inhibits
binding of TNF-α to receptors
Intravenous administration
every 4–8 weeks
Essential to
co-prescribe
Etanercept Binds TNF-α and lymphotoxin and competitive
inhibitor of TNF receptor
Subcutaneous twice weekly Optional to
co-prescribe
Adalimumab Binds soluble/transmembrane TNF-α and inhibits
binding of TNF-α to receptors
Subcutaneous fortnightly Optional to
co-prescribe
Certolizumab Binds soluble/transmembrane TNF-α and inhibits
binding of TNF-α to receptors
Subcutaneous fortnightly Optional to
co-prescribe
Golimumab Binds soluble/transmembrane TNF-α and inhibits
binding of TNF-α to receptors
Subcutaneously monthly Optional to
co-prescribe
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Other new agents
A number of other biological treatments have been licensed, and in some cases approved by NICE,
for treating RA. An early agent, anakinra, which is an interleukin-1 (IL1) receptor protein, is relatively
ineffective93 and is not often used for treating RA. It is, however, highly effective in a range of other
disorders including acute gout, some forms of juvenile arthritis and some familial periodic fevers. Further
anti-IL1 agents are in late-stage development, currently for these indications.
Rituximab targets B cells and is highly effective in active RA.94 Its mechanism of action is controversial as the
presence of rheumatoid factor is not essential for its efficacy. Tocilizumab targets IL-6 and is also highly
effective in active RA.95 The third effective biological treatment, abatacept, targets costimulatory molecules
on T lymphocytes.96 Although some of these other biological treatments are licensed to be used as first-line
treatment in methotrexate incomplete responders with RA, network meta-analysis and similar comparative
studies84,85 show that these different biologics have comparable efficacy. TNFis are the most widely used
treatment in methotrexate incomplete responders. Therefore, comparing cDMARDs with TNFis will provide
results of general interest.
Several new non-biological agents such as kinase inhibitors97,98 are being developed. One of these agents,
tofacitinib, has been licensed in the USA99 but is not yet approved for use in Europe. Depending on their
cost, and relative efficacy and toxicity, such orally active agents may also change the treatment pathways
for RA. However, for the present their roles are uncertain.
Non-TNFi biologics and new oral DMARDs are not part of the TACIT trial. Most of their actual or projected
use is for patients who have failed to respond to both conventional DMARDs and TNFis. This late-stage
treatment pathway for RA, which is complex and less well defined than the earlier management stages for
RA, is not the key focus of the TACIT trial. We have therefore not reviewed it in detail.
Treatment strategies
Supportive and symptomatic treatment
As with all long-term disorders the management of RA requires multiple inputs from a range of health-care
professionals from primary and secondary care. Patients need to be fully informed about their condition and
be able to access advice; this is one of the key roles of the specialist nurses. Patients need effective treatment
for pain, using analgesics and non-steroidal anti-inflammatory drugs,100,101 and their comorbidities, notably
ischaemic heart disease, need to be appropriately managed.102 Finally, they need access to physiotherapists
and in some cases occupational therapists and need to be encouraged to take regular exercise.103,104 The
appropriate use of all of these treatments is crucial to ensure a good outcome. However, they are outside
the focus of the TACIT trial and so have not been considered in detail.
Treat to target
There is evidence that intensive treatment is important in early RA both to suppress disease activity105–109 and
to maintain low disease activity when it has been reduced. Welsing et al.110 investigated the longitudinal
relationship between disease activity and radiological progression in two independent follow-up cohorts.
Both showed significant relationships between disease activity and radiological progression, but only in
patients seropositive for rheumatoid factor. The results support systematic monitoring to achieve persistent
low disease activity. This approach, termed ‘tight control’ or ‘treat to target’, includes several standard
procedures such as:
l a predefined treatment protocol to which the treatment of individual patients is adjusted
l being able to assess whether or not the treatment chosen is necessary and effective
l incorporating measures to ensure that patients are not overtreated.
INTRODUCTION
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Many groups have reported on aspects of tight control.111–114 Most used the Disease Activity Score (DAS)
or DAS28 to guide treatment or as the primary end point. Overall clinical and radiological outcomes were
more favourable in patients receiving tight-control regimens; in particular, remission rates were generally
higher with tight control than with conventional therapy. These improved clinical and radiological
outcomes did not appear to be at the cost of increased drug toxicity.
Access to high-cost treatments
Different countries have taken divergent approaches to the use of high-cost treatments such as biologics.
A range of international groups, specialist societies and regulatory bodies recommends TNFis for patients
with active RA who have failed to respond to conventional DMARDs.115–118 The current UK consensus
recommends that TNFis are started only in patients who have a DAS28 of > 5.1115 and who have failed to
respond to adequate therapeutic trials of two standard DMARDs including methotrexate.119 Some UK
experts believe that the threshold for active RA should be reduced to a DAS28 of > 3.2 with at least three
or more tender joints and three or more swollen joints.120 There are major national differences in the
guidelines followed by rheumatologists for starting biological treatments and considerable diversity in
biological treatment use across Europe.121–124
Economic modelling and biological treatments
Economic modelling conventionally extends beyond conventional RCTs,125,126 bringing together cost and
outcome evidence from a range of sources. Several modelling methods are used including simple decision
trees, Markov models and individual sampling models. Most economic studies evaluate the impact of
biological treatments on quality-adjusted life-years (QALYs). In the absence of direct QALY measures,
values may be inferred from other available outcomes.127 Recent systematic reviews of health economic
studies in RA highlight the different conclusions reached based on assessments of the much the same set
of published evidence. Schoels et al.128 identified 21 relevant studies of biological treatments and, based
on willingness-to-pay thresholds of US$50,000–100,000 per QALY, they concluded that combinations
of TNFis with methotrexate were cost-effective after conventional DMARD failure. The sequential use of
TNFis has been a difficult problem to resolve; however, Brennan et al.129 reported favourable incremental
cost-effectiveness ratios (ICERs) for using a second TNFi compared with DMARD treatment. A different
perspective was taken in a systematic review by van der Velde et al.130 They concluded that the economic
evidence suggests that biological treatments are not cost-effective compared with DMARDs for RA in
adults at a cost-effectiveness threshold of C$50,000 per QALY and that there is mixed evidence of
cost-effectiveness in selected populations at a willingness-to-pay threshold of C$100,000 per QALY.
Rationale for the Tumour necrosis factor inhibitors Against
Combination Intensive Therapy trial
Alternative approaches for accessing high-cost biological treatments in
rheumatoid arthritis
Different groups of experts have reached widely differing views on when biological treatments in general
and TNFis in particular should be started in RA. Almost all experts recommend usually using them in
combination with methotrexate or other DMARDs. There is also universal agreement that they should be
reserved for active RA, although there is uncertainty about what constitutes active disease.
Most experts recommend that they are used in patients who have failed to respond fully to methotrexate
and who continue to have active RA. Many trials have been undertaken in such patients with positive
findings. Most countries in continental Europe and North America have adopted this approach. The UK is
more conservative and TNFis are generally used after patients have failed two DMARDs and still have
active disease.
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There are many alternative ways in which TNFis could be used in RA. One approach, which might be the
most effective and cost-effective, is to reserve them until RA patients have tried and failed to respond
to intensive DMARD combination treatments. Such an approach would place TNFis slightly lower down the
therapeutic cascade; however, this might be of greater overall benefit to the health service by optimising
the use of resources without causing patients any problems. This option is specifically explored in the
TACIT trial.
Limiting the use of high-cost treatments has always been a component of Western health care. No country
allows universal access to all high-cost treatments for all patients who would like to have them. It is equally
important to ensure that patients are not denied effective treatments. If intensive cDMARDs are effective
in some patients and the use of biological treatments can be changed so that they are given to patients
most likely to show substantial benefits, the needs of both patients and health-care funders can be met.
TNFis are not universally effective in RA; they have a response failure rate in the region of 20–30% of
patients.131–134 Some patients who would fail TNFis may respond to intensive cDMARD regimens. As the
number of treatment options is limited in RA, and as patients rarely move from biological to non-biological
treatment, there is a sound logic in exhausting treatment options in an organised sequence. If TNFis were
curative such an argument would be misplaced; however, the balance of evidence indicates that DMARDs
and biological treatments are both suppressive therapies that do not appear to alter the long-term
clinical phenotype.
Systematic reviews of intensive treatments
The two treatment strategies used in the TACIT trial – cDMARDs and TNFis given in combination with
methotrexate or another DMARD – have both been studied in RCTs in RA. Systematically reviewing these
previous trials is crucial for both designing the TACIT trial and interpreting its findings.
We have previously published three systematic reviews of combination therapy trials: one looked at
all combinations at all time points;70 the second compared DMARD combinations and TNFi/methotrexate
combinations in early RA;135 and the third specifically examined the toxicity of combination therapies.136
A number of other groups have also published systematic reviews of both cDMARDs and TNFis.65,85,137–144
These systematic reviews all show that both DMARD combinations and TNFi/methotrexate combinations
are effective in both active early and established RA. Their effectiveness in clinical trials is broadly
comparable, although there are insufficient head-to-head clinical trials of these two treatment strategies.
Overall, these published systematic reviews provide strong clinical support for undertaking a head-to-head
trial such as the TACIT trial.
In early RA the relative clinical effectiveness and cost-effectiveness of conventional DMARD combinations
have been considered in detail in guidance from NICE.72 This guidance recommends cDMARDs, including
methotrexate, as first-line treatment for early active RA. Biological treatments were excluded as first-line
therapy by NICE because they were not considered cost-effective in these patients. Not all guidance
accepts this conclusion; for example, the ACR advises the use of biological treatments (TNFis) combined
with methotrexate as one initial therapy for active early RA patients with a poor prognosis118
as an alternative to cDMARDs.
In patients with established RA disease the overall value of intensive DMARD combination regimens
compared with TNFi/methotrexate combinations is less certain, particularly as these patients will usually
have failed one or more previous DMARDs. The TACIT trial is aimed at these patients because there is
genuine uncertainty about the relative merits of cDMARDs in such cases.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
8
Aims and trial design
The TACIT trial focuses on the treatment of patients with active RA who have failed two DMARDs and
who meet the current NICE criteria for starting TNFis. These NICE criteria are based partly on evidence from
RCTs, partly on economic modelling and partly on expert opinion. Our alternative view is that many of
these patients will do equally well on intensive combination therapy with conventional DMARDs.
Agreeing the research hypothesis and designing a RCT to test the hypothesis required considering the
following three crucial issues:
l the key outcome
l the duration of the trial
l minimising the risk that patients randomised to receive cDMARDs are disadvantaged.
Our previous research has shown that the HAQ is a sensitive patient-assessed outcome measure in active
RA trials of DMARDs.145,146 It also has a crucial role in the economic modelling that is used to justify
prescribing biological treatments. The HAQ was also the primary outcome measure in the Behandel
Strategieen (BeSt) trial;147 the only previous trial involving comparisons between cDMARDs and biological
treatments published before the start of the TACIT trial, albeit in early RA. We therefore decided that
changes in HAQ score should be the primary outcome measure.
The trial duration was more straightforward. Six months is probably too short a period of time to judge
both clinical effectiveness and cost-effectiveness. A duration longer than 12 months appeared to be
impractical and had no obvious advantage. As a consequence we decided that 12 months was the optimal
time. This was also the time point at which the BeSt trial was first analysed.147
The final issue, about minimising risks to patients randomised to cDMARDs, was more complex. There
were two potential risks. The first was that cDMARDs may have excessive toxicity. This risk would be
minimised by independent oversight of the trial by the Data Monitoring and Ethics Committee. The other
risk was inefficacy. We considered that if patients showed no response to cDMARDs after 6 months of
treatment they should then be offered TNFis. We also considered that a response should adopt the same
criterion that NICE recommends for maintaining patients on TNFis – a change in DAS28 of ≥ 1.20.
The final issue for the TACIT trial was whether it could be a placebo-controlled trial or an open-label
strategy trial. As cDMARDs need to be individualised it would be impractical to deliver a placebo-controlled
trial; instead, we considered that the trial had to be open label.
Hypothesis
The TACIT trial was designed to test the hypothesis that patients with active RA who meet the NICE
criteria for treatment with TNFis will gain equivalent benefit over 12 months at substantially less expense
and without increased toxicity from starting treatment with intensive combination therapy with DMARDs.
Primary and secondary outcomes
As a result of these various considerations the TACIT trial used the following outcome measures:
l primary outcome measure: HAQ, the key patient-completed disability measure in RA
l secondary outcome measures: joint damage, quality of life, disease activity, withdrawal rates, adverse
effects, costs, QALYs, cost-effectiveness and cost–utility.
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Testing the hypothesis
The TACIT hypothesis would be rejected if the primary outcome measure – the HAQ – showed substantial
clinically important improvements at 12 months in patients randomised to receive TNFis. The TACIT trial
was designed to confirm or refute the equivalence of treatment with TNFis and cDMARDs in improving
HAQ scores over 12 months.
The TACIT hypothesis would also be either rejected or substantially weakened if economic evaluations at
12 months – including health and social care costs, societal costs, cost-effectiveness and cost–utility – showed
disadvantages in patients randomised to receive cDMARDs or if the adverse event profile was substantially
worse with cDMARDs.
The TACIT trial also collected a range of secondary outcomes to help evaluate the clinical usefulness of
cDMARDs in these patients. These included assessing joint damage, quality of life, disease activity using
the DAS28 and retention rates on such DMARD treatment. We considered also collecting other outcomes
such as ACR response rates and responses on other indexes such as the Simplified Disease Activity Index.
However, we concluded that measuring the same outcome in multiple ways, particularly using methods
not followed in the UK where the trial is based to inform routine practice, would be counterproductive.
Systematic reviews
In the last few years more trials have been published about DMARD combinations and TNFi/methotrexate
combinations. To ensure that the results of the TACIT trial can be placed into an appropriate context it
is essential to provide an updated systematic review.
As there are different issues in early RA and established RA we have undertaken two reviews of these
different aspects of RA treatment. As it is crucial to define whether or not there are differences in these
two clinical settings in the relative efficacy of cDMARDs and TNFis, we used similar methods in both
reviews. Our analytical approach is also comparable.
Consequently, the two systematic reviews assess the efficacy and toxicity of combination treatment with
both cDMARDs and TNFis with methotrexate in the two groups of RA patients. The first group was
patients with early disease, which is disease of < 3 years’ duration. The second group was patients with
established disease who have failed one or more DMARDs. The reviews evaluate treatments in trials that
compared (1) cDMARDs with DMARD monotherapy; (2) TNFis plus methotrexate with methotrexate
monotherapy; and (3) cDMARDs with TNFis plus methotrexate. The trials that enrolled patients with early
RA were analysed separately from the trials that enrolled patients with established RA.
INTRODUCTION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
10
Chapter 2 Methods
Trial design
The TACIT trial was an open-label, pragmatic, randomised, multicentre, two-arm trial. Patients were
allocated to each arm in equal numbers. The duration of the TACIT trial was 12 months.
The trial compared intensive cDMARDs with TNFis given together with methotrexate or another DMARD
in active established RA. Patients who failed to respond to cDMARDs were eligible to receive TNFis after
6 months; this period was considered optimal to judge responsiveness to DMARDs. Patients in the
TNFi arm were assessed for response to their first TNFi at 6 months, reflecting NICE guidance. Those who
did not respond tried another TNFi. If they failed they were offered alternative treatment such
as cDMARDs.
The trial was unblinded because individually optimised intensive cDMARD therapy cannot be given blind.
Many previous RCTs in RA using such treatments have been unblinded. This approach provided the closest
possible approximation to routine clinical care. The disadvantage of unblinded studies – that clinicians have
excessive influence on the results – was ameliorated because the primary outcome measure, the HAQ,
was a patient self-completed questionnaire. In addition, another key outcome, radiographic changes, was
measured without knowledge of treatment group.
The TACIT trial raised a number of ethical issues related to whether or not patients were being potentially
denied access to highly effective treatments. These are considered in detail in the discussion.
Eligibility criteria
The trial was aimed at patients with RA attending outpatient rheumatology clinics in England who met the
current NICE criteria for receiving TNFis.81
Inclusion criteria
l Men and women aged > 18 years.
l Established RA according to the 1987 criteria of the ACR.5
l Disease duration of at least 12 months.
l Meet NICE criteria for being prescribed TNFis:81 DAS28 > 5.1; failure to respond to two DMARDs
including methotrexate; no contraindications to TNFis (including possibility of pregnancy).
Exclusion criteria
l Unable or unwilling to give informed consent.
l Failure of, or contraindications to, all proposed DMARD combinations (including possibility
of pregnancy).
l Serious intercurrent illness.
l On high-dose steroids (in excess of 10mg prednisolone or equivalent per day at trial entry).
Settings, locations and patient identification
Patients were recruited from rheumatology clinics in England and Wales, divided into three sectors:
London/south, the Midlands and the north. The trial was undertaken in a routine outpatient setting with
patient management shared between rheumatology specialist nurses and consultant rheumatologists.
The supervising consultant was responsible for all aspects of patient care within the trial.
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Before starting recruitment the primary care trusts (health-care commissioners) associated with each
collaborating centre were contacted to ensure that they were informed about the nature and purpose of
the trial and understood its clinical and economic implications. Collaborating rheumatologists and their
specialist nurses were fully briefed to ensure that they had a good understanding of the rationale behind
the study and of the principles and practice of using combinations of DMARDs in an intensive regimen.
These processes were designed to allowed unhindered recruitment into the study.
Patients likely to be eligible to receive TNFis were managed in the following way (in line with
NICE guidance):
l ensure that they have failed adequate treatment with two DMARDs and have a DAS28 > 5.1.
l negative screen for tuberculosis including chest radiography (and other local measures such as
Mantoux testing where applicable)
l repeat the DAS28 assessment 4 weeks after the initial DAS28 assessment to ensure that it
remains > 5.1.
Patients were eligible to enter the trial only at this stage, when they received full information about the
trial and informed consent was obtained. Patients had adequate time and information to decide whether
or not they wished to participate.
Patients were pre-screened and the following data were collected:
l number of patients who were potentially eligible to receive TNFis
l reasons why patients chose not to enter the trial (insufficient disease activity, consent not obtained and
other reasons).
l numbers of patients randomised.
Trial interventions
The TACIT trial compared two treatment algorithms, one for TNFis and one for cDMARDs. Treatments
were individualised and depended on patients’ responses.
Tumour necrosis factor inhibitors
The three licensed agents available when the trial started – adalimumab, etanercept and infliximab – were
allowed at standard doses (British National Formulary148). The choice of TNFi reflected patient preference
and local circumstances. Methotrexate was also given to maximise efficacy and (in the case of infliximab)
reduce the formation of antichimeric antibodies. Patients intolerant to methotrexate took another DMARD.
DAS28 at 3 and 6 months defined responses to therapy.
Patients had their TNFi stopped for one or more of three reasons:
l lack of effect as defined by the NICE criterion,81 that is, a change in DAS28 of < 1.2 at 3 or 6 months
l an adverse event that, in the opinion of the supervising specialist, necessitated treatment withdrawal
l patients could stop therapy for any reason should they wish (reasons to be specified if patient willing).
Patients in whom one TNFi was stopped were able to start another. This option represented current UK
practice when the trial started. Patients who failed two TNFis for whatever reason were not able to start a
third agent and required alternative treatment such as cDMARDs.
METHODS
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The principles of the treatment algorithm were as follows:
(a) start a TNFi of choice on the basis of local circumstances and patient preference
(b) assess at 3 months: no change if good response (change in DAS28 ≥ 1.2); change to second TNFi if
change in DAS28 is < 1.2
(c) assess at 6 months: no change if good response (change in DAS28 ≥ 1.2); change to second TNFi
if change in DAS28 is < 1.2; if two biologics already given and DAS28 change is < 1.2, TNFi stopped
and patient offered DMARD combination or other therapy.
Combination disease-modifying antirheumatic drugs
Those cDMARDs with proven efficacy over DMARD monotherapy in RCTs were used, including:
l triple therapy with methotrexate (methotrexate–sulfasalazine–hydroxychloroquine)
l other methotrexate combinations (methotrexate–ciclosporin, methotrexate–leflunomide
and methotrexate–gold)
l a sulfasalazine combination (sulfasalazine–leflunomide)
l additional monthly steroids [intramuscular Depo-Medrone (120mg stat) or equivalent] were used
if needed.
The DMARD combinations were stopped for three reasons: adverse events, patient-initiated withdrawals
(which are identical to those reasons for stopping a TNFi) and lack of effect (change in DAS28 < 1.2),
which is similar to that for TNFis but was implemented only at 6 months.
The principles of the treatment algorithm were:
l initially: maximise initial DMARD/optimise administration (e.g. parenteral methotrexate); start second/
third DMARD; give intramuscular Depo-Medrone® (methylprednisolone, Pfizer) (whenever possible)
l second step: maximise dose of second/third DMARD
l third step: change combination (repeated if needed)
l additional option: continue with intramuscular Depo-Medrone monthly short term if RA remains active
l assess monthly and change treatment if change in DAS28 is < 1.2 or DAS28 is > 3.2
l at 6 months start a TNFi if change in DAS28 is < 1.2.
The target doses of different DMARDs used in combinations were as follows:
l methotrexate: 25mg weekly – preferably by intramuscular injections although could be oral
(achieved by 5-mg increments)
l sulfasalazine: 3 g daily (starting at 500mg daily and increasing by 500-mg increments)
l hydroxychloroquine: 400mg daily (starting at 200mg and increasing as one increment)
l ciclosporin: 3.5mg/kg (starting at 2mg/kg and increasing incrementally depending on creatinine levels)
l leflunomide: 20mg/day (staring at 10mg/day and not increasing if used in combination
with methotrexate)
l gold: 50mg/month (starting with test dose, then 50mg/week for 20 weeks, then 50mg/month)
l intramuscular Depo-Medrone: 120mg/month for 3 months; further courses were given if the RA was
still active.
Dose adjustments to all drugs depended on both disease activity and evidence of adverse events. Decisions
about changes in treatment were made by the supervising rheumatologist but were reviewed by the
principal investigator (DS) or deputy to ensure that the algorithm was followed.
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Concomitant therapy
Non-opiate analgesics and non-steroidal anti-inflammatory drugs were used as needed at standard
doses. Patients taking methotrexate also received folic acid (5 mg/week) to limit adverse events.
Patients taking steroids received bone protection (e.g. alendronate and calcium/vitamin D). Other drugs
(e.g. antihypertensives) were used as needed. Patients taking oral prednisolone up to 10mg at entry stayed
on treatment. Intra-articular steroids were used as required.
Safety monitoring
Safety monitoring followed national guidelines with monthly blood counts and liver function tests
plus measurement of renal function (creatinine), urinalysis and blood pressure recording for some
DMARDs.149–151 Patients were screened for tuberculosis.
Trial outcomes
Primary clinical outcome
Patient self-assessed outcomes were used in the TACIT trial.152 The HAQ was the primary clinical outcome
measure.153 Although it is sometimes termed the HAQ Disability Index, most reports refer to it simply as
the HAQ. The HAQ is a self-assessed questionnaire that is completed by patients. It primarily measures
disability and is the dominant disability assessment in RA.154 Scores range from 0 to 3, with higher scores
indicating greater disability. It has established reliability and validity and has been used in many published
RCTs in RA. HAQ scores were measured initially and at 6 and 12 months.
Secondary clinical outcomes
The European Quality of Life-5 Dimensions (EQ-5D)155 and the Short Form questionnaire-36 items (SF-36)156
were measured initially and at 6 and 12 months. These are also self-assessed questionnaires completed by
patients. They measure health-related quality of life and can be used to estimate health utility and have
been extensively studied in RA.157–160
Plain radiographs of the hands (including the wrists) and the feet were taken initially and at 6 and
12 months. These are widely used outcome measures.161 Digital images of the radiographs were read at
the end of the trial by a single observer (DS) experienced in reading radiographs using the Larsen score,162
modified for minor changes.163 The radiographs were assessed in known date order without knowledge
of the treatments that patients had received.
Disease activity scores for 28 joint counts were measured initially and every month throughout the trial.164
Scores are calculated using tender joint counts and swollen joint counts for 28 joints assessed by trained
specialist nurses, the ESR and patients’ global assessments of their disease activity recorded on a 100-mm
visual analogue scale (VAS). DAS28 was used to guide treatment based on the predefined treatment
targets and to assess responses to treatment.
Adverse effects were recorded each month by patient reporting. Specific events such as hospital admission
were also recorded following international guidance.165
International recommendations
These outcome measures have all been recommended by international bodies including the European
Medicines Agency166 and the US Food and Drug Administration.167
Health economic assessments
An adapted version of the Client Service Receipt Inventory (CSRI) was used168 to measure individual-level
resource use. It covered sociodemographics, the use of (all-cause) secondary and community-based health
and social care services, time off work because of illness, receipt of social security benefits and medication
prescribed in addition to the study treatments. The CSRI has been previously used successfully in trials in
METHODS
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arthritis.169 We also measured take-up rates (without intention to attribute costs) for NHS/social services
contributions towards more exceptional resources, such as special mobility equipment, adaptations to
the home or transport to health care. The CSRI was administered as a self-complete questionnaire
retrospectively for the previous 3-month period at three assessment points: baseline, 6 months after
randomisation and 12 months after randomisation. Use of trial medications was recorded separately and
prospectively by the clinical/research teams over the entire study period in the form of medication name,
dose, frequency and duration of use.
As discussed earlier, health-related quality of life was assessed by self-report questionnaires at baseline,
and 6 and 12 months using the EQ-5D and SF-36 for the purpose of estimating QALY gains.
Data collection
Patient details and outcomes, with the exception of radiographic outcomes, were collected using an
academic online database system with direct entry of data into the electronic case record form
(see www.medscinet.net/tacit). This electronic data capture (EDC) system collected information
anonymously using patients’ initials and date of birth as identifiers.
Sample size
The TACIT trial sought to show equivalence between treatment strategies; in this setting the calculation of
sample size is more complex than in conventional trials intended to show that one treatment is superior.
One specific issue is that high-cost treatments such as TNFis can be justified only if they show substantial
benefits over conventional inexpensive treatments. Key issues in this respect are the extent to which a
difference in HAQ score (the primary outcome) between groups is clinically relevant, the degree of
certainty in avoiding a type II error and the degree of conservatism in the statistical approach taken.
The final sample size calculation has taken into account these various considerations.
This sample size was defined by the trial hypothesis that treating active RA patients who have failed to
respond to two DMARDs with intensive conventional treatment using cDMARDs and steroids gives
equivalent results to treatment with TNFis.
The sample size calculation was based on changes in HAQ scores in:
l the ATTRACT (Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy) trial
(infliximab versus placebo in RA patients receiving concomitant methotrexate), in which the mean HAQ
score at baseline was 1.7, which was reduced after treatment by 25%; the standard deviation (SD)
of the change in HAQ score was 0.4170
l the CARDERA (Combination Anti-Rheumatic Drugs in Early Rheumatoid Arthritis) trial, an Medical
Research Council-funded UK trial of 464 patients in which the mean HAQ score at baseline was 1.6,
which was reduced after treatment by 31%; the SD of the change in HAQ score was 0.6.171
We used the average SD for change in HAQ score in these two trials, estimated at 0.5.
Most experts consider that the minimal clinically important change in HAQ score in RA is considered to be
≥ 0.22.48,172–175 The trial was therefore designed under the assumption that cDMARDs and TNFis produce
equivalent reductions in HAQ score and that a difference of < 0.22 would be regarded as equivalence.
Formally, the trial was designed to test the null hypothesis of a difference > 0.22. With a (one-sided)
testing level of 5%, a sample size of 176 was required to achieve 90% power. To allow for a dropout rate
of 5–7%, we planned to recruit 190 patients.
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Recruitment method, randomisation and baseline assessments
Recruitment
Patients were recruited from rheumatology clinics in England, which were divided into three sectors:
London and the south of England, the Midlands and the north of England.
Potentially eligible patients were identified by rheumatologists and clinic nurses at the participating centres.
Rheumatologists approached potentially eligible patients and outlined the trial to them. Patients interested
in participating were given the patient information sheet and were then contacted by telephone at least
24 hours after receiving the patient information sheet to see whether or not they were interested in
participating. If they were, a screening assessment was arranged.
Screening involved making the following checks against NICE guidance to ensure that patients were
eligible to receive TNFis:
l ensure that patient has failed adequate treatment with two DMARDs and has a DAS28 > 5.1
l negative screen for tuberculosis including chest radiography (and other local measures such as
Mantoux testing where applicable)
l repeat DAS28 assessment 4 weeks after the initial DAS28 assessment to ensure that it remains > 5.1.
The screening assessment pages were collected anonymously using the EDC system. Once complete and
eligible, the EDC system automatically assigned consecutive patient numbers to patients in chronological order.
Randomisation
Randomisation numbers were formed of four numbers and prefixed by the region identifier (i.e. 1 for London
and the south, 2 for the Midlands and 3 for the north). The allocation sequence for randomisation was
generated by the EDC system. Block randomisation was used in blocks of four with allocation balancing.
Randomisation was stratified by region. Formally, the trial was designed to test the null hypothesis of a
difference of > 0.22. With a (one-sided) testing level of 5%, a sample size of 176 was required to achieve
90% power. To allow for a dropout rate of 5–7%, we planned to recruit 190 patients. The clinicians at each
of the trial centres and the trial co-ordinator were unaware of the allocation sequence.
Once a randomisation number was allocated, the EDC system automatically informed the researcher at the
individual centre and the trial co-ordinator by e-mail. The trial co-ordinator informed the pharmacy at site
of the randomisation. The patient was then informed that they had been recruited to the trial and the
baseline assessment was arranged.
Data collected during screening
As part of screening data were collected on:
l number of patients who were potentially eligible to receive TNFis
l reasons why patients chose not to enter the clinical trial (insufficient disease activity, consent not given
and other reasons)
l numbers of patients randomised.
Baseline assessment
Delays between screening and baseline were anticipated because of the pragmatic nature of the trial and
local practices relating to the supply and delivery of TNFis. It was recognised that patients may therefore
require additional treatment between the screening assessment and the baseline assessment, which would
usually be an intramuscular steroid injection. The following rules were therefore applied:
l patients were given an appropriate dose of intramuscular steroid if needed
l the baseline assessment was delayed for 1 month after the date of injection.
METHODS
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Eligibility based on a DAS28 of > 5.1 at screening was not required to be maintained at the baseline
assessment as this is not a requirement for receiving TNFis in routine practice.
Blinding
The TACIT trial was not blinded and both clinicians and patients knew to which treatment strategy patients
had been allocated.
Statistical methods
Recruitment and follow-up patterns
Recruitment was recorded by year and region. The numbers of patients enrolled – excluding patients who
had been withdrawn from therapy and who were unwilling to continue follow-up – were reported by
treatment arm. The numbers of patients who withdrew from therapy, who were lost to follow-up or who
died while taking part in the study were also reported by treatment arm.
Baseline comparability
Baseline characteristics were summarised by randomised group. Summary measures for the baseline
characteristics of each group have been presented as means and SDs for continuous (approximate)
normally distributed variables, medians and interquartile ranges (IQRs) for non-normally distributed
variables, and frequencies and percentages for categorical variables.
Intention-to-treat population
Except for enrolled patients who withdrew consent or who were found to be ineligible at the baseline visit
and so never received any treatment and for whom no data were therefore available, analyses on an
intention-to-treat (ITT) basis reflect the randomisation process. We also carried out two additional analyses
on the following populations:
1. a complete-case population: these were observations that subjects completed without missing data or
violation of the protocol; this analysis is therefore referred to as a ‘complete-case analysis’ throughout
this report
2. a per-protocol population: these were observations that excluded those patients who were found to
deviate from the protocol.
The allowed variations to the protocol are shown in Appendix 1. The results of the per-protocol analysis
were similar to those of the ITT analysis. Therefore, the results of the ITT and complete-case analyses have
been presented in this report.
Imputing missing data
All participants had observations at baseline. However, some subjects had missing data on the outcome
variables at 6 months, 12 months or both. The outcome variables that were measured at baseline and
6 and 12 months (HAQ, SF-36, EQ-5D and Larsen score) were imputed under different assumptions from
those used for the DAS28 and its components, because DAS28 was measured monthly.
All missing data were imputed regardless of the reasons why it was missing. For the subjects who had
missing outcomes, the baseline outcomes and other explanatory covariates (treatment group, sex, age,
ethnicity, region and disease duration) were used to impute the missing data, assuming that unobserved
measurements were missing at random.
For the subjects who had missing outcomes at 6 months, under the monotone assumption, baseline
outcomes and explanatory covariates were used to impute these missing values. Then, for those
patients who had missing outcomes at 12 months, baseline and 6-month outcomes with explanatory
covariates were used to impute the missing values at 12 months. If the outcome variables were missing
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at 6 and 12 months then the outcome variables at 6 months were imputed first followed by the outcome
variables at 12 months.
The DAS28 and its component were imputed using multivariate sequential imputation using chained
equations. First, all missing values were filled in by simple random sampling with replacement from the
observed values. The first variable with missing values, say DAS28 at month 1, was regressed on all other
variables, DAS28–0, DAS28–2 through to DAS28–12, restricted to individuals with the observed DAS28–1.
Missing values for DAS28–1 were replaced by simulated data points drawn from the corresponding
posterior predictive distribution of DAS28–1. Then, the next variable with missing values was replaced
using the same cycle.176
The imputation was 20 cycles; at the end of the first cycle one imputed data set was created and the process
was then repeated to create 20 imputed data sets. The 20 data sets were combined using Rubin’s rules;177–179
therefore, the estimates and standard errors presented here are the combined ones. As an additional check
of the robustness of the analyses performed to the missing at random assumption, we further analysed the
individual HAQ scores, EQ-5D scores, Larsen scores and DAS28 and its components) using the linear
increments method of Diggle et al.180 to handle the missingness. As the results obtained using this approach
were qualitatively the same as those of the multiple imputation approach adopted, we report only the
findings from the standard multiple imputation analyses.
Adjustment for design factors
Randomisation was stratified by region and therefore analyses of outcomes in the univariate or
multivariable analyses were adjusted for region.
Outcomes assessed every 6 months
The primary outcome (HAQ score) and three of the secondary outcomes (EQ-5D score, SF-36 summary
scores and Larsen score) were measured at baseline and 6 and 12 months. As there were not a significant
number of zero values for the HAQ and other outcomes during follow-up, a linear regression model was
used to analyse the change in these outcomes at 6 and 12 months. Thus, change was defined as either
12- or 6-month score minus baseline score. The unadjusted univariate analysis (model 1) was adjusted for
region to account for design effect. The adjusted multivariable model (model 2) included sex, ethnicity,
age, region, disease duration and baseline covariate as explanatory variables. Interactions between
treatment and sex were assessed in the adjusted model 2 using the Wald test. The sex-specific interactions
were not significant (for all outcomes p> 0.70). The treatment regression coefficient provided an estimate
of the mean differences in HAQ, EQ-5D, SF-36 and Larsen scores.
For individual components of the SF-36 we used generalised estimating equations (GEEs) to estimate the
effect of treatment including baseline values as a covariate for these outcomes. Working correlation
matrices were unstructured, which was not unduly restrictive given that measurements were taken only at
three time points. As the data were analysed longitudinally, time was included as a covariate in models 1
and 2. A final model tested specifically for interactions between treatment and sex and treatment and time
using the Wald test. The sex-specific interactions were not significant (for all outcomes p> 0.50 in the
overall test of all interaction terms). However, the interaction term between time and treatment was
of borderline significance for some SF-36 domains (physical functioning, general health perception).
We therefore report the period-specific treatment effect for those variables that had significant
interaction terms.
Outcomes assessed every month
The DAS28 and its components were measured monthly and were therefore analysed separately. Changes
in DAS28 and its components were analysed using GEEs to estimate the effect of treatment including
baseline values as a covariate. Working correlation matrices were autoregressive with lag 1. In this
analysis interactions between time and treatment and sex and treatment were also assessed and were
METHODS
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found to be non-significant. Treatment effects were examined as subanalyses in two periods (1–6 months
and 7–12 months). The estimates were presented as mean treatment effects (beta coefficients) with
95% confidence intervals (CIs). The sandwich estimator of error was used with the aim of obtaining robust
estimates of precision. Statistical significance was determined at the 5% level using a two-sided test
throughout. These analyses were based on the assumption that patients stayed in their original
randomised treatment arm and thus ignored subsequent treatment switches.
Exploratory analyses
The patients randomised to start cDMARDs fell into two categories. The first category included those patients
who remained on cDMARDs throughout the TACIT trial. The second category included those patients who
switched to a TNFi after ≥ 6 months because they had not fully responded to cDMARDs. The outcomes
of these two categories of patients have been compared in a series of exploratory analyses, recognising that
these are non-randomised in their original treatment arm. These analyses were carried out for all populations
(ITT, complete case and per protocol).
Four additional analyses used all observed data only and missing data were not imputed. This approach
was taken when patients were divided into discrete response categories. These analyses comprised:
(a) changes in Larsen score; (b) the development of new erosions shown by categorical increases in Larsen
score; (c) clinical response to treatment indicated by a decrease in DAS28 of ≥ 1.2; and (d) achieving
remission indicated by a DAS28 of ≤ 2.6. Analytical approaches used specifically with all observed data
were the construction of Kaplan–Meier plots and a comparison of treatments using the log-rank test.
Toxicity
The proportion of serious adverse events was compared across randomised groups using Fisher’s exact test
as appropriate.
Software specification
All data management and analyses were carried out using Stata version 12.0 (StataCorp LP, College Station,
TX, USA) and the R statistical package (The R Foundation for Statistical Computing, Vienna, Austria181).
Economic evaluation methods
Costs
Unit costs were applied to resource use data to calculate cost per participant. Unit cost estimates, their
sources and any assumptions made for their estimation are detailed in Appendix 2. Medication unit costs
were converted into cost per mg based on the most cost-efficient pack size, choosing maintenance prices
over initial treatment prices and generic prices over branded ones to obtain conservative estimates.
Total costs were computed for each participant at each assessment point from two perspectives: health
and social care and societal. Health and social care costs included the costs of inpatient services, outpatient
services, primary care services, other community-based services, social services, trial medications and other
prescribed medications. Two sets of societal costs were calculated, one that included health and social care
costs plus participant lost productivity because of absence from work and one that included health and
social care costs, participant lost productivity because of absence from work and, additionally, the cost
of social security benefit payments received.
For the economic evaluation, costs generated from the 3-month CSRI data were extrapolated (multiplied
by 2) to cover the full 6 months before each follow-up point. All costs are reported in pounds sterling at
2010/11 prices. Discounting was not necessary as all costs were related to a 1-year period.
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Outcome measures
Cost-effectiveness analyses were based on the primary outcome measure (the HAQ). Cost–utility analyses
were based on QALYs derived from both the SF-36 and the EQ-5D. Utility weights appropriate to
each measure were attached to the SF-36- and EQ-5D-produced health states at baseline and 6 and
12 months.182,183 QALY gains between baseline and 6 months and between 6 months and 12 months
were then calculated using the total area under the curve approach with linear interpolation between
assessment points (and baseline adjustment for comparisons184).
Analyses, missing data and sensitivity analyses
Data were analysed using IMB Statistical Product and Service Solutions (SPSS) Statistics for Windows
(version 20; IBM Coporation, Armonk, NY, USA) and Stata (version 11.2). Participants had individual unit
costs applied based on the exact medication that they were prescribed, not on which arm they were in.
Therefore, appropriate costs were applied regardless of switching during the trial.
Costs and outcomes were compared at 6 and 12 months and are presented as means and SDs. Mean
differences and 95% CIs were obtained using non-parametric bootstrap regressions (1000 repetitions) to
account for the non-normal distribution commonly found in economic data, with adjustment for region as
this was a stratification factor in the randomisation process. Although this was a RCT and participants in all
groups were expected to be balanced at baseline, baseline costs and outcomes could be predictors of
follow-up costs. To provide more relevant treatment effect estimates,185 regressions to calculate mean
differences in costs at follow-up included covariates for baseline cost from the same cost perspective,
baseline HAQ score, duration of illness, age, sex, region and ethnicity. Outcome comparisons (for the
economic evaluation) at follow-up included covariates for baseline values of the same outcome plus
baseline HAQ score, duration of illness, age, sex, region and ethnicity.
Data were entered via an EDC system using the MedSciNet database (MedSciNet AB, Stockholm, Sweden;
http://medscinet.com) which was programmed to disallow individual-item non-response on the CSRI
service use section. There was thus no item non-response for this part of the CSRI. For lost employment
data, if the CSRI indicated that this was positive but the amount was missing, the mean lost employment
cost for that arm at that time point (only for those who had lost employment and had valid data) was
substituted. For social security benefit data, if the CSRI indicated that this was positive but the amount was
missing, unit costs for specified benefits were applied. When receipt of benefits was positive but specific
benefits were unspecified, the mean benefit cost for that arm at that time point (only for those who
received benefits and had valid data) was substituted. For non-trial medication data, if the medication
name was missing but other information (e.g. dose) indicated some use, an average prescription cost
(from Department of Health prescription cost analyses; see http://data.gov.uk/dataset/prescription_cost_
analysis_england) was assumed. If a medication name was provided but usage quantity was missing, an
average prescription cost for that particular medication was assumed.
Analyses were based on available cases for each analysis, that is, they excluded non-responders to the
CSRI, HAQ, EQ-5D or SF-36 at each time point if there were any. To explore the potential impact of
excluding non-responders we examined the sociodemographic and clinical characteristics of those included
in the analyses and those in the full sample. We also carried out an ITT analysis, imputing missing 6- and
12-month total costs and outcomes using the multiple imputation command in Stata (version 11).
Imputations of missing 6- and 12-month costs were based on variables expected to predict follow-up
costs: baseline HAQ score, duration of illness, age, sex, region, ethnicity, trial arm and equivalent baseline
cost (and equivalent cost at 6 months for 12-month imputations). Imputations of HAQ scores at
6 and 12 months were based on baseline HAQ score, duration of illness, age, sex, region, ethnicity
and trial arm (and HAQ score at 6 months for 12-month imputations). Imputations of missing QALYs at
6 and 12 months were based on baseline HAQ score, duration of illness, age, sex, region, ethnicity, trial
arm and equivalent baseline utility score (and utility score at 6 months for 12-month imputations). Cost
and outcome data for the resulting imputed full sample were analysed and presented as per the
base (available) case data.
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Cost-effectiveness and cost–utility analyses
Accounting for the three cost perspectives and three outcomes, there were nine possible cost–outcome
combinations to consider in the economic evaluation. ICERs were calculated for any combination that
showed both significantly higher costs and better outcomes in either the intervention group or the
control group.
Uncertainty around cost-effectiveness/cost–utility was explored using cost-effectiveness acceptability curves
(CEACs) based on the net-benefit approach. This followed the Bayesian approach to cost-effectiveness
analysis outlined by Briggs.186 These curves address some of the problems associated with examining
ICERs and show the probability that one intervention is cost-effective compared with another other for a
range of values that a decision-maker would be willing to pay for an additional unit of each outcome
(i.e. per additional QALY or per additional point improvement in HAQ score). Net benefits for each
participant were calculated using the following formula, where λ is the willingness to pay for one
additional unit of outcome:
Net benefit = (λ outcome) − cost (1)
A series of net benefits were calculated for each individual for λ values ranging between £0 and £50,000
per QALY gained and per point improvement on the HAQ. After calculating net benefits for each
participant for each value of λ, coefficients of differences in net benefits between the trial arms were
obtained through a series of bootstrapped linear regressions (1000 repetitions) of group upon net benefit,
which included the baseline values of the same cost category and the same outcome as covariates plus
baseline HAQ score, duration of illness, age, sex, region and ethnicity. The resulting coefficients were then
examined to calculate for each value of λ the proportion of times that the cDMARDs group had a greater
net benefit than the TNFi group. These proportions were then plotted to generate CEACs for all three
outcomes from the health and social care perspective at 6 and 12 months.
Systematic review methods
The systematic reviews were carried out according to the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) 2009 checklist.187
Search strategies
Ovid MEDLINE and EMBASE were searched from 1946 to 2013. The terms used in the search strategies are
found in Appendix 5. This was then limited to English language and clinical trials. The Cochrane Library was
also searched using the terms ‘early rheumatoid arthritis and combination therapy’ or ‘early rheumatoid
arthritis and anti-TNF’ for the early RA search and ‘rheumatoid arthritis and combination therapy’ or
‘rheumatoid arthritis and anti-TNF’ for the established RA search. The titles and abstracts were then
assessed by two reviewers (MM, DS) independently. If there were any doubts regarding the eligibility of a
particular study it was discussed between the two reviewers until agreement was reached.
Selection criteria
Early rheumatoid arthritis
The following criteria were used to select studies for evaluation:
(a) the study was a RCT
(b) patients fulfilled the ACR classification criteria for RA
(c) disease duration was < 3 years (this threshold was chosen to maximise the number of studies included
in this systematic review)
(d) the ‘treatment’ arms comprised one or other or both of cDMARDs and TNFi/methotrexate
(e) the ‘control’ arm comprised DMARD monotherapy.
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Established rheumatoid arthritis
The following criteria were used to select studies for evaluation:
(a) the study was a RCT
(b) patients fulfilled the ACR classification criteria for RA
(c) patients were treatment resistant to at least one previous DMARD given for at least 3 months
(d) the ‘treatment’ arms comprised one or other or both of cDMARDs and TNFi/methotrexate; when
more than one dosage of TNFi was used the treatment arm that mirrored clinical practice the closest
was chosen
(e) the ‘control’ arm comprised DMARD monotherapy.
Assessing the risk of bias
The risk of bias was assessed using criteria recommended by Viswanathan et al.188
Outcome measures
American College of Rheumatology responses and patient withdrawals
because of inefficacy and toxicity
These dichotomous outcomes were used to calculate random-effects odds ratios (ORs) with 95% CIs.
Patient withdrawals because of inefficacy and toxicity are routinely reported in clinical trials and are
increasingly used as outcome measures. They have face validity and are used to assess effectiveness in
clinical practice.
Health Assessment Questionnaire
Our meta-analysis included only studies reporting mean changes in HAQ scores; these were used to
calculate random-effects weighted mean differences (WMDs).
Radiological progression
This was variously expressed as mean or median values, as changes over time or as final values. The
meta-analysis included only studies reporting mean changes in radiological scores. To allow for different
periods of observation, the annual rate of radiological progression was calculated (mean change in
radiological score divided by duration of follow-up in years). As different radiological scoring systems were
used (Sharp score, van der Heijde modified Sharp score and Larsen–Dale score), these were standardised as
per cent maximal change (annual rate of progression divided by maximum possible score expressed as a
percentage). The mean percentage annual changes were used to calculate random-effects WMDs.
Statistical analysis
Results were analysed using Review Manager 5.1.6 (The Cochrane Collaboration, The Nordic Cochrane
Centre, Copenhagen, Denmark). The random-effects model based on DerSimonian and Laird’s method189
was used to estimate the pooled effect sizes; this gives more equal weighting to studies of different precision
than a simple inverse variance weighted approach, so accommodating between-study heterogeneity.
For all meta-analyses we performed Cochran’s chi-squared test to assess between-study heterogeneity
and quantified I2-statistics.190,191 We considered a p-value< 0.05 as statistically significant.
In RCTs with two or more combination arms, the treatment arm with the best outcome was used. We also
carried out sensitivity analyses using methotrexate monotherapy as the comparator arm. Methotrexate is
the most commonly used DMARD monotherapy and is considered the most effective DMARD. Therefore,
including this DMARD as a comparator ensures that trials had an effective comparator agent.
METHODS
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Chapter 3 Results
Introduction
Results of the Tumour necrosis factor inhibitors Against Combination
Intensive Therapy trial
The results of the TACIT trial are presented in five sections. The first section describes screening,
randomisation, patients studied and the treatments that they received. The second section describes the
impact of treatment on disability, quality of life and erosive damage; these outcomes were assessed every
6 months and include the HAQ, which was the primary outcome. The third section describes the impact of
treatment on disease activity; it focuses on the DAS28 and its individual components, with outcomes
assessed every month. The fourth section describes adverse effects encountered during the trial and the
final section reports the economic evaluation.
The report presents the results from the ITT and complete-case populations. The results of the per-protocol
population were similar to those of the ITT population and these findings are considered only in summary
form. However, detailed tables of the complete-case analyses are presented in Appendix 3.
Results of the systematic reviews
The two systematic reviews focus on early RA and established RA and these are reported after the
trial results.
The Tumour necrosis factor inhibitors Against Combination
Intensive Therapy trial: screening, randomisation, patients
studied and drug treatments
Screening and randomisation
Between September 2008 and December 2010 432 patients were screened at 24 rheumatology clinics in
England. In total, 218 patients were excluded, 196 because they did not consent to participate and a
further 20 because they were not eligible to participate; in addition, for two patients no reasons were
recorded. The remaining 214 patients were randomised: 107 to receive cDMARDs and 107 to receive
TNFis (Figure 1). The final assessment for the TACIT trial was in December 2011.
After randomisation three patients in the cDMARD group did not receive the intervention; this was
because the patients changed their minds about participating in the trial after randomisation but before
receiving treatment. There were also six patients in the TNFi group who did not receive the intervention.
In three cases this was also because the patients changed their minds about taking part in the trial
after randomisation but before receiving treatment. In one patient new information about a previous
non-melanotic skin cancer resulted in the supervising rheumatologist considering that the patient should
not receive biological treatment; in another patient the supervising rheumatologist changed his opinion
about the suitability of the patient for intensive treatment; and the final patient mistakenly self-injected the
TNFi, which had been delivered before the formal baseline assessment had been carried out.
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Patients studied
Although 214 patients were randomised (107 to receive cDMARDs and 107 to receive TNFis), only
104 patients started cDMARDs and 101 patients started TNFis and the trial report focuses on these
205 treated patients. Their baseline characteristics are summarised in Table 3. Both groups had similar
demographic characteristics including region, sex, ethnicity, disease duration, weight and height.
Most clinical variables were also similar between groups including DAS28, the individual components of
the DAS28, HAQ and EQ-5D scores, and SF-36 domain and summary scores. The only variable to show a
baseline difference was Larsen score, with a mean score of 45.1 (SD 41.9) in the cDMARD group and
37.9 (SD 38.8) in the TNFi group.
During the 12 months of the trial 16 out of the 205 treated patients (8%) were lost to follow-up,
nine patients in the cDMARD arm and seven in the TNFi arm (see Figure 1). A further 42 out of the
205 patients (20%) discontinued their intervention but remained under follow-up; these comprised
23 patients in the cDMARD arm and 19 patients in the TNFi arm.
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Assessed for eligibility (n = 432)
Randomised (n = 214)
DMARD combinations (n = 107)
•   Received intervention, n = 104
•   Did not receive intervention, n = 3
TNF inhibitors (n = 107)
•   Received intervention, n = 101
•   Did not receive intervention, n = 6
Excluded (n = 218)
•   Not consented, n = 196
•   Ineligible, n = 20
•   No data recorded, n = 2
Lost to follow-up (n = 9)
•   Patient decision, n = 1
•   Toxicity of treatment, n = 4
•   Other, n = 4
Lost to follow-up (n = 7)
•   Disease progression, n = 1
•   Patient decision, n = 1
•   Toxicity of treatment, n = 1
•   Other, n = 4
Discontinued intervention (n = 23)
•   Disease progression, n = 1
•   Patient decision, n = 7
•   Toxicity of treatment, n = 6
•   Other, n = 9
Discontinued intervention (n = 19)
Intention to treat (n = 104)
Completers (n = 72)
Intention to treat (n = 101)
Completers (n = 75)
•   Disease progression, n = 3
•   Patient decision, n = 1
•   Toxicity of treatment, n = 5
•   Other, n = 10
FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for the TACIT trial.
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TABLE 3 Baseline demographic and clinical characteristics
Variable cDMARDs (N= 104), n (%) TNFis (N= 101), n (%)
Demographic variables
Region
London/south 65 (63) 63 (62)
Midlands 9 (9) 7 (7)
North 30 (29) 31 (31)
Age (years), mean (SD) 58 (13) 57 (11)
Sex
Female 73 (70) 79 (78)
Male 31 (30) 22 (22)
Ethnic group
White 89 (86) 92 (91)
Black (African, Caribbean, black other) 6 (6) 2 (2)
Asian (Bangladeshi/Indian, Pakistani) 8 (8) 6 (6)
Chinese 0 (0) 1 (1)
Other/mixed ethnic group 1 (1) 0 (0)
Disease duration (years), median (IQR) 4.4 (1.6–9.9) 5.9 (2.2–13.4)
Height (m), mean (SD) 1.64 (0.11) 1.66 (0.09)
Weight (kg), mean (SD) 78.3 (19.5) 80.6 (16.9)
BMI (kg/m2), median (IQR) 28.5 (23.8–32.8) 29.0 (25.0–32.4)
Clinical variables
DAS28, mean (SD) 6.21 (0.92) 6.30 (0.81)
Tender joint count, mean (SD) 16.4 (7.1) 17.5 (6.74)
Swollen joint count, mean (SD) 10.5 (6.1) 10.8 (6.74)
ESR (mm/hour), mean (SD) 33.1 (26.1) 30.1 (22.84)
VAS, mean (SD) 68.1 (19.7) 68.2 (21.30)
HAQ score, mean (SD) 1.80 (0.59) 1.90 (0.67)
Larsen score, mean (SD) 45.1 (41.9) 37.9 (38.8)
EQ-5D utility score, mean (SD) 0.39 (0.31) 0.35 (0.31)
SF-36 scores, mean (SD)
Physical functioning 30.1 (22.6) 24.6 (21.0)
Role physical 14.9 (30.1) 12.4 (26.1)
Pain 28.1 (16.3) 26.3 (17.8)
General health perception 35.8(18.2) 31.4 (16.8)
Vitality 30.3 (21.4) 26.6 (19.0)
Social functioning 50.2 (25.2) 42.1 (25.3)
Role emotion 43.9 (44.9) 35.3 (44.9)
Mental health 61.9 (20.2) 58.8 (23.1)
PCS 28.4 (6.8) 27.3 (7.0)
MCS 43.4 (12.4) 40.7 (12.3)
BMI, body mass index; MCS, mental component score; PCS, physical component score.
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In total, 10 out of 104 patients (10%) in the cDMARD arm stopped treatment because of toxicity, one
(1%) stopped because of disease progression and 21 (15%) stopped for other reasons, including because
a patient decided to stop treatment. In the TNFi arm six out of 101 (6%) patients stopped treatment
because of toxicity, four (4%) stopped because of disease progression and 16 (16%) stopped for other
reasons, including because a patient decided to stop treatment.
The main analysis evaluated 205 patients in the ITT group (104 in the cDMARD group and 101 in the TNFi
group). The complete-case analysis evaluated the 147 completers (72 in the cDMARD group and 75 in
the TNFi group).
Drug treatments
General
Drug treatments have been considered in two different ways: first, by describing treatments received by
individual patients and, second, by reporting the numbers of prescriptions issued.
Patient received drug treatments in the TACIT trial using standard NHS prescribing mechanisms. DMARDs
and steroids were prescribed from hospital pharmacies and were usually immediately available. TNFis were
either delivered to patients’ homes (adalimumab and etanercept) by a private company (Healthcare at
Home, Burton on Trent, Staffordshire, UK) or given as day-case infusions (infliximab) in hospital. In both
circumstances there were variable delays between making the clinical decision to initiate TNFis and starting
treatment so that home deliveries or infusions could be arranged. These delays varied from weeks to
months. In the group randomised to receive TNFis, the timing of the baseline assessment was adjusted
to enable this initial assessment to coincide with delivery of the TNFis or the first infusion. However, when
patients switched to start a TNFi (in the group randomised to start cDMARDs) or changed TNFis (in the
group randomised to start TNFis), then the delay in starting a TNFi occurred with the trial time frame.
Individual treatments in the combination disease-modifying antirheumatic
drug group
Most patients received combinations of two or three DMARDs during the course of the trial (Table 4).
A minority had four or five DMARDs. As patients were receiving DMARDs when enrolled, combinations
were usually given in a step-up approach. The most common combination was methotrexate and
leflunomide. Other frequently used combinations included methotrexate and ciclosporin, methotrexate,
sulfasalazine and hydroxychloroquine and methotrexate and gold. A variety of other combinations
were used occasionally.
In total, 27 patients received glucocorticoids (steroids). In 24 patients these were given as oral prednisolone.
Most of these patients receiving steroids (16 cases) had oral prednisolone combined with two DMARDs.
An additional three patients received Depo-Medrone injections.
After 6 months, patients who had failed to achieve a decrease in DAS28 of ≥ 1.2 could receive a TNFi.
Altogether, 46 out of 104 patients (44%) were recommended to switch to a TNFi. Three patients
withdrew from the trial before starting a TNFi and therefore 43 out of 104 patients (41%) actually
switched to a TNFi. The majority of these patients received adalimumab (see Table 4). The times at which
the new treatments were actually started (as opposed to when they were recommended) are shown in
Figure 2. TNFis were started after an average of 9 months (range 7–12 months).
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FIGURE 2 Actual month that TNFis were started in cDMARD patients switching to TNFis.
TABLE 4 Individual treatment regimens in the cDMARD group
Therapies No. of patients
No. of DMARDs combined
One 0
Two 46
Three 48
Four 8
Five 2
Total 104
DMARD combinations
Methotrexate/leflunomide 62
Methotrexate/ciclosporin 17
Methotrexate/sulfasalazine/hydroxychloroquine 13
Methotrexate/gold 10
Other 2
Total 104
Use of steroids
Oral prednisolone 24
Depo-Medrone injections 3
Total 27
Switched to TNFis
Adalimumab 25
Etanercept 14
Infliximab 4
Withdrew before startinga 3
Total 46
a Three patients were to have switched to a TNFi but never started because they withdrew from the trial.
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Individual treatments in the tumour necrosis factor inhibitor group
Most patients received adalimumab with etanercept and infliximab being used less often (Table 5). All patients
received DMARDs: these comprised methotrexate (82 patients), sulfasalazine (13 patients), leflunomide
(10 patients) and hydroxychloroquine (eight patients). In 13 patients the initial DMARD treatment involved a
combination of two or more DMARDs. These combinations reflected pretrial treatment regimens and they
were reduced to monotherapies during the trial.
In total, 19 patients received glucocorticoids (steroids). All of these patients received oral steroids with
none receiving Depo-Medrone injections.
After 6 months 16 patients received a second TNFi. Four patients were subsequently recommended to
switch to DMARDs; however, none of these patients completed the trial.
Numbers of prescriptions
Overall, 4608 prescriptions were issued in the TACIT trial, 2418 for patients in the DMARD group and
2190 for patients in the TNFi group (Table 6). The most widely used DMARD was methotrexate, followed
by leflunomide, hydoxychloroquine and sulfasalazine. The most widely used TNFi was adalimumab.
TABLE 5 Individual treatment regimens in the TNFi group
Therapies No. of patients
Initial TNFi
Adalimumab 58
Etanercept 34
Infliximab 9
Total 101
Second TNFi
Adalimumab 7
Etanercept 9
Infliximab 0
Total 16
Use of steroids
Oral prednisolone 19
Depo-Medrone injections 0
Total 19
Note
All of the patients received concomitant DMARDs (usually methotrexate) but these are not shown in detail. Four patients
were recommended to switch to DMARDs; however, none of these patients completed the trial.
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Disability, quality of life and erosive damage (assessed every
6 months)
The outcome measures specifically collected every 6 months include the primary outcome measure,
HAQ score, and three secondary outcome measures – EQ-5D score, SF-36 scores and Larsen score for
radiological progression.
Changes in Health Assessment Questionnaire scores
Primary outcome in intention-to-treat population
Initial HAQ scores were similar in patients randomised to receive cDMARDs (mean 1.80, 95% CI 1.68 to
1.91) and TNFis (mean 1.90, 95% CI 1.77 to 2.03) (Table 7).
After 12 months HAQ scores had changed by a mean of 0.45 (95% CI 0.34 to 0.55) in patients
randomised to cDMARDs and by a mean of 0.30 (95% CI 0.19 to 0.42) in patients randomised to TNFis
(see Table 7). The unadjusted and adjusted linear regression analyses (Table 8) showed that patients
randomised to start cDMARDs had a greater reduction in HAQ score than those randomised to start TNFis.
The unadjusted coefficient (adjusted for region only) was 0.14 (95% CI −0.01 to 0.29). After adjusting for
demographic factors (age, sex, ethnicity, disease duration and region) and baseline score the adjusted
coefficient was 0.15 (95% CI −0.003 to 0.31). The unadjusted linear regression analysis showed that the
reduction in HAQ score was of borderline statistical significance in patients randomised to cDMARDs
(p= 0.075). After adjusting for demographic factors and baseline score, the reduction in HAQ score was of
stronger statistical significance in patients in the cDMARDs group (p= 0.046) (see Table 8).
TABLE 6 Monthly prescriptions for the cDMARD and TNFi groupsa
Treatment cDMARDs (n= 104) TNFis (n= 101) Total (n= 205)
Methotrexate 810 830 1640
Leflunomide 435 75 510
Hydroxychloroquine 355 72 427
Sulfasalazine 226 97 323
Ciclosporin 128 0 128
Gold injections 61 0 61
Penicillamine 26 0 26
Azathioprine 1 2 3
Prednisolone 199 134 333
Depo-Medrone 3 0 3
Adalimumab 112 580 692
Etanercept 49 331 380
Infliximab 13 69 82
Total 2418 2190 4608
a The numbers of prescriptions for each drug in each arm of the trial over the whole year of treatment are shown.
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The minimum clinically detectable difference in HAQ score is 0.22. The difference in HAQ change scores
from 0 to 12 months between patients starting cDMARDs and those starting TNFis was 0.15 and the
95% CIs fell within 0.22 of this difference. The TACIT trial therefore provides no evidence of a clinically
important difference in 12-month HAQ scores between groups.
Six-month outcomes in the intention-to-treat population
At 6 months the HAQ score decreased by a mean of 0.28 (95% CI 0.18 to 0.38) in patients randomised to
cDMARDs and by a mean of 0.35 (95% CI 0.23 to 0.46) in patients randomised to TNFis (see Table 7).
This difference was not significant in either the unadjusted or the adjusted model (see Table 8). The overall
pattern of change is shown in Figure 3.
TABLE 8 Analysis of treatment effects on primary and secondary outcome measures: adjusted and unadjusted
linear regression analyses of treatment effects in the ITT population
Outcome
Model 1 (unadjusted): treatment+ region
Model 2 (adjusted): treatment+demographics+
baseline score
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Change in HAQ score
12 months 0.14 (−0.01 to 0.29) 0.075 0.15 (0.00 to 0.31) 0.047
6 months −0.07 (−0.22 to .08) 0.360 −0.08 (−0.23 to 0.07) 0.311
Change in EQ-5D score
12 months −0.06 (−0.15 to 0.04) 0.245 −0.11 (−0.18 to −0.03) 0.009
6 months 0.03 (−0.06 to 0.11) 0.500 0.01 (−0.07 to 0.08) 0.882
Change in Larsen score
12 months 0.11 (−1.45 to 1.67) 0.891 0.35 (−1.37 to 2.06) 0.689
6 months 0.03 (−1.09 to 1.15) 0.958 0.24 (−1.02 to 1.51) 0.704
Change in SF-36 PCS
12 months −0.23 (−3.26 to 2.79) 0.880 −1.40 (−4.22 to 1.41) 0.327
6 months 2.66 (1.50 to 3.83) <0.001 1.75 (0.64 to 2.86) 0.002
Change in SF-36 MCS
12 months 0.42 (−3.51 to 4.35) 0.832 −1.73 (−5.07 to 1.61) 0.307
6 months 0.68 (−3.17 to 4.54) 0.728 −1.62 (−4.94 to 1.70) 0.336
MCS, mental component score; PCS, physical component score.
Demographics adjusted for are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs.
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The effects of patients in the combination disease-modifying antirheumatic
drug group switching to tumour necrosis factor inhibitors
In total, 58 of the 104 patients in the cDMARD group remained on cDMARDs and 46 switched to TNFis
after 6 months. Over 12 months both sets of patients showed similar changes in HAQ score and there was
no evidence of a difference between groups by linear regression analysis (Table 9 and Figure 4). Comparing
changes in HAQ scores in both of these groups using general estimating equations provided no evidence
that there were any significant differences between the two groups in both an unadjusted and an adjusted
model (Table 10).
Complete-case analysis
Initial HAQ scores and changes in HAQ scores were similar between patients randomised to cDMARDs
and those randomised to TNFis. There was no evidence of any significant differences between groups
(see Appendix 3, Tables 50 and 52 and Figure 28). However, in the longitudinal analysis (see Appendix 3,
Table 55), there was some evidence of a treatment difference in the unadjusted and adjusted models.
Changes in European Quality of Life-5 Dimensions scores
Intention-to-treat population
Initial EQ-5D scores were similar in patients randomised to receive cDMARDs (mean 0.39, 95% CI 0.33
to 0.45) and patients randomised to receive TNFis (mean 0.35, 95% CI 0.28 to 0.41) (see Table 7).
At 12 months EQ-5D scores changed by a mean of −0.20 (95% CI −0.27 to −0.13) in patients
randomised to cDMARDs and by a mean of −0.14 (95% CI −0.21 to −0.08) in patients randomised to
TNFis (see Table 7). There was no significant difference between groups in the unadjusted model
(see Table 8). The adjusted model, in which the coefficient was −0.11 (95% CI −0.18 to −0.03), showed
a significant change in EQ-5D score in patients randomised to cDMARDs compared with those randomised
to TNFis (p= 0.009).
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FIGURE 3 (a) Health Assessment Questionnaire; and (b) EQ-5D mean scores (95% CIs) by treatment group in the
ITT population.
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At 6 months EQ-5D scores changed by a mean of −0.14 (95% CI −0.20 to −0.08) in patients randomised
to cDMARDs and by −0.17 (95% CI −0.23 to −0.11) in patients randomised to TNFis (see Table 7).
The difference between treatment groups was not significant in either the unadjusted or the adjusted
model (see Table 8). The overall pattern of change is shown in Figure 3.
The effects of patients in the combination disease-modifying antirheumatic
drug group switching to tumour necrosis factor inhibitors
Over 12 months both sets of patients saw changes in EQ-5D scores (see Table 9 and Figure 4). In patients
remaining on cDMARDs, EQ-5D scores improved by a mean of −0.26 (95% CI −0.35 to −0.17) and in
patients switching to TNFis, EQ-5D scores improved by a mean of −0.13 (95% CI −0.24 to −0.02).
Comparing these changes in EQ-5D scores over 12 months by linear regression (see Table 9) showed that
the difference was of borderline significance (p= 0.069).
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FIGURE 4 (a) Health Assessment questionnaire; and (b) EQ–5D mean scores (95% CIs) in cDMARD arm patients
(n= 104) in the ITT population by treatment status.
TABLE 10 Effects on HAQ score in cDMARD arm patients (n= 104) in the ITT population by treatment status:
adjusted and unadjusted assessments of treatment effect using GEEs
Outcome
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score+ time
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Change in HAQ score
12 months 0.14 (−0.03 to 0.31) 0.103 0.12 (−0.05 to 0.29) 0.185
Demographic variables are age, sex, ethnicity, disease duration and region. The reference group is no switch.
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Complete-case analysis
Initial EQ-5D scores and changes in EQ-5D scores were similar between patients randomised to cDMARDs
and those randomised to TNFis. There was no evidence of any significant differences between groups
(see Appendix 3, Tables 50 and 52 and Figure 28).
Changes in Short Form Questionnaire-36 items scores
Intention-to-treat population
Changes in the SF-36 profiles and physical component score (PCS) and mental component score (MCS) are
summarised in Table 11. There was a complex pattern of change. There were large mean changes (> 20)
in the role physical domain at both 6 and 12 months in both groups. At 12 months physical functioning,
pain, vitality, social functioning and role emotion showed changes of between 10 and 20 in both groups.
General health perception and mental health showed smaller changes over 12 months (< 10) in both
groups. We have not undertaken an in-depth statistical analysis of changes in the individual domains.
However, longitudinal analyses assessing changes in these SF-36 domains at both 6 and 12 months
(Table 12) mainly showed no significant differences between treatment groups in the unadjusted model
or in the adjusted model.
Initial PCS scores were similar in the two groups: in patients randomised to cDMARDs the mean score was
28.4 (95% CI 27.1 to 29.7) and in patients randomised to TNFis the mean score was 27.3 (95% CI 25.9 to
28.7). At 12 months PCS scores changed by a mean of −6.0 (95% CI −8.1 to −3.8) in patients randomised
to cDMARDs and by a mean of −5.8 (95% CI −7.9 to −3.7) in patients randomised to TNFis (see Table 11).
There was no significant difference between the groups in the unadjusted or adjusted model on linear
regression analysis (see Table 8). At 6 months PCS scores changed by a mean of −4.2 (95% CI −6.2
to −2.1) in patients randomised to cDMARDs and by a mean of −7.6 (95% CI −9.5 to −5.8) in patients
randomised to TNFis (see Table 11). This difference was significant on linear regression analysis in both the
unadjusted model (2.66, 95% CI 1.50 to 3.83; p< 0.001) and the adjusted model (−1.75, 95% CI 0.64 to
2.86; p= 0.002) (see Table 8).
Initial MCS scores were similar in the two groups: in patients randomised to cDMARDs the mean score was
43.4 (95% CI 41.0 to 45.8) and in patients randomised to TNFis the mean score was 40.7 (95% CI 38.3 to
43.1). At 12 months MCS scores changed by a mean of −5.0 (95% CI −7.8 to −2.2) in patients randomised
to cDMARDs and by −5.4 (95% CI −8.2 to −2.7) in patients randomised to TNFis (see Table 11). There was
no significant difference between the groups in the unadjusted or adjusted model (see Table 8). At 6 months
MCS scores changed by a mean of −3.6 (95% CI −6.1 to −1.1) in patients randomised to cDMARDs and
by a mean of −4.3 (95% CI −7.2 to −1.4) in patients randomised to TNFis (see Table 11). There was no
significant difference between treatment groups in the unadjusted or adjusted model in linear regression
analysis (see Table 8).
Complete-case analysis
Changes in SF-36 profiles and initial scores and changes in scores for the PCS and MCS were similar
between patients randomised to cDMARDs and those randomised to TNFis. There was no evidence of a
significant difference between groups in the longitudinal analysis (see Appendix 3, Tables 51 and 53).
Changes in Larsen scores
Intention-to-treat population
The initial Larsen scores differed between groups (see Table 7): in the cDMARD group the initial mean
score was 45.1 (95% CI 37.0 to 53.2) and in the TNFi group it was 37.9 (95% CI 30.2 to 45.6).
The Larsen score was the only clinical variable to show baseline differences and no clinical significance
was attached to this difference.
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Progression over 12 months was similar between the groups (Figure 5). With cDMARDs the Larsen score
increased by 1.26 and with TNFis it increased by 1.37. Progression over 6 months was also similar.
These differences between the treatment groups were not statistically significant (see Tables 8 and 12).
An exploratory analysis examined individual changes over 12 months using all observed data for both
groups (Figure 6); this showed no evidence of a different pattern of progression between the groups.
TABLE 12 Longitudinal analysis of treatment effects on SF-36 domains: adjusted and unadjusted longitudinal
analyses using GEEs in the ITT population
Variable
Model 1 (unadjusted): treatment+ region
Model 2 (adjusted): treatment+
demographics+baseline score
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
No period-specific treatment effects
SF-36 role physical −0.77 (−6.52 to 4.97) 0.793 0.40 (−4.74 to 5.53) 0.879
SF-36 pain −1.50 (−4.76 to 1.76) 0.368 −0.21 (−2.95 to 2.53) 0.880
SF-36 vitality −2.92 (−6.05 to 0.21) 0.067 −1.76 (−4.54 to 1.02) 0.215
SF-36 social functioning −1.81 (−5.66 to 2.03) 0.356 1.80 (−1.43 to 5.04) 0.274
SF-36 role emotion −0.43 (−7.64 to 6.78) 0.907 3.98 (−1.58 to 9.54) 0.160
SF-36 mental health −0.31 (−3.46 to 2.85) 0.848 1.35 (−1.06 to 3.76) 0.272
Period-specific treatment effects
Period (1−6 months)
SF-36 physical functioning 8.69 (1.04 to 16.34) 0.026 5.52 (−1.74 to 12.77) 0.136
SF-36 general health perception 7.37 (1.43 to 13.30) 0.015 4.20 (−0.78 to 9.18) 0.098
Period (7–12 months)
SF-36 physical functioning 1.16 (−6.49 to 8.81) 0.767 −3.12 (−10.44 to 4.19) 0.403
SF-36 general health perception −0.79 (−7.24 to 5.66) 0.81 −4.14 (−10.05 to 1.76) 0.169
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs
when appropriate.
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FIGURE 5 Mean Larsen scores (95% CIs) by treatment group in the ITT population.
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Another exploratory analysis evaluated the development of one (increase in Larsen score of 2–5) or many
new erosions (increase in Larsen score of > 5) using all observed data for both groups; this is summarised
in Figure 7, showing that there were no differences between the groups. By the end of the trial, 23 out
of 91 patients (25%) randomised to receive cDMARDs developed one new erosion and 12 out of
91 patients (13%) developed two or more erosions. In the group randomised to receive TNFis, 19 out
of 93 patients (20%) developed one new erosion and 13 out of 93 patients (14%) developed two or
more erosions.
The effects of patients in the combination disease-modifying antirheumatic
drug group switching to tumour necrosis factor inhibitors
Over 12 months both sets of patients showed small increases in Larsen scores (see Table 9). In patients
remaining on cDMARDs Larsen scores increased by a mean of −1.13 (95% CI −2.63 to 0.38) and in patients
switching to TNFis Larsen scores increased by a mean of −1.43 (95% CI −2.92 to 0.06). Comparing these
changes in Larsen scores over 12 months by linear regression provided no evidence that the difference was
significant (see Table 11). We also examined individual changes over 12 months for both sets of patients
using all observed data (Figure 8); this showed no evidence of a different pattern of progression between
the two groups.
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FIGURE 6 Individual changes in Larsen score over 12 months using all observed data.
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FIGURE 7 Development of new erosions over 12 months using all observed data.
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Complete-case analysis
Changes in Larsen scores were similar between patients randomised to cDMARDs and those randomised to
TNFis. There was no evidence of a significant difference between groups (see Appendix 3, Tables 50 and 53).
Disease activity scores (assessed every month)
Outcomes that were collected monthly comprised the DAS28 and its components – tender joint count,
swollen joint count, ESR and VAS patient global assessments. We assessed changes in DAS28 and changes
in its components in the ITT population. We also assessed the occurrence of a clinical response (decrease
in DAS28 of ≥ 1.2) and low DAS28 indicative of remission (DAS28 of ≤ 2.6) using all observed data;
imputation was not undertaken for these summary data because evaluating clinical responses and DAS28
remissions were exploratory analyses rather than predefined analyses as explained in the statistical analysis
plan (see Chapter 2).
Changes in Disease Activity Score for 28 Joints scores
Intention-to-treat population
Initial DAS28 were similar in both groups. In the cDMARD group the initial mean DAS28 was 6.21
(95% CI 6.04 to 6.39) and in the TNFi group the initial mean score was 6.30 (95% CI 6.14 to 6.46).
The patterns of change are shown in Table 13 and Figure 9.
By 6 months the DAS28 had fallen in the cDMARDs group to 4.78 (95% CI 4.45 to 5.12) and in
the TNFis group to 4.23 (95% CI 3.89 to 4.58). By 12 months the DAS28 had fallen further in the
cDMARDs group to 4.04 (95% CI 3.74 to 4.34) and in the TNFis group to 3.89 (95% CI 3.53 to 4.24).
The initial change in DAS28 was greater in patients randomised to TNFis and there was a significant
difference between groups within the first month of treatment. After 1 month the mean DAS28 in the
cDMARDs group fell to 5.32 (95% CI 5.05 to 5.59) and the mean score in the TNFis group fell
to 4.67 (95% CI 4.38 to 4.95, p= 0.001).
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FIGURE 8 Individual changes in Larsen score over 12 months in the cDMARD group by treatment status using all
observed data.
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Longitudinal analysis (Table 14) showed that there was a significant difference between treatment groups
over the whole 12-month period. Patients randomised to TNFis achieved greater overall reductions in
DAS28 than those randomised to cDMARDs in both the unadjusted model (−0.48, 95% CI −0.79 to
−0.17; p= 0.002) and the adjusted model (−0.40, 95% CI −0.69 to −0.10; p= 0.009). Comparing the
initial and final treatment periods in the adjusted model showed a difference in the pattern of change.
In the first 6 months there was a greater reduction in DAS28 in patients randomised to TNFis than
in patients randomised to cDMARDs, with a coefficient of −0.63 (95% CI −0.93 to −0.34, p< 0.001).
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FIGURE 9 Mean DAS28 (95% CIs) by treatment group in the ITT population.
TABLE 14 Longitudinal analysis of treatment effects on disease activity: analysis of changes in DAS28 and its
components using GEEs in the ITT population
Time period Variable
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Months 1–6 DAS28 −0.68 (−0.99 to −0.37) < 0.001 −0.63 (−0.93 to −0.34) < 0.001
Tender joint count −2.42 (−4.22 to −0.63) 0.008 −1.79 (−3.31 to −0.26) 0.022
Swollen joint count −1.35 (−2.76 to 0.07) 0.062 −1.16 (−2.20 to −0.12) 0.029
ESR (mm/hour) −6.46 (−10.23 to −2.68) 0.001 −7.18 (−10.60 to −3.76) < 0.001
VAS −6.97 (−13.10 to −0.84) 0.026 −6.41 (−11.66 to −1.15) 0.017
Months 7–12 DAS28 −0.31 (−0.69 to 0.07) 0.111 −0.19 (−0.55 to 0.18) 0.317
Tender joint count −1.10 (−3.22 to 1.01) 0.307 −0.13 (−1.79 to 1.53) 0.879
Swollen joint count −0.69 (−2.27 to 0.88) 0.388 −0.31 (−1.36 to 0.75) 0.570
ESR (mm/hour) −1.63 (−5.88 to 2.62) 0.452 −2.15 (−5.73 to 1.44) 0.241
VAS 0.60 (−6.47 to 7.67) 0.867 2.04 (−4.08 to 8.17) 0.513
Months 1–12 DAS28 −0.48 (−0.79 to −0.17) 0.002 −0.40 (−0.69 to −0.10) 0.009
Tender joint count −1.69 (−3.50 to 0.11) 0.066 −0.93 (−2.36 to 0.51) 0.205
Swollen joint count −0.86 (−2.27 to 0.55) 0.233 −0.63 (−1.57 to 0.31) 0.186
ESR (mm/hour) −4.04 (−7.67 to −0.40) 0.029 −4.62 (−7.77 to −1.47) 0.004
VAS −2.83 (−8.85 to 3.20) 0.358 −1.96 (−7.04 to 3.11) 0.448
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs.
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In the second period there was no difference between groups, with a coefficient of −0.19 (95% CI −0.55
to 0.18, p= 0.317).
Complete-case analysis
Mean DAS28 fell in both groups with treatment (see Appendix 3, Table 56 and Figure 30). Longitudinal
analysis using GEEs showed that the decreases were significantly greater with TNFis (see Appendix 3,
Table 57) in both the unadjusted model (p< 0.001) and the adjusted model (p< 0.001).
Changes in Disease Activity Score for 28 Joints components
Intention-to-treat population
Baseline tender joint counts, swollen joint counts, ESR and patient global assessments were similar in both
groups and they all improved when patients received either cDMARDs or TNFis. The patterns of change are
shown in Table 13 and Figures 10 and 11.
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FIGURE 10 Mean tender and swollen joint counts (95% CIs) by treatment group in the ITT population.
(a) Tender joints; and (b) swollen joints.
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Longitudinal analysis (see Table 14) showed that in the overall adjusted model changes in ESR were
significantly different between patients randomised to cDMARDs and those randomised to TNFis; the
decrease in ESR was significantly larger in the TNFis group (coefficient −4.62, 95% CI −7.77 to −1.47;
p= 0.004). There were no significant differences between treatment groups in the other components over
the whole 6 months.
In the first 6 months of treatment the adjusted mean treatment effects for all of the components were
significantly greater in patients randomised to TNFis than in those randomised to cDMARDs. In the second
6 months there were no statistically significant differences between the groups.
The speed of onset of changes was particularly marked for the ESR in patients randomised to TNFis. With
cDMARDs the ESR fell from an initial mean of 33.1 (95% CI 28.1 to 38.2) mm/hour to 32.4 (95% CI 27.4
to 37.5) mm/hour by 1 month. With TNFis the ESR fell from an initial mean of 30.1 (95% CI 25.7 to
34.6) mm/hour to 19.6 (95% CI 15.8 to 23.3) mm/hour by 1 month.
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FIGURE 11 Mean ESR (mm/hour) and patient global VAS (95% CIs) by treatment group in the ITT population.
(a) ESR; (b) patient global VAS.
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Complete-case analysis
Tender joint counts, swollen joint counts, ESR and patient global assessments improved in both patients
receiving cDMARDs and patients receiving TNFis (see Appendix 3, Table 56). Longitudinal analysis
(see Appendix 3, Table 57) showed that the improvements were significantly greater in the TNFis group for
tender joint counts, swollen joint counts and ESR in both the unadjusted model and the adjusted model.
The effects of patients in the combination disease-modifying antirheumatic
drug group switching to tumour necrosis factor inhibitors
Patients were selected to switch from cDMARDs to TNFis after 6 months if the change in DAS28 was
< 1.2. As a consequence, the mean DAS28 for the switchers would be expected to be more than that in
those who remained on cDMARDs. This difference is shown in Table 15, together with changes in the
individual components of the DAS28, and is also illustrated in Figure 12. The difference is confirmed to
be significant in the longitudinal analysis shown in Table 16. The adjusted model showed a significant
reduction in DAS28 in the switchers. The same effect was seen for the components of the DAS28 and was
most marked for tender joint count and patient global VAS score.
Achieving a clinical response
Time to achieve a response
An exploratory analysis examined the time taken to achieve a clinically meaningful response – a decrease
in DAS28 of ≥ 1.2. The time to achieve a clinically meaningful response was compared between
the groups using Kaplan–Meier plots (Figure 13). In total, 98 of 104 patients (94%) randomised to receive
cDMARDs and 94 of 101 patients (93%) randomised to receive TNFis achieved such responses. The
responses occurred sooner in the patients randomised to TNFis and this difference was significant in
a log-rank test (p= 0.035). Patients randomised to receive cDMARDs who had a clinically meaningful
DAS28 response achieved it within a mean of 3 months. Patients randomised to receive TNFis who had a
clinically meaningful DAS28 response achieved it within a mean of 2 months.
Persistence of response
There was a complex pattern of achieving responses. In some patients the response was persistent and in
others it was unsustained. Examples of these variations are shown in Figure 14 for four patients randomised
to the TNFi group. As a consequence of these variations we evaluated the frequency of response each
month in the two treatment groups (Figure 15). There was a different pattern of response in the two
groups. Patients randomised to cDMARDs showed a gradual increase in the rate of response from ≤ 45%
at 3 months or earlier to > 70% by 10 months. By contrast, patients randomised to TNFis achieved a
response rate of > 70% by 2 months and the response rate remained at > 70% thereafter, with the
highest response rate achieved in this group being 84% (achieved at month 11).
Impact of switching from combination disease-modifying antirheumatic
drugs to tumour necrosis factor inhibitors
There was a difference in response rate between the patients randomised to cDMARDs who remained on
cDMARDs and those who were randomised to cDMARDs but who switched to TNFis (Figure 16). Patients
remaining on cDMARDs had a response rate of > 50% from 2 months onwards and after 6 months the
response rate increased to > 70%. Those patients who switched to TNFis had an initial response rate of
< 50% and the response rate did not increase to 70% until 10 months.
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TABLE 16 Longitudinal analysis of treatment effects on disease activity in the cDMARD group (n= 104) by
treatment status: analysis of changes in DAS28 and its components using GEEs in the ITT population
Variable
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
DAS28 0.35 (−0.03 to 0.74) 0.071 0.51 (0.16 to 0.86) 0.005
Tender joint count 0.69 (−1.47 to 2.85) 0.532 2.42 (0.75 to 4.10) 0.004
Swollen joint count 0.97 (−1.04 to 2.97) 0.344 1.94 (0.65 to 3.22) 0.003
ESR (mm/hour) 2.54 (−2.65 to 7.73) 0.338 2.44 (−1.97 to 6.84) 0.278
VAS 10.26 (2.70 to 17.83) 0.008 8.29 (2.14 to 14.44) 0.008
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is no switch.
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FIGURE 16 Frequency of response in cDMARD patients by treatment status: patients with a reduction in DAS28 of
≥ 1.2 using all observed data.
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Achieving a Disease Activity Score for 28 Joints of ≤ 2.6
Time to achieve a Disease Activity Score for 28 Joints of ≤ 2.6
The time taken to achieve remission (DAS28 of ≤ 2.6) was compared using Kaplan–Meier plots (Figure 17).
In total, 36 out of 104 patients (35%) randomised to receive cDMARDs and 44 out of 101 patients (44%)
randomised to receive TNFis achieved remission at any time. There was no evidence that the speed of
onset of remission was significantly different between groups (p= 0.085). Those patients randomised to
receive both cDMARDs and TNFis who achieved DAS28 remission achieved it within a mean of 4 months.
Persistence of Disease Activity Score for 28 Joints of ≤ 2.6
There was a complex pattern of achieving remission. In some patients remission was persistent and in
others it was unsustained. Examples of these variations are shown in Figure 18 for four patients
randomised to the TNFi group. As a consequence of these variations we have also evaluated the frequency
of response each month for each group (Figure 19). There was a different pattern of response between
the groups. Patients randomised to cDMARDs showed a gradual increase in the rate of response from
≤ 5% at 3 months or earlier to a maximum of 20% by 12 months. By contrast, those patients randomised
to TNFis had achieved a remission rate of 16% by 3 months, which gradually increased to a maximum of
32% by 11 months.
Impact of switching from combination disease-modifying antirheumatic
drugs to tumour necrosis factor inhibitors
There was a difference in response rate between the patients randomised to cDMARDs who remained
on cDMARDs and those randomised to cDMARDs who switched to TNFis (Figure 20). In both groups
< 10% of patients achieved a DAS28 of ≤ 2.6 at ≤ 5 months. From 6 to 12 months between 13% and
24% of patients remaining on cDMARDs and between 5% and 21% of patients who switched
to TNFis achieved a DAS28 of ≤ 2.6.
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all observed data.
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Adverse events
Serious adverse events
In total, 10 patients in the cDMARDs group had a serious adverse event, eight in the first 6 months and
two in the second 6 months (Table 17). Seven of these serious adverse events involved or prolonged
inpatient treatment. In the TNFis group, 19 patients had a serious adverse event, six in the first 6 months
and 13 in the second 6 months; 13 of these serious adverse events involved or prolonged inpatient
treatment. One patient in the TNFi group died from pneumonia and multiple organ failure during the
second 6 months of treatment. Cardiovascular, respiratory, digestive and genitourinary systems were most
commonly involved. Although there were more serious adverse events in the TNFi group, there was no
evidence of major clinically important differences between the treatment groups and the frequency of
adverse events was not significantly different (Fisher’s exact test p= 0.110).
Stopping treatment because of adverse events
In total, 10 out of 104 patients (10%) in the cDMARD arm and six out of 101 patients (6%) in the TNFi
arm stopped treatment because of toxicity (see Figure 1). Although more patients withdrew from
treatment because of toxicity in the cDMARDs arm, there was no evidence of major clinically important
differences between the treatment groups and the frequency of withdrawals because of adverse events as
this was not significantly different (Fisher’s exact test p= 0.441).
Individual adverse events
There were 635 different adverse events reported by patients in the cDMARD group. The most frequent
events are listed in Table 18 and they are grouped by system involved in Table 19. All reported events are
listed in Appendix 4.
TABLE 17 All serious adverse events
Adverse event
cDMARDs TNFis
0–6 months 6–12 months Total 0–6 months 6–12 months Total
Cardiovascular 2 0 2 1 1 2
Digestive 0 0 0 2 2 4
Ear, nose and throat 0 0 0 0 1 1
Endocrine/metabolic 0 0 0 1 0 1
Genitourinary 3 0 3 0 1 1
Haematological 1 0 1 0 1 1
Mental 0 0 0 0 0 0
Musculoskeletal 0 0 0 0 1 1
Nervous system 0 1 1 1 1 2
Ophthalmological 0 0 0 0 0 0
Respiratory 2 1 3 1 2 3
Skin 0 0 0 0 2 2
Total 8 2 10 6 12 18
Patient died 0 0 0 0 1 1
Involved/prolonged
inpatient hospitalisation
5 2 7 5 8 13
Life-threatening 1 0 1 0 1 1
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TABLE 18 Most common adverse eventsa
Adverse event No. of events Percentage of total no. of adverse events
cDMARDs group
Diarrhoea 30 4.7
Headache 30 4.7
Nausea 26 4.1
Vomiting 26 4.1
Chest infection 19 3.0
Flare of RA 17 2.7
Sore throat 15 2.4
Cold 12 1.9
Ulcers – mouth 12 1.9
Fatigue 11 1.7
Dizziness 9 1.4
Elevated alanine aminotransferase 7 1.1
Flu 7 1.1
High blood pressure 7 1.1
Itchy skin 7 1.1
Low white cell count 7 1.1
TNFis group
Chest infection 27 5.8
Cold 16 3.4
Elevated alanine aminotransferase 16 3.4
Headache 15 3.2
Flare of RA 14 3.0
Sore throat 13 2.8
Diarrhoea 12 2.6
Urinary tract infection 9 1.9
Nausea 8 1.7
Breathlessness 7 1.5
Cold sore 7 1.5
Shoulder pain 6 1.3
Upper respiratory tract infection 6 1.3
Chest pain 5 1.1
Cough – productive 5 1.1
Fatigue 5 1.1
Injection site reaction 5 1.1
Vaginal thrush 5 1.1
Knee pain 5 1.1
a Adverse events accounting for > 1% of the total events are shown.
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There were 465 different adverse events reported by patients in the TNFis group. The most frequent events
are listed in Table 18 and they are grouped by system involved in Table 19. All reported events are listed
in Appendix 4.
Chest infections (46 events), headaches (45 events), diarrhoea (42 events), nausea (34 events), sore throats
(28 events), colds (28 events), elevated liver enzymes (alanine aminotransferase) (23 events) and fatigue
(16 events) were the most common adverse events across both groups. Some types of adverse events
spanned systems, in particular infections, which accounted for 112 adverse events in the cDMARDs group
and 117 in the TNFis group.
There was no evidence of any major clinically important differences between the two treatment groups.
However, the cDMARDs group had 37% more adverse events overall (635 vs. 465). This difference
was mainly due to there being 88 more adverse events related to the digestive system (148 vs. 60) and
20 more adverse events related to the nervous system (61 vs. 41) in the cDMARDs group.
Economic evaluation
Response rates
The response rates for the CSRI and outcome questionnaires and the availability of trial medication data
are summarised in Tables 20–22 respectively. These were > 90% and were similar for all of the
questionnaires at baseline and 6 and 12 months and across both trial arms.
Table 23 summarises the joint availability of both cost and outcome data (a requirement for the construction
of CEACs) by outcome measure. In total, 191 of the 205 study participants (93%) had both cost and
outcome data at 6 months’ follow-up and 186–188 of the 205 study participants (91–92%) had both cost
and outcome data at 12 months’ follow-up. There were thus very few cases excluded from the available
case analyses.
Tables 24–26 suggest that there were no notable differences in characteristics between the subsamples
included in the available case analyses and the full sample.
TABLE 19 All adverse events
Adverse event cDMARDs group TNFis group
Cardiovascular 22 17
Digestive 148 60
Ear, nose and throat 88 76
Endocrine/metabolic 7 7
Genitourinary 28 27
Haematological 25 10
Mental 24 15
Musculoskeletal 104 94
Nervous system 61 41
Ophthalmological 12 5
Respiratory 59 66
Skin 57 47
Total 635 465
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TABLE 20 Client Service Receipt Inventory response rates
Group
Baseline 6 months 12 months
n % n % n %
TNFis (n= 101) 101 100 97 96 93 92
cDMARDs (n= 104) 104 100 94 90 95 91
Total (n= 205) 205 100 191 93 188 92
TABLE 21 Health Assessment Questionnaire, EQ-5D and SF-36 response rates
Group
Baseline 6 months 12 months
n % n % n %
HAQ
TNFis (n= 101) 101 100 97 96 94 93
cDMARDs (n= 104) 104 100 94 90 95 91
Total (n= 205) 205 100 191 93 189 92
EQ-5D
TNFis (n= 101) 101 100 97 96 93 92
cDMARDs (n= 104) 104 100 94 90 94 90
Total (n= 205) 205 100 191 93 187 91
SF-36
TNFis (n= 101) 101 100 97 96 94 93
cDMARDs (n= 104) 104 100 94 90 95 91
Total (n= 205) 205 100 191 93 189 92
TABLE 22 Availability of trial medication data
Group
6 months 12 months
n % n %
TNFis (n= 101) 97 96 94 93
cDMARDs (n= 104) 97 93 96 92
Total (n= 205) 194 95 190 93
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TABLE 23 Availability of cost and outcome data by outcome measure
Group
6 months 12 months
n % n %
HAQ
TNFis (n= 101) 97 96 93 92
cDMARDs (n= 104) 94 90 95 91
Total (n= 205) 191 93 188 92
EQ-5D
TNFis (n= 101) 97 96 92 91
cDMARDs (n= 104) 94 90 94 90
Total (n= 205) 191 93 186 91
SF-36
TNFis (n= 101) 97 96 93 92
cDMARDs (n= 104) 94 90 95 91
Total (n= 205) 191 93 188 92
TABLE 24 Characteristics of the full sample and the subsample with cost and HAQ data
Characteristic
Full sample (N= 205)
Subsample with 6-month
cost and HAQ data (N= 191)
Subsample with 12-month
cost and HAQ data (N= 188)
n % n % n %
Sex
Male 53 26 45 24 46 25
Female 152 74 146 76 142 76
Ethnicity
White 181 88 168 88 164 87
Other 24 12 23 12 24 13
Region
London and south 128 62 127 67 121 64
Midlands 16 8 13 7 13 7
North 61 30 51 27 54 29
Mean SD Mean SD Mean SD
Age (years) 57.34 11.97 57.11 11.94 56.91 12.02
Duration of illness (years) 8.20 8.82 8.35 8.98 8.24 8.88
HAQ score at baseline 1.85 0.63 1.86 0.63 1.85 0.64
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TABLE 25 Characteristics of the full sample and the subsample with cost and EQ-5D data
Characteristic
Full sample (N= 205)
Subsample with 6-month
cost and EQ-5D data (N= 191)
Subsample with 12-month
cost and EQ-5D data (N= 186)
n % n % n %
Sex
Male 53 26 45 24 45 24
Female 152 74 146 76 141 76
Ethnicity
White 181 88 168 88 162 87
Other 24 12 23 12 24 13
Region
London and south 128 62 127 67 121 65
Midlands 16 8 13 7 11 6
North 61 30 51 27 54 29
Mean SD Mean SD Mean SD
Age (years) 57.34 11.97 57.11 11.94 56.84 12.08
Duration of illness (years) 8.20 8.82 8.35 8.98 8.25 8.92
HAQ score at baseline 1.85 0.63 1.86 0.63 1.85 0.64
EQ-5D-based utility
at baseline
0.37 0.31 0.37 0.31 0.37 0.31
TABLE 26 Characteristics of the full sample and the subsample with cost and SF-36 data
Characteristic
Full sample (N= 205)
Subsample with 6-month
cost and EQ-5D data (N= 191)
Subsample with 12-month
cost and EQ-5D data (N= 186)
n % n % n %
Sex
Male 53 26 45 24 46 25
Female 152 74 146 76 142 76
Ethnicity
White 181 88 168 88 164 87
Other 24 12 23 12 24 13
Region
London and south 128 62 127 67 121 64
Midlands 16 8 13 7 13 7
North 61 30 51 27 54 29
Mean SD Mean SD Mean SD
Age (years) 57.34 11.97 57.11 11.94 56.91 12.02
Duration of illness (years) 8.20 8.82 8.35 8.98 8.24 8.88
HAQ score at baseline 1.85 0.63 1.86 0.63 1.85 0.64
SF-36-based utility
at baseline
0.54 0.11 0.54 0.11 0.54 0.11
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Resource use
Resource use differences between the groups were not compared statistically, first, because the economic
evaluation was focused on costs and cost-effectiveness/utility and, second, to avoid problems associated
with multiple testing. Therefore, resource use patterns are described in Tables 27–29 without statistical
comparisons. Use of services appeared similar in both groups at all three time points. General practitioner
(GP) surgery visits, practice nurse surgery visits, repeat prescription requests and hospital outpatient
TABLE 27 Resource use at baseline (in previous 3 months)
Resource use Unit
cDMARDs group (n= 94) TNFis group (n= 97)
No. of users Mean usea SD No. of users Mean usea SD
GP
At surgery Visit 70 2 2 73 3 2
At home Visit 3 1 1 3 1 1
Telephone call Call 16 2 1 15 2 1
Repeat prescription request
without GP contact
Prescription 93 3 2 92 3 2
Nurse
At surgery Visit 42 3 4 50 2 2
Telephone call Call 6 1 < 1 7 1 < 1
Physiotherapist
At hospital Unit 7 2 2 9 2 1
At home Visit 0 – – 1 3 –
At GP surgery Visit 2 11 13 1 3 –
Elsewhere Visit 0 – – 0 – –
Occupational therapist
At hospital Unit 5 4 5 5 1 1
At home Visit 3 2 1 5 1 1
At GP surgery Visit 0 – – 0 – –
Elsewhere Visit 0 – – 2 2 < 1
Hospital services
A&E Unit 9 1 < 1 6 1 < 1
Hospital stay overnight Night 4 2 1 3 12 6
Outpatient appointment Unit 77 3 2 85 3 2
Social services
Meals on Wheels Meal 0 – – 0 – –
Home help Visit 0 – – 1 90 –
Social worker Hour 0 – – 2 3 1
Social worker telephone call Call 0 – – 3 1 < 1
Other health or social service Contact 1 1 < 1 4 3 2
Non-trial medication Medication 102 – – 100 – –
A&E, accident and emergency.
a Mean for users only.
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TABLE 28 Resource use at 6 months’ follow-up (in previous 3 months)
Resource use Unit
cDMARDs group (n= 94) TNFis group (n= 97)
No. of users Mean usea SD No. of users Mean usea SD
GP
At surgery Visit 42 2 1 55 2 1
At home Visit 2 1 < 1 3 2 1
Telephone call Call 9 2 1 14 1 1
Repeat prescription request
without GP contact
Prescription 63 3 1 70 3 1
Nurse
At surgery Visit 31 3 3 31 3 4
Telephone call Call 2 2 1 2 1 < 1
Physiotherapist
At hospital Unit 8 4 3 4 3 1
At home Visit 0 – – 0 – –
At GP surgery Visit 2 3 < 1 1 1 –
Elsewhere Visit 0 – – 2 2 1
Occupational therapist
At hospital Unit 4 2 1 3 1 1
At home Visit 2 1 < 1 4 1 < 1
At GP surgery Visit 0 – – 0 – –
Elsewhere Visit 1 1 – 0 – –
Hospital services
A&E Unit 4 1 < 1 9 1 < 1
Hospital stay overnight Unit/night 4 4 5 5 7 5
Outpatient appointment Unit 55 3 2 58 3 1
Social services
Meals on Wheels Meal 1 60 – 0 – –
Home help Visit 1 1 – 2 46 63
Social worker Hour 3 1 1 3 1 1
Social worker telephone call Call 1 2 – 1 3 –
Other health or social service Contact 3 31 51 3 14 11
Non-trial medication Medication 88 – – 94 – –
A&E, accident and emergency.
a Mean for users only.
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TABLE 29 Resource use at 12 months’ follow-up (in previous 3 months)
Resource use Unit
cDMARDs group (n= 104) TNFis group (n= 101)
No. of users Mean usea SD No. of users Mean usea SD
GP
At surgery Visit 60 2 1 58 2 2
At home Visit 4 2 1 3 1 1
Telephone call Call 16 1 1 13 1 1
Repeat prescription request
without GP contact
Prescription 68 3 2 61 2 1
Nurse
At surgery Visit 24 2 1 31 2 2
Telephone call Call 2 1 < 1 5 2 1
Physiotherapist
At hospital Unit 11 5 6 7 3 2
At home Visit 0 – – 0 – –
At GP surgery Visit 1 8 – 2 3 3
Elsewhere Visit 1 1 – 1 2 –
Occupational therapist
At hospital Unit 6 2 1 1 1 –
At home Visit 1 1 – 1 1 –
At GP surgery Visit 0 – – 0 – –
Elsewhere Visit 1 1 – 1 3 –
Hospital services
A&E Unit 10 1 < 1 5 1 1
Hospital stay overnight Unit/night 5 2 1 2 11 13
Outpatient appointment Unit 56 2 1 55 3 2
Social services
Meals on Wheels Meal 0 – – 0 – –
Home help Visit 0 – – 3 31 51
Social worker Hour 1 1 – 2 2 < 1
Social worker telephone call Call 2 2 1 1 1 –
Other health or social service Service 2 19 16 2 1 < 1
Non-trial medication Contact 90 – – 91 – –
A&E, accident and emergency.
a Mean for users only.
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appointments were common in both groups at all time points, with other service use being relatively rare.
The number of participants using non-trial medications was also similar in both groups at all time points.
Data on the use of NHS/social services-funded transport, equipment and home adaptations (costs of which
are excluded from cost calculations) are presented in Table 30.
Costs
Cost components at baseline, 6 months and 12 months are summarised in Table 31. Costs for both
groups were equivalent at baseline. Costs of social security benefits and employment losses are small
compared to the cost of health and social care. At 6 and 12 months’ follow-up all cost components
remained equivalent between groups except for the cost of trial medications, which was significantly
lower in the cDMARDs group (6-month adjusted mean difference −£3637, 95% CI −£3838 to −£3420;
12-month adjusted mean difference −£1894, 95% CI −£2320 to −£1427). The additional trial medication
cost in the TNFis group overshadowed all other cost components in that group.
The increase in trial medication costs in the cDMARDs group between 6 and 12 months was due to a
significant proportion of this group switching to the more expensive TNFis at 6 months because of
non-response to cDMARDs by 6 months. Switching in the reverse direction was uncommon (a total of
four participants) and so trial medication costs in the TNFis group did not fall a great deal between
6 and 12 months.
Table 32 shows total costs at 6 and 12 months from a health and social care perspective and the two
societal perspectives that we adopted (with and without social security benefit costs). All figures (including
those for trial medication) represent a 3-month period. The cDMARDs group has significantly lower total
costs from all perspectives at both follow-up points. The difference is greater at 6 months than at
12 months because of the greater trial medication cost differential before switching taking place.
TABLE 30 Use of NHS/social services-funded transport, equipment and home adaptations at baseline and 6 and
12 months
Resource use
cDMARDs group TNFis group
No. of users/
total no.
No. paid
by NHS
No. paid by
social services
No. of users/
total no.
No. paid
by NHS
No. paid by
social services
Baseline
Transport 5/104 4 1 3/101 2 1
Equipment 4/104 1 3 2/101 0 2
Home adaptations 4/104 1 3 1/101 0 1
Other 2/104 1 1 3/101 1 2
6 months
Transport 6/94 6 0 4/97 3 1
Equipment 2/94 0 2 4/97 0 4
Home adaptations 4/94 2 2 3/97 0 3
Other 0/94 0 0 2/97 0 2
12 months
Transport 2/95 2 0 6/93 6 0
Equipment 3/95 1 2 2/93 0 2
Home adaptations 1/95 1 0 3/93 0 3
Other 1/95 0 1 1/93 0 1
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61
Costs from each of the societal perspectives are similar to those from a health and social care perspective
because of the dominance of trial medication costs.
For the purpose of combining cost and outcome data for the cost-effectiveness/cost–utility analyses,
all costs were equivalised to 6-month values. Trial medication costs were available for the 0- to 6-month
and 7- to 12-month periods so all other costs were multiplied by 2 to represent 6-month rather
than 3-month periods. The extrapolated figures are shown in Table 33. Imputing missing cost data
(based on the extrapolated costs) for those lost to follow-up confirmed the findings from the unimputed
available case analysis (Table 34).
Outcomes
The cDMARDs arm had an advantage of four points based on the SF-36-based utility scores at baseline
but this did not carry through as an advantage in (baseline-adjusted) utility scores at either of the two
follow-up points or in the resulting QALY estimates (Table 35). The cDMARDs group did, however,
show advantages in terms of the HAQ and EQ-5D-based utility scores at 12 months, although the latter
did not translate into an advantage in terms of the QALYs estimated from the EQ-5D. As with cost data,
imputing missing outcome data for those lost to follow-up did not alter the conclusions from the available
case analyses (Table 36).
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Cost-effectiveness and cost–utility analyses
Table 37 presents the ICERs for the cost-effectiveness and cost–utility analyses based on costs from each
perspective (based on extrapolations representing 6-month periods) and outcomes at 6 and 12 months.
For the ICERs, the mean difference in the HAQ score was reversed (negatives turned to positives and
vice versa) as a reduction in HAQ score indicates a better outcome. Of the 18 cost–outcome combinations,
three showed statistically significant between-group differences for both costs and outcomes: at 12 months,
the cDMARDs group dominated with the group having better outcomes (mean difference −0.16,
95% CI −0.32 to −0.01) and lower costs from a health-care perspective (mean difference −£1930, 95% CI
−£2599 to −£1301), societal perspective excluding benefits (mean difference −£1974, 95% CI −£2648 to
−£1334) and societal perspective including benefits (mean difference −£1977, 95% CI −£2644 to −£1338).
These translated into ICERs of −£12,063, −£12,338 and −£12,356 per QALY respectively. All other
cost–outcome combinations suggest that the cDMARDs group is superior, with equivalent outcomes
achieved at a significantly lower cost. The conclusions remained the same when costs and outcomes for
those lost to follow-up were imputed. It was not necessary to compute any ICERs as none of the
combinations suggested a significantly better outcome at a significantly lower cost.
TABLE 37 Cost-effectiveness and cost–utility summary
Cost per additional point
improvement on the HAQ (£),
cDMARDs vs. TNFis
Cost per additional QALY
(SF-36 based) (£),
cDMARDs vs. TNFis
Cost per additional QALY
(EQ-5D based) (£),
cDMARDs vs. TNFis
6 months
Health and social care
perspective
51,643 −3615 −3615
Societal perspective
excluding benefits
52,614 −3683 −3683
Societal perspective
including benefits
52,629 −3684 −3684
12 months
Health and social care
perspective
cDMARDs dominate: −12,063 −193,000 −96,500
Societal perspective
excluding benefits
cDMARDs dominate: −12,338 −197,400 −98,700
Societal perspective
including benefits
cDMARDs dominate: −12,356 −197,700 −98,850
Note
Only three cost–outcome combinations showed a significant difference: at 12 months the cDMARDs group had significantly
lower costs and significantly better HAQ scores for all three perspectives.
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Figures 21 and 22 show the probability that the cDMARDs group is cost-effective compared with the TNFis
group for each outcome from a health and social care perspective at 6 and 12 months respectively.
Both EQ-5D- and SF-36-based QALYs at each time point suggest that the probability that the cDMARDs
group is cost-effective is ≥ 99% at all willingness-to-pay thresholds that were examined.
The probability that the cDMARDs group is cost-effective at 6 months based on the HAQ is 100% for
willingness-to-pay thresholds of up to £10,000 per point improvement on the HAQ but decreases at
higher willingness-to-pay thresholds. At 12 months the probability of cost-effectiveness is 100% for
willingness-to-pay thresholds of up to £10,000 per point improvement on the HAQ and remains at 99%
up to a threshold of £50,000.
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FIGURE 21 Cost-effectiveness acceptability curves at 6 months from a health and social care perspective for all
outcomes. (a) HAQ; (b) SF-36; and (c) EQ-5D.
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FIGURE 22 Cost-effectiveness acceptability curves at 12 months from a health and social care perspective for all
outcomes. (a) HAQ; (b) SF-36; and (c) EQ-5D.
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Systematic reviews
Early rheumatoid arthritis
Trials
The preliminary search identified 463 papers, of which 36 were potentially relevant trials and were
selected for full-text review (Figure 23). Of these, four trials were excluded: one included patients with a
disease duration of > 3 years, two used treatment strategies in which the same approaches were included
in both arms and one used steroids with methotrexate in the control monotherapy arm. The remaining
32 trials68,111,147,171,192–219 formed the basis of this systematic review.
The baseline characteristics of the 32 RCTs are summarised in Table 38. The trials randomised between
20 and 1049 patients and enrolled over 8400 patients. In total, 19 trials compared cDMARDs with
methotrexate,68,111,171,192–207 10 trials compared TNFis/methotrexate with methotrexate monotherapy208–217
and three trials compared cDMARDs with TNFis/methotrexate directly (head-to-head trials).147,218,219 The
Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis
(OPTIMA)217 and High Induction Therapy with Anti-Rheumatic Drugs (HIT-HARD)216 studies withdrew
anti-TNF treatment from 24 and 26 weeks, respectively; therefore, only outcomes at 24 and 26 weeks,
respectively, were considered. The BeSt220 and Swedish Farmacotherapy (Swefot)221 trials initially published
12-month results and subsequently 24-month results.
Preliminary search identified 
463 citations
378 of records after duplicates
removed
342 citations excluded on basis of 
titles and abstract
Four full-text articles excluded as:
•
•
•
 
Disease duration over 3 years, n = 1
Treatment strategies used both
approaches in each arm, n = 2
Monotherapy arm included
steroids and DMARD, n = 1
36 of full-text articles assessed
for eligibility
32 studies included in qualitative
and quantitative synthesis
FIGURE 23 Selection of trials in early RA.
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Baseline characteristics
The baseline characteristics of the patients are summarised in Table 39. The average age ranged from
46 to 55 years in the TNFis/methotrexate RCTs, from 37 to 59 years in the cDMARDs RCTs and from
49 to 54 years in the direct comparison trials. Mean disease duration ranged from 0.5 to 3 years in the
TNFis/methotrexate RCTs, from 0.5 to 3 years in the cDMARDs RCTs and from 1 to 3 years in the direct
comparison trials. Not all trials reported initial DAS28; in the 14 trials in which this was recorded the mean
score ranged from 4.8 to 6.7 with an overall average score of 5.58.
TABLE 39 Baseline characteristics in early RA trials in combined arms
Study Cases
Age (years),
mean (SD) Female (%)
Baseline DAS28,
mean (SD)
Indirect comparisons
Boers et al.68 76 50 (11.9) 66 Not stated
Breedveld et al.208 82 50a 79 Not stated
Breedveld et al.212 268 51.9 (14) 72 6.3 (0.9)
Capell et al.200 84 55 (range 25–76) 65 Not stated
Choy et al.171 116 55 67 5.6 (1.2)
Detert et al.216 87 47 (12) 70 6.2 (0.8)
Dougados et al.194 68 52 77 DAS: 4.23
Durez et al.213 15 50 (9.9) 67 DAS28-CRP: 5.3 (1.1)
Emery et al.214 265 50.5 (0.9) 74 6.5 (1.0)
Ferraccioli et al.197 42 59 (7.7) 86 Not stated
Gerards et al.198 60 53 (10.6) 62 Not stated
Grigor et al.111 55 51 (15) 71 DAS: 4.9 (0.9)
Haagsma et al.192 36 57 (12.2) 66 DAS: 5.0 (0.8)
Hetland et al.206 60 53.2a 64 5.31 (1.34)
Ichikawa et al.202 24 49.1 (12.9) 71 Not stated
Kavanaugh et al.217 515 50.7 (14.5) 74 DAS28-CRP: 6.0 (1.0)
Marchesoni et al.199 30 46.6 (10.5) 93 5.2 (1.2)
Miranda et al.201 75 37 (11) 92 Not stated
Mottonen et al.195 97 47 (range 23–65) 58 Not stated
O’Dell et al.207 24 49.5 67 Not stated
Proudman et al.196 40 51 (13.7) 65 5.4 (1)
Quinn et al.211 10 51.3 (9.5) Not stated Not stated
Sarzi-Puttini et al.203 30 53 (10) 63 Not stated
Soubrier et al.215 65 46.3 (16.3) 79 6.31 (0.78)
St Clair et al.209 363 50 (13) 68 6.7 (1.0)
Svensson et al.204 119 51 (14) 65 5.28 (1.11)
Taylor et al.210 12 55 (11.8) Not stated 5.4 (1.1)
van den Borne et al.193 30 51 (11.1) 73 Not stated
Wassenberg et al.205 80 53 (12.6) 75 Not stated
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American College of Rheumatology responses and withdrawals for inefficacy
Indirect comparisons showed that in trials of DMARD combinations (Table 40 and Figure 24) more patients
achieved ACR20–70 responses with combination therapy (OR 1.76–2.81) and less patients withdrew
because of inefficacy with combination therapy (OR 0.47, 95% CI 0.34 to 0.64). In trials of
TNFi/methotrexate combinations more patients achieved ACR20–70 responses with combination
therapy (OR 1.88–2.22) and fewer patients withdrew because of inefficacy with combination therapy
(OR 0.44, 95% CI 0.22 to 0.85). Sensitivity analysis of trials using only methotrexate monotherapy showed
similar results.
Direct comparisons showed that there were no differences between DMARD combinations (Table 41) and
TNFi/methotrexate with regard to ACR20 outcomes or patient withdrawals because of inefficacy. However,
fewer patients achieved ACR50 and ACR70 responses using cDMARDs than using TNFi/methotrexate
(ORs 0.54 and 0.53 respectively). A more detailed analysis of data from each of these trials is shown in
Figure 25. Overall, there were small differences in favour of TNFi/methotrexate compared with cDMARDs at
most time points but these were not always significant. There were also marked differences in response
rates in the different trials.
Disability
In the indirect comparisons there were greater improvements in HAQ scores with both combination
regimens when compared with DMARD monotherapy (OR −0.15, 95% CI −0.23 to −0.07) or
methotrexate monotherapy (OR −0.17, 95% CI −0.33 to −0.01) (see Table 40). No RCTs that made a
direct comparison between cDMARDs and TNFi/methotrexate reported HAQ outcomes.
Toxicity
Indirect comparisons (see Table 40) showed that more patients withdrew with DMARD combinations
because of toxicity than with DMARD monotherapy (OR 1.50, 95% CI 1.11 to 2.03) or with methotrexate
monotherapy (OR 2.69, 95% CI 1.49 to 4.83). There were no differences between TNFi/methotrexate
and methotrexate monotherapy in terms of withdrawals because of toxicity. The direct comparisons
showed no differences in patient withdrawal because of toxicity (see Table 41).
TABLE 39 Baseline characteristics in early RA trials in combined arms (continued )
Study Cases
Age (years),
mean (SD) Female (%)
Baseline DAS28,
mean (SD)
Direct comparisons
Goekoop et al.
(DMARDs)147
133 55 (14) 65 DAS44: 4.4 (0.9)
Goekoop et al.
(TNFi/methotrexate)147
128 54 (14) 66 DAS44: 4.3 (0.9)
Moreland et al.
(DMARDs)219
132 48.8 (12.7) 77 5.8 (1.1)
Moreland et al.
(TNFi/methotrexate)219
244 50.7 (13.4) 74 5.8 (1.1)
van Vollenhoven et al.
(DMARDs)218
130 52.9 (13.9) 78 4.79 (1.05)
van Vollenhoven et al.
(TNFi/methotrexate)218
128 51.1 (13.3) 76 5.91 (0.93)
DAS44, Disease Activity Score for 44 Joints.
a Median.
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TABLE 40 Indirect comparisons in early RA: summary of meta-analysis of key outcomes – ACR responses, patient
withdrawals, HAQ score and radiological progression
Outcome Treatment regimen Studies
Random-effects analyses
OR (95% CI)
Categorical outcomes
ACR20 DMARD combinations 14 1.76 (1.26 to 2.46)
DMARD combinations (methotrexate only) 5 2.01 (1.08 to 3.72)
TNFi/methotrexate 8 1.88 (1.61 to 2.19)
ACR50 DMARD combinations 13 2.34 (1.40 to 3.91)
DMARD combinations (methotrexate only) 5 1.64 (1.15 to 2.34)
TNFi/methotrexate 7 2.09 (1.80 to 2.43)
ACR70 DMARD combinations 8 2.81 (1.48 to 5.33)
DMARD combinations (methotrexate only) 4 2.00 (1.32 to 3.02)
TNFi/methotrexate 7 2.22 (1.78 to 2.76)
Inefficacy withdrawals DMARD combinations 15 0.47 (0.34 to 0.64)
DMARD combinations (methotrexate only) 7 0.52 (0.33 to 0.82)
TNF/methotrexate 9 0.44 (0.22 to 0.85)
Toxicity withdrawals DMARD combinations 15 1.86 (1.42 to 2.44)
DMARD combinations (methotrexate only) 7 2.69 (1.49 to 4.83)
TNFi/methotrexate 9 1.42 (0.87 to 2.34)
WMD (95% CI)
Continuous outcomes
Disability (HAQ) DMARD combinations 7 −0.03 (−0.12 to 0.07)
DMARD combinations (methotrexate only) 2 −0.17 (−0.33 to −0.01)
TNFi/methotrexate 2 −0.16 (−0.24 to −0.08)
Radiological progression DMARD combinations 7 −0.99% (−1.11% to −0.87%)
DMARD combinations (methotrexate only) 4 −1.21% (−1.37% to −1.04%)
TNFi/methotrexate 4 −0.61% (−0.79% to −0.43%)
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FIGURE 24 Forest plots of ACR20 responses in early RA: results for (a) cDMARD vs. methotrexate trials; and
(b) TNFi/methotrexate vs. methotrexate trials.
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TABLE 41 Direct comparisons (cDMARDs vs. TNFi/methotrexate) in early RA: summary of meta-analysis of all
outcomes – ACR responses, patient withdrawals and radiological progression
Outcome Studies
Random-effects analyses
OR (95% CI)
Categorical outcomes
ACR20 2 0.74 (0.42 to 1.29)
ACR50 1 0.54 (0.33 to 0.90)
ACR70 2 0.53 (0.36 to 0.79)
Inefficacy withdrawals 3 3.28 (0.51 to 21.28)
Toxicity withdrawals 3 1.63 (0.78 to 3.43)
WMD (95% CI)
Continuous outcome
Radiological progression 2 0.22 (−0.02 to 0.45)
Note
TNFi/methotrexate was the control group and cDMARDs was the comparison group (OR < 1 indicates reduced response.
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FIGURE 25 American College of Rheumatology responses in head-to-head trials in early RA. (a) ACR20; and
(b) ACR70 responses from the BeSt,147 Treatment of Early Aggressive Rheumatoid (TEAR)219 and Swefot trials.218
The trials variously reported outcomes at 6, 12 and 24 months.
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Radiological progression
Indirect comparisons showed less erosive progression with both combination regimens compared with
DMARD monotherapy (see Table 40). Sensitivity analysis of cDMARDs including only those trials in which
the comparator was methotrexate monotherapy showed similar results. The direct comparison showed
that there was no difference in radiological progression between cDMARDs and TNFi/methotrexate
(see Table 41).
Heterogeneity
The cDMARD trials showed evidence of heterogeneity in ACR20 scores (p< 0.007), ACR50 scores
(p< 0.0001) and ACR70 scores (p= 0.02). In contrast, the TNFi trials showed no heterogeneity.
There was also no heterogeneity in the head-to-head trials.
Established rheumatoid arthritis
Trials
The preliminary search identified 3642 papers, of which 28 were potentially relevant and were selected
for full-text review (Figure 26). Of these, nine studies were excluded: in four patients were treatment
naive, in two patients had not received DMARDs for > 3 months, two did not specify previous DMARD
treatment and one was a duplicate of an included study. The remaining 19 studies66,67,170,222–237 were
included in the systematic review and are summarised in Table 42. In total, 10 trials compared cDMARDs
with DMARD monotherapy,66,67,222–229 of which six used methotrexate monotherapy as the control
arm,66,67,222,223,227,229 and eight compared TNFi/methotrexate with methotrexate monotherapy,170,230–236
with one involving infliximab,170 two etanercept,230,232 one adalimumab,231 two golimumab233,236 and
two certolizumab pegol.234,235 For the Trial of Etanercept and Methotrexate with Radiographic Patient
Outcomes (TEMPO)232 and Rheumatoid Arthritis Prevention of Structural Damage 1 (RAPID1)234 trials,
2-year follow-up data were subsequently published.238,239 Finally, one trial made a direct comparison
between methotrexate/sulfasalazine/hydroxychloroquine and etanercept/methotrexate.237
3642 records identified
through preliminary search
3046 records after
duplicates removed
3018 excluded on basis of
titles and abstract
28 full-text articles assessed
for eligibility
19 studies included in
quantitative synthesis
Nine full-text articles excluded as:
1. Treatment naive, n = 4
2. Did not specify previous DMARD treatment, n = 2
3. No DMARDs > 3 months, n = 2
4. Duplicate study, n = 1
FIGURE 26 Selection of trials in established RA.
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Baseline characteristics
The baseline characteristics of the patients are summarised in Table 43. The trials enrolled between 40 and
982 patients; overall, > 5500 patients were randomised. The average age ranged from 49 to 59 years in
the TNFi/methotrexate trials and from 44 to 56 years in the cDMARD trials. Mean disease duration ranged
from 6.7 to 13 years in the TNFi/methotrexate trials and from 1–12.7 years in the cDMARDs trials. Disease
activity, assessed using the DAS28 or its component parts, was reported in the majority of trials and
showed active disease. In the six trials reporting initial DAS28, these ranged from a mean of 3.6 to a mean
of 7.0, with an average of 5.75.
TABLE 43 Baseline characteristics in established RA trials
Study Year Treatment
Age
(years)
RF
(% positive)
Disease
duration
(years) DAS28
ESR
(mm/hour) SJC TJC PGAa
cDMARDs
Ferraz et al.222 1994 MTX vs.
MTX/chloroquine
50 71 9 – – – – –
Tugwell et al.66 1995 MTX vs. CsA/MTX 55 – 11 – – 17 23 62
Wilkens et al.223 1995 MTX vs. MTX/AZA 54 – 8 – – – – –
Bendix et al.224 1996 PGT vs. PGT/CsA 55 81 11 – – – – –
O’Dell et al.67 1996 MTX vs. MTX/
SSZ/HCQ
50 84 10 – 36 27 29 60
Kremer et al.225 2002 MTX vs.
leflunamide/MTX
56 79 11 – – – – –
Dougados
et al.226
2005 SSZ vs.
leflunamide/SSZ
56 78 6 6.2 – – – –
Lehman et al.227 2005 MTX vs. MTX/
IM gold
51 67 3 – 29 11 21 42
Karanikolas
et al.228
2006 Leflunamide vs.
CsA/leflunamide
– – 7 – – – – –
Capell et al.229 2007 MTX vs. MTX/SSZ 56 68 1 3.6 – – – –
TNFis/methotrexate
Weinblatt
et al.230
1999 MTX vs.
etanercept/MTX
48 84 13 – – – – –
Lipsky et al.170 2000 MTX vs. 3mg
infliximab/MTX
54 84 10 – 49 22 32 70
Weinblatt
et al.231
2003 MTX vs. 40mg
adalimumab/MTX
57 369b 12 – – 17 28 55
Klareskog
et al.232
2004 MTX vs.
etanercept/MTX
53 76 7 5.5 – 22 34 –
Kay et al.233 2008 MTX vs. 50mg
golimumab/MTX
57 – 6 6.4 – 14 28 70
Keystone
et al.234
2008 MTX vs. 200mg
certolizumab/MTX
52 84 6 7.0 44 22 31 –
Smolen
et al.235
2009 MTX vs. 200mg
certolizumab/MTX
52 76 6 – 29 21 30 61
Kremer
et al.236
2010 MTX vs. 2mg/kg
golimumab/MTX
50 – 8 – – 16 27 60
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
American College of Rheumatology responses and withdrawals for inefficacy
In trials of DMARD combinations more patients achieved ACR20–70 responses with combination therapy
(OR 2.75–5.07), as shown in Table 44 and Figure 27. More patients withdrew with combination
therapy (OR 1.51, 95% CI 1.02 to 2.25). Sensitivity analysis of RCTs that included a methotrexate
monotherapy arm showed that more patients achieved ACR20–70 responses with combination therapy
(OR 3.55–4.74) but few patients withdrew because of inefficacy (OR 0.34, 95% CI 0.20 to 0.59).
TABLE 43 Baseline characteristics in established RA trials (continued )
Study Year Treatment
Age
(years)
RF
(% positive)
Disease
duration
(years) DAS28
ESR
(mm/hour) SJC TJC PGAa
Direct comparison
O’Dell et al.237 2013 MTX/SSZ/HCQ 58 66 6 5.8 27 11 13 54
O’Dell et al.237 2013 Etanercept/MTX 56 70 4.9 5.9 30 11 13 56
AZA, azathioprine; CsA, ciclosporin; HCQ, hydroxychloroquine; IM, intramuscular; MTX, methotrexate; PGA, patient global
assessment; PGT, gold aurothiomalate; RF, rheumatoid factor; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender
joint count.
a Scored out of 100.
b IU/l.
TABLE 44 Summary of outcomes in established RA trials
Outcome Treatment Studies
Random-effects analyses
OR (95% CI)
Categorical outcomes
ACR20 DMARDs (all) 6 2.75 (1.79 to 4.22)
DMARDs (methotrexate only) 4 3.55 (2.43 to 5.17)
TNFi/methotrexate 8 5.32 (3.03 to 9.34)
ACR50 DMARDs (all) 6 5.07 (3.10 to 8.29)
DMARDs (methotrexate only) 4 4.70 (2.40 to 9.20)
TNFi/methotrexate 8 8.13 (4.26 to 15.52)
ACR70 DMARDs (all) 5 4.85 (2.34 to 10.05)
DMARDs (methotrexate only) 3 4.74 (1.65 to 13.61)
TNFi/methotrexate 8 5.36 (2.92 to 9.83)
Inefficacy withdrawals DMARDs (all) 10 0.38 (0.24 to 0.62)
DMARDs (methotrexate only) 7 0.34 (0.20 to 0.59)
TNFi/methotrexate 8 0.12 (0.06 to 0.25)
Toxicity withdrawals DMARDs (all) 10 1.51 (1.02 to 2.25)
DMARDs (methotrexate only) 7 1.58 (0.97 to 2.59)
TNFi/methotrexate 8 0.94 (0.62 to 1.41)
WMD (95% CI)
Continuous outcome
Disability (HAQ) DMARDs (all) 3 −0.19 (−0.27 to −0.10)
DMARDs (methotrexate only) 1 −0.30 (−0.42 to −0.18)
TNFi/methotrexate 1 −0.35 (−0.56 to −0.14)
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In trials of TNFi/methotrexate combinations more patients achieved ACR20–70 responses with combination
therapy (OR 5.32–8.13), as shown in Table 44. Fewer patients withdrew because of inefficacy with
combination therapy (OR 0.12, 95% CI 0.06 to 0.25).
The trial comparing triple DMARD therapy with etanercept/MTX237 showed no statistical difference
between groups in ACR20 (57% vs. 66%), ACR50 (35% vs. 43%) and ACR70 (18% vs. 26%). This study
did not report patient withdrawals for inefficacy.
Disability
Five randomised trials of cDMARDs reported change in HAQ scores (Table 45).224–227,229 Only three of these
trials reported both mean changes and SDs for these changes.224–226 A combined analysis of these three
trials’ HAQ scores (see Table 45) showed that, overall, there were greater improvements with cDMARDs
than with DMARD monotherapy (WMD −0.19, 95% CI −0.27 to −0.10). Only one of these RCTs used
methotrexate as the monotherapy (see Table 45);225 this trial also showed greater improvement with
cDMARDs (WMD −0.30, 95% CI −0.42 to −0.18).
0.1
DMARD monotherapy Combination DMARDs
1 10 100
Study
Odds ratio
M–H, random, 95% Cl
Capell 2007229
Dougados 2006194
Karanilolas 2006228
Kremer 2002225
Lehman 2005227
Tugwell 199566
(a)
0.1
Methotrexate monotherapy TNFis methotrexate
1 10 100
Odds ratio
M–H, random, 95% ClStudy
Kay 2008233
Keystone 2008234
Klareskog 2004232
Kremer 2010236
Lipsky 2000170
Smolen 2009235
Weinblatt 1999230
Weinblatt 2003231
(b)
FIGURE 27 Forest plots of ACR20 responses in established RA: results for (a) cDMARD vs. DMARD monotherapy
trials; and (b) TNFi/methotrexate vs. methotrexate trials.
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For TNFi/methotrexate combinations five trials reported change in HAQ scores (see Table 45).231,232,234–236
In all of these trials there was an improvement in HAQ score in the combination arm. One trial reported
mean (SD) change in HAQ score (WMD −0.35, 95% CI −0.56 to −0.14).231
The trial that made a direct comparison between methotrexate/sulfasalazine/hydroxychloroquine and
etanercept/methotrexate reported mean HAQ scores at 48 weeks.237 There was no difference in HAQ
scores between triple DMARD therapy (0.93± 0.85) and etanercept/methotrexate (0.83± 0.81).
Toxicity
For cDMARDs, all 10 trials66,67,222–229 reported patient withdrawals because of toxicity. The overall OR for
withdrawal with combination therapy was 1.51 (95% CI 1.02 to 2.25). Seven66,67,222,223,225,227,229 of these
studies used methotrexate as the monotherapy arm; the OR for withdrawal was 1.58 (95% CI 0.97
to 2.59).
For TNFi/methotrexate combinations, eight trials170,230–236 reported patient withdrawals because of toxicity.
There were no significant differences between treatments, with an OR of 0.94 (95% CI 0.62 to 1.41).
The direct comparison trial237 did not report patient withdrawals because of toxicity.
Heterogeneity
The cDMARD trials showed no evidence of heterogeneity in ACR20–70 scores. In contrast, the TNFi trials
showed significant heterogeneity in ACR20 scores (p< 0.00001) and ACR50 scores (p< 0.0002) and
borderline heterogeneity in ACR70 scores (p= 0.06).
RESULTS
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Chapter 4 Discussion
The Tumour necrosis factor inhibitors Against Combination
Intensive Therapy trial
Key findings
Patients with active established RA who meet current NICE criteria to receive TNFis achieve equivalent
reductions in disability and improvements in quality of life over 12 months by treating initially with
cDMARDs and reserving TNFis for cDMARD non-responders. The cDMARD strategy costs substantially less.
However, neither treatment strategy was ideal. The majority of patients in both groups failed to achieve a
DAS28 of ≤ 2.6, which is often considered to indicate remission.
The DAS28 improved more rapidly in patients receiving TNFis. Overall, monthly DAS28 were lower in
patients receiving TNFis and more patients receiving TNFis achieved a DAS28 response (decrease in score
of ≥ 1.2) within the first 6 months. This benefit of TNFis with regard to the DAS28 response particularly
reflected rapid and sustained reductions in ESR in this group. However, the benefits of TNFis with regard to
the DAS28 response were small and did not result in improvements in disability or quality of life. There
was also no evidence that patients who received cDMARDs had more erosive progression. Larsen scores
showed that both groups had comparable, minimal radiological progression.
Serious adverse events and withdrawals because of toxicity were equally common with cDMARDs and
TNFis. However, the total number of adverse events, spanning both serious and more minor events, was
higher with cDMARDs. This was most marked for adverse reactions involving the digestive system.
As TNFis are more expensive than cDMARDs, the economic evaluation showed that the cDMARD group
was substantially more cost-effective, whatever approach was taken to assessing costs and relevant
outcomes. This included incorporating societal costs such as lost time from work and social security benefit
claims into the calculations.
In total, 44% of the patients in the cDMARD group were recommended to switch to a TNFi because their
disease activity had not improved after 6 months of treatment. However, there was no evidence that
patients who switched in this way had a worse quality of life, more disability or more erosive progression.
There was therefore no evidence that these ‘switchers’ had any long-term disadvantages from taking
cDMARDs for 6 months.
Limitations and sources of bias
Not all patients invited to participate agreed to do so; overall, 192 out of 432 patients (44%) declined to
take part in the trial. We cannot be certain that the patients who did not consent to the trial would have
responded in the same way as those who took part.240 However, this is only one of a number of causes
of bias in trials of long-term diseases241 and does not seem a crucial factor compared with the range of
issues influencing such trials. In addition, patient choice is of crucial importance and accepting that not
everyone will agree to participate is an inevitable consequence of informed choice around clinical trials.
In addition, as considered below, TACIT patients receiving TNFis were similar to those in the UK national
register (see pp. 90).
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Those patients who did not respond to cDMARDs in the TACIT trial were treated with TNFis. It could
therefore be argued that over time the two arms of the trial become very similar if not identical. However,
only a minority of patients were involved in switching, with 44% of patients who started cDMARDs
switching to TNFis in the second 6 months. As a consequence, the two trial arms remained sufficiently
different to make this a genuine comparison. Furthermore, the 6-month comparisons did not include any
patients randomised to cDMARDs who had received TNFis (because no-one switched until after 6 months).
Therefore, at 6 months there was a genuine head-to-head comparison within the TACIT trial. Switching
between treatment strategies is normal clinical practice and over time many RA patients starting DMARDs
or biologics will switch to other treatments.
The cDMARD treatment was not standardised and it could be argued that the therapy given was too
heterogeneous, making it an intervention that could be difficult to reproduce. This is an intellectual
challenge as the only way to standardise cDMARD treatment is to study early RA patients who are DMARD
naive or study methotrexate non-responders. These patients do not meet existing NICE criteria for receiving
TNFis. If anything, the cDMARD treatments used were too conservative. We had hoped that patients
would receive more intensive treatment and more short-term steroids in the cDMARD arm. However,
supervising clinicians and patients placed more emphasis on slowly changing treatment to limit toxicity
rather that giving maximal-dose therapy as soon as possible. Over time we anticipate that the use of
cDMARDs will increase and concerns about toxicity may consequently lessen. We also accept that some
combinations may be more effective, although this could not be resolved in the TACIT trial. More trials of
different cDMARDs would be needed to answer this question.
Steroid use in the cDMARD group, including intramuscular injections, was less than anticipated when
designing the TACIT trial based on our previous experience with steroids in established RA.242 UK
rheumatologists may have concerns about treating many patients with steroids because of the risk of
adverse events. However, the relatively limited use of steroids would serve to reduce rather than magnify
the impact of cDMARDs. More intensive steroid use could make cDMARD treatment even more effective.
It could be argued that the same results could have been obtained from starting another DMARD
monotherapy and that the use of intensive DMARD combinations in the TACIT trial was not needed. This is
a theoretical rather than a practical issue as there is no reason to stop one DMARD and start another in
active RA in the absence of adverse events. DMARDs often have long half-lives, particularly agents such as
leflunomide. Consequently, washing out current DMARDs and then starting a new DMARD monotherapy
has limitations for patients as well as being of limited interest as the toxicity of modern DMARDs used in
combination is not excessive.
The use of DMARDs other than methotrexate in combination with TNFis could have reduced the efficacy of
these treatments in some patients. However, to do otherwise would be to move away from current UK
practice, in which a range of DMARDs are given with TNFis. There is some evidence supporting the use of
these different DMARDs in combination, as shown in our systematic reviews.
The use of the HAQ as the primary outcome measure might be viewed by some experts as being
inappropriate, as the opportunity to reverse HAQ scores decreases with increasing disease duration.243,244
Although this is theoretically correct, both of our groups showed clinically relevant reductions in HAQ
scores over 12 months. In addition, the disease duration of patients in the TACIT trial (median duration
of < 6 years in both groups) was below that in the Phase III trials that have led to the approval of the
different TNFis. Furthermore, the degree of reduction in HAQ scores in the TACIT trial was similar to that
reported in previous trials of biologics. In our view, if TNFis do not substantially reduce HAQ scores
compared with other treatments then their potential clinical value is limited.
DISCUSSION
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The TACIT trial was not a blinded trial. It could be argued that being unblinded influenced patients and
clinicians to favour cDMARDs inappropriately. However, it was impractical to have a fully blinded treatment
strategy involving multiple drugs, all of which need careful monitoring. Given the enthusiasm of most
clinicians and most patients for receiving high-cost biological treatment, we consider that unblinding
would, if anything, benefit TNFis. The issue of blinding is related to a number of ethical matters; these are
considered in detail in the subsequent section on ethical issues.
The TACIT trial and similar trials of efficacy are not able to completely assess the relative impacts of
different types of adverse event on clinical outcomes. Many adverse events reported in patients taking
cDMARDs in the TACIT trial, particularly gastroenterological events, may have been relatively minor. Many
patients might have felt that the treatment was ‘worth it’, irrespective of these adverse events. Although
we collected detailed information about such adverse events, we did not assess their specific impacts on
patient outcomes and whether they affected patients’ quality of life. We are therefore not able to fully
determine the clinical consequences of such adverse events. Large long-term observational studies are
needed to fully assess the impact of adverse events on treatment outcomes. Despite this limitation, the
data that we collected in the TACIT trial on serious adverse events and adverse events linked to stopping
treatment provided no evidence that there were more such events in the cDMARDs group than in the
TNFis group.
The trial involved dividing patients into two groups after 6 months based on change in DAS28: responders
and non-responders. This approach resulted in 46 out of 104 (44%) patients switching to TNFis after
starting with intensive DMARDs. However, more than half (56%) of patients did not switch. This simple
concept hides a more complex problem. Patients can fall on one side and then the other of such an
arbitrary response without there being a major change in their condition, and the duration that patients
remain within a defined state is not captured using such as approach, a problem discussed by Farewell
and Su.245 This general issue applies whenever arbitrary cut-offs are used at single time points in
longitudinally collected data. It shows the difficulty of comparing the extent to which patients benefited
from treatment.
Analytical issues
The TACIT trial was analysed on an ITT basis using multiple imputations and the primary outcome was
compared using logistic regression methods. The HAQ is a complex assessment and it does not invariably
behave as a conventional numerical scale.246 There are identical issues with regard to the linearity of the
scales of other key outcome measures, including the EQ-5D and Larsen scores. As both trial arms gave very
similar outcomes using the HAQ, EQ-5D and Larsen scores, there is little merit in such an argument.
In addition, the overwhelming balance of advice that we received favoured the analytical method that
we preselected.
Not all of the outcomes confirmed equivalence. Changes in DAS28 and ESR favoured TNFis, particularly
within the first 3–6 months. In part, this reflects the rapid onset of response with TNFis and the slow
onset of response with DMARDs, which historically, and probably more accurately, used to be known as
slow-acting drugs. Most DMARDs show maximal effects only by 6 months.
Measurement issues
There are several relevant measurement issues when measuring HAQ scores, radiological progression
and DAS28. The HAQ was the primary outcome measure and its validity as an assessment instrument is
therefore of most concern. The validity, reliability and responsiveness of the HAQ were reviewed by
Linde et al.158 Overall, the HAQ has appropriate measurement properties for a patient-generated outcome
measure. It is not necessarily a simple scale and Rasch analysis by Wolfe247 and Tennant et al.246 have
highlighted some relative weaknesses. Our own previous research contributions suggest that the HAQ is
the best available measure to use in trials such as the TACIT trial.145,248,249
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There is debate about the minimum clinically important difference in HAQ score in routine practice as
opposed to clinical trials. Pope et al.250 suggest that this is smaller than the difference that is considered
important in trials. From this perspective the change in HAQ score in patients randomised to receive
cDMARDs, which was overall 0.15 greater than that seen in patients randomised to receive TNFis, might
be clinically relevant. However, this perspective appears questionable. We predetermined the minimum
clinically important difference in HAQ score in trial settings and believe that it is inappropriate to change it
retrospectively. It is also a theoretical rather than a practical issue as our aim was to show that the TNFi
strategy was not better than the cDMARD strategy; showing that the cDMARD strategy has benefits is an
identical conclusion in terms of its influence in clinical practice.
The use of Larsen scores to assess erosive damage merits consideration. The radiographs were all scored
using the modified Larsen method by one investigator (DS), who has contributed to a number of published
trials using this method and has achieved appropriate reproducibility of scoring.171,242,251–260 There is debate
about the relative merits of different approaches to scoring radiographs. The TACIT trial followed the
approach taken in the British Rheumatoid Outcome Study Group (BROSG) trial in established RA261 and we
have no reason to doubt its validity or appropriateness.
The TACIT trial used the DAS28, which was scored by many clinicians in different clinics. Each centre
received detailed information during initiation on the methods of scoring the DAS28.262 However, we did
not give either explicit standardisation training nor did we retrain observers periodically to assess whether
or not they maintained consistent standards. There are challenges in assessing patients using the DAS28.263
Although training increases clinicians’ short-term agreement when measuring joint counts,264 the overall
benefit of such training is uncertain.265 Training is useful within the national context to deliver high-quality
care, but its value in an individual clinical trial is limited. As the TACIT trial is a strategy trial within
routine care settings we consider that it needs to replicate standard methods and should not adopt more
stringent approaches because these would limit its generalisability.
Strengths of the Tumour necrosis factor inhibitors Against Combination
Intensive Therapy trial
The TACIT trial was undertaken in outpatient rheumatology clinics in England in conditions that, as far as
is possible within a clinical trial, mirrored routine practice. The patients enrolled were typical of those
treated within England and included patients from a range of ethnicities and levels of deprivation. They are
similar to those reported in the British Society for Rheumatology (BSR) Biologics Register.266 A comparison
between patients enrolled in the BSR Biologics Register and those enrolled in the TACIT trial is shown in
Table 46. As there is evidence that the patients enrolled in the BSR Biologics Register have changed over
TABLE 46 Comparison between patients enrolled in the BSR Biologics Register and TNFi patients in the TACIT trial
Outcome Time
BSR Biologics Register (by year)235 TACIT TNFi cases
2001 2002 2004 2004 2005 2006 2007 2008 ITT Completers
n 119 1206 2930 3138 1553 1056 782 432 101 75
Mean HAQ
score
Baseline 2.21 2.14 2.10 2.04 1.98 1.95 1.87 1.87 1.90 1.84
6-month
change
0.26 0.33 0.32 0.32 0.34 0.33 0.33 0.32 0.35 0.41
12-month
change
0.31 0.33 0.33 0.33 0.34 0.35 0.34 0.37 0.30 0.38
Mean DAS Baseline 6.77 6.75 6.67 6.56 6.51 6.41 6.34 6.38 6.30 6.28
6-month
change
2.08 2.20 2.17 2.33 2.33 2.29 2.26 2.31 2.07 2.35
12-month
change
2.03 2.33 2.35 2.41 2.46 2.38 2.46 2.32 2.41 2.84
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time, data from all available years are shown. For the HAQ and DAS28, patients in the TACIT trial had
similar initial scores and similar changes in scores (in the TNFi group) to those of patients most recently
enrolled in the BSR Biologics Register.
The TACIT trial focused on patient-centred outcomes. We consider this vital because such patient-centred
outcomes have a central place in clinical trials in RA. Changes in measures such as the ESR, although of
interest to clinicians, are of limited value to patients. There are also concerns about the interobserver
reproducibility of assessing joint counts.
The TACIT trial was of sufficient size to provide robust assessments of the changes in measures. In addition, it
showed benefits favouring cDMARD treatment. In other words, cDMARDs give somewhat better outcomes
than just achieving equivalence. Although we do not think that the trial shows that cDMARDs are preferable,
the chance of the conclusions being incorrect and of TNFis being better appears remote.
The TACIT trial showed that only a minority of patients randomised to TNFis achieved DAS28 of ≤ 2.6 and
the use of cDMARDs also resulted in relatively few DAS28 of ≤ 2.6. These low scores are often considered
to reflect remission although, as discussed earlier, defining remission is an ongoing challenge. The
frequency of such ‘remission scores’ in the TACIT trial is similar to that reported by both the BSR Biologics
Register266 and other international registers of patients receiving TNFis in routine clinical practice267–271
(Table 47). In addition to achieving few single low DAS28 of ≤ 2.6, few TACIT trial patients achieve
sustained remission. There is a need for more research on the nature and predictors of sustained low
DAS28 and other indicators of remission, but this problem lies outside the remit of the TACIT trial.
TABLE 47 Disease Activity Score for 28 Joints remission rates in TNFi registries: comparison of DAS28 remission
rates at 6 and 12 months in registries of RA patients receiving a first TNFi
Registry
TACITBSR BR266 CORONA267 DANBIO268 DREAM269 GISEA270 RABBIT271 Overall
Patients, n 11,216 326 1839 1531 591 775 16,278 101
6-month DAS28
remission rate (%)b
14 25 21 27 26 – 17a 15
12-month DAS28
remission rate (%)b
16 29 – – – 16 17a 23
BR, Biologics Register; CORONA, Consortium of Rheumatology Researchers of North America; DANBIO, Danish Registry for
Biological Therapies in Rheumatology; DREAM, Dutch Rheumatoid Arthritis Monitoring; GISEA, Gruppo Italiano di Studio
sulla Early Arthritis (Italian Group for the Study of Early Arthritis); RABBIT, Rheumatoide Arthritis: Beobachtung der
Biologika-Therapie (Rheumatoid Arthritis – Observation of Biologic Therapy).
a Per cent patients achieving remissions in all studies with data at 6 or 12 months; larger studies had most influence on
average per cent.
b Per cent patients from whom data were available at 6 or 12 months.
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Economic evaluation
Key findings
The economic evaluation indicates that initiating treatment with cDMARDs produces similar HAQ and
QALY outcomes at 6 months as initiating treatment with TNFis, at a significantly lower cost (from all cost
perspectives). By 12 months, the cDMARD approach additionally brings advantages as measured using the
HAQ (−0.16, 95% CI −0.32 to −0.01), although a difference of this size is not considered to be clinically
significant and so this approach can thus be regarded as being clinically similar to the TNFi approach.
The cost advantage in the cDMARDs group is almost entirely due to cDMARD medications being cheaper
than TNFis.
In the cDMARDs group, costs at 12 months are significantly larger than at 6 months because of the high
proportion of the group who switched from cDMARDs to TNFis at 6 months. Given that there is no
outcome disadvantage in the cDMARD arm at 6 or 12 months, there may be some merit in a strategy of
initiating treatment with cDMARDs as this incurs lower costs for those who remain on that treatment and
delays the additional costs associated with TNFis for those who go on to switch treatment.
These findings are likely to be robust because of the breadth of the cost perspectives taken and the
individual-level nature of the data, which represents the variation in the sample. A pragmatic trial design
performed within NHS settings also makes the findings applicable to the NHS.
Limitations
The economic evaluation has one notable limitation. Taking a broader cost perspective and a multicentre
approach necessitated collating data by self-report questionnaires, which carries the risk of recall bias.
Although we collected the CSRI data at 6 and 12 months, we limited the recall period to the previous
3 months to guard against recall inaccuracies. The disadvantage of this approach was that it necessitated
extrapolating cost data to represent the full 6-month periods. This approach may not accurately reflect any
variations that may exist across the measured and non-measured periods. However, we did have data for
trial medication use over the entire period of follow-up and any biases associated with recall of other
resource use would not be expected to impact on the findings given the dominance of trial medication
costs. We also have no reason to believe that any such recall bias would differ by randomisation group.
We accept that there was a theoretical possibility that patients switching from cDMARDs to TNFis might
have resulted in the introduction of some bias, although many patients did not switch treatment until
month 9. It could also be argued that we should also have reviewed patients’ medical records to ensure
that no major health-care costs were missed. However, this would be unachievable over multiple sites that
were dispersed throughout England and which collect clinical data in a variety of different ways. In any
case, there is no evidence to suggest that the groups completed the CSRI in different ways. In addition,
the differences in costs between groups were almost entirely accounted for by the treatment costs and all
trial medication use was directly recorded each month for all patients in the trial.
Economic modelling
Our economic analysis used data from within the trial only. It could be argued that long-term modelling
is needed to make a more convincing case for different treatment strategies including both the more
extensive use of cDMARDs and the role of TNFis in non-responders to conventional DMARDs with
active RA.
Marra et al.126 have outlined the reasons for carrying out long-term modelling studies to justify the use of
high-cost treatments including TNFis and other biologics in RA. Barton et al.272 provide similar justifications.
The key points are as follows:
l Randomised controlled trials of biological treatments for RA are too short to capture relevant long-term
costs and outcomes. Decision models that extrapolate the evidence from RCTs to longer-term
outcomes are needed to meet the requirements of policy-makers.
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l Such models can link intermediate end points such as HAQ score with final health outcomes such as
death, morbidity and employability.
l Because only a minority of RCTs collect relevant data about both costs and health-related quality of life,
it is important to use economic models to relate clinical benefits to economic outcomes.
l The constraints inherent in all RCTs limit the generalisability of their findings for routine clinical care.
Modelling can help translate their findings into different clinical settings.
Without the use of long-term modelling it would be challenging to justify the use of high-cost biologics
such as TNFis in RA. However, this approach has been accepted and the balance of opinion, summarised
by Bathon and McMahon,273 is that TNFis are now the preferred next step when methotrexate and
DMARD monotherapy have proved insufficient.
The economic case for using conventional DMARDs more intensively, including assessments of potential
long-term benefits, is somewhat different. It has been reviewed by Fautrel,274 who stressed the following
key points:
l As RA medical costs increase with rising disability levels, delaying sustained disability by better disease
control will have economic benefits.275
l These benefits will be largest when outcomes can be improved by optimising low-cost treatments,
including conventional DMARDs and glucocorticoids.
l Early combination treatment with cDMARDs and glucocorticoids gives better efficacy at lower costs and
its benefits extend over time.276,277
l Increasing the intensity of low-cost treatment, for example by adding modified-release prednisone to
synthetic DMARDs, reduces the proportion of patients eligible for biologics, resulting in substantial cost
savings. These economic benefits increase when the effects of modified-release prednisone persist.278
Other groups have provided evidence that cDMARDs are cost-effective in RA.279,280 The evidence is
strongest in early RA with there being less information about established disease.
Showing that the use of cDMARDs before the use of biologics such as TNFis is cost-effective in the long
term requires different sorts of modelling studies from those required to establish the cost-effectiveness of
TNFis. It requires information about the persisting effects of cDMARDs beyond 12 months, including
evidence that their clinical benefits are sustained and more information about their potential long-term
risks. None of this crucial information is currently available. The duration of both RCTs and observational
studies is usually too short to provide definitive assessments of medium- to long-term RA outcomes.
Despite the potential importance of long-term modelling, it falls outside the scope of our research goals in
the TACIT trial. As cDMARDs have been used for many years without major toxicity concerns and as the
TACIT trial shows that their use is cost-effective in the short term, we are unconvinced that there is a need
to measure their overall long-term cost-effectiveness compared with biologics. Although we cannot
estimate the overall extent of any savings, all of the evidence suggests that their use along the lines
adopted in the TACIT trial is effective and cost-effective and has no identifiable risks.
Finally, we analysed patients from the economic perspective within their original groups. Although some
patients in the cDMARD group switched to TNFis after 6 months, we have not analysed these separately
from the economic perspective, although we have provided a separate analysis for clinical outcomes. From
the clinical perspective we wished to make certain that there was no disadvantage for patients from either
remaining on cDMARDs or switching to TNFis. Our analysis provided no evidence that this was the case
in terms of disability, quality of life, disease activity or erosive damage. From the economic analysis it is
unclear that comparisons of patients who remained on cDMARDs with those who switched to TNFis would
provide relevant information. If all patients switched to TNFis this would clearly have meant that the
cDMARDs strategy was not a viable strategy. However, enough patients remained on cDMARDs to ensure
that there was still an economic benefit from the cDMARD strategy in the second 6 months of treatment.
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Analysing data for patients who remained on cDMARDs separately from data for those who switched to
TNFis in the second 6-month period would show that remaining on cDMARDs cost less; however, this
inevitable finding might overemphasise the benefits of cDMARDs.
Clinical implications
This economic evaluation suggests that, at 6 months and 12 months following randomisation, cDMARDs
are a more cost-effective treatment approach for RA as the cDMARDs group achieved similar outcomes as
the TNFi group at a significantly lower cost.
Systematic reviews
Key findings
Compared with DMARD monotherapy, including methotrexate monotherapy, these systematic reviews
show that combination treatment regimens involving either cDMARDs or TNFis with methotrexate were
both superior in terms of ACR responses, reduced withdrawals because of lack of effect, reduced disability
scores and reduced erosive progression. The findings are similar in early and established RA. The three
head-to-head trials in early RA gave similar findings.
In our systematic review, HAQ scores showed a WMD in favour of cDMARDs, including methotrexate,
of −0.30 and a WMD in favour of TNFis combined with methotrexate of −0.35. Interestingly, a systematic
review of clinical trials of leflunomide in active RA,281 one of the most intensively studied DMARDs, showed
a WMD in favour of leflunomide at 6 months of −0.43 (95% CI −0.52 to −0.33) compared with placebo
in three trials involving 387 patients receiving leflunomide and 292 control patients.281 These results with
leflunomide suggest that starting a new DMARD is likely to have the same impact on HAQ scores as
starting a new biological treatment.
Compared with the substantial benefits of combination treatments, there appeared to be relatively little to
choose between cDMARDs and TNFis combined with methotrexate. There are some potential benefits of
TNFi/methotrexate combinations in that there appear to be fewer withdrawals for toxicity and there was
some evidence that ACR responses occurred more rapidly with biological treatments. Not all evaluations
have drawn a similar conclusion; some reviews conclude that biologics have more advantages than
cDMARDs and others are less optimistic about combination treatment approaches in general. Of interest
are two observational studies of the impact of DMARDs compared with TNFis. Analysis of data on
DMARDs from a national register collected in Germany271 and from an observational study in the UK282
resulted in very different conclusions. The German register considered that DMARDs were relatively
ineffective whereas the UK study found that they were often highly effective in patients who met the
criteria for receiving TNFis. Non-randomised studies can often result in very different conclusions.
The main implication from our systematic review was the need for head-to-head studies that directly
compare the clinical effectiveness and cost-effectiveness of cDMARDs with those of biologics in established
RA. The TACIT trial fitted exactly with this requirement. A broader outstanding challenge is to identify how
best to integrate the use of DMARD combinations with biologics so that the maximal number of patients
achieve the best possible response in an effective and cost-effective manner. These issues extend beyond
the TACIT trial and indicate the need for an ongoing research programme in the field.
Limitations
Our systematic reviews have several limitations. First, only three RCTs directly compared cDMARDs with
TNFi/methotrexate combinations and all of these were in early RA. Although we have relied more on
indirect comparisons, these are invariably less informative than direct comparisons. Second, there was
diversity in the range of cDMARDs used and some are not commonly used in clinical practice, for example
bucillamine and doxycycline. However, we felt that these agents should be included in the meta-analysis to
avoid bias and because we are examining the concept of DMARD combinations rather than the effects of
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specific combinations. Third, there were differences in the designs of the trials. Some trials, such as BeSt,
used a tight-control regimen whereas others, such as the CARDERA trial, used a step-down design.
There are also technical limitations in assessing RA outcomes in trials. First, not all studies report the same
measures in the same way. Such variability in reporting affected HAQ scores and radiological assessments.
Second, not all studies had the same duration of treatment; early findings may mask longer-term
limitations and therefore some comparisons may be flawed. Third, erosive damage was conventionally
assessed using plain radiographs, and newer imaging methods, particularly ultrasound and MRI, may show
benefits of one form of combination therapy that are not seen using conventional radiography. Fourth,
reporting of adverse events is variable and assessing withdrawals because of side effects is open to
criticism as a crude evaluation of a complex issue. A fifth problem is that conventional clinical measures
may miss important improvements with biologics, for example work disability may be particularly
reduced by TNFis. Finally, the studies may have recruited patients with different initial disease activities.
We examined the entry criteria and baseline measures in all studies. Although they showed a degree of
variability, all patients had active disease and there was no evidence that patients receiving cDMARDs had
less active disease than those receiving TNFi/methotrexate combinations.
We mainly focused on trials in which methotrexate monotherapy was used as the control treatment.
We considered that this provided the best approach for comparing cDMARDs with TNFi/methotrexate.
On balance, we believe that it preferable to standardise different DMARD combinations against
methotrexate monotherapy, especially in early RA, as trials with less effective monotherapy arms create
uncertainty when interpreting the findings.
Strengths
Both systematic reviews were large and they each enrolled > 5000 patients. They also showed very similar
findings and the head-to-head trials gave similar supportive results. The findings in the TACIT trial are
replicated in the different trials comparing cDMARDs and TNFi/methotrexate combinations with DMARD
monotherapy, indicating that the trial results are likely to be generalisable.
Ethical issues
Trial design
The last decade has seen substantial progress in trial designs.283 Regulatory pathways that demonstrate
efficacy of new therapeutic agents have been agreed. The use of pure placebo treatment beyond
12–16 weeks is no longer considered ethical and consequently background therapy and early rescue has
become regular practice. Identification of rare adverse events associated with new therapies has resulted in
intensive safety evaluation during RCTs, a greater focus on post-marketing surveillance and use of
registries, particularly for biological agents such as TNFis.
A crucial question before starting the TACIT trial was whether or not the trial was genuinely ethical. This is
because the TACIT trial potentially involved restricting access to TNFis in patients with RA who met the
criteria to receive these agents. This section deals with the relevant ethical issues. Although observational
studies often provide similar results to those of randomised trials,284 these similarities are not universal,285
and clinical practice is unlikely to change in the absence of clinical trials that establish equivalence between
cDMARDs and TNFis
Risks and anticipated benefits for trial participants and society
Equipoise, or the uncertainty principle, is a key requirement for RCTs in which the best treatment
must be unknown so that participants do not suffer harm by assignment to one particular arm.286,287
Alternative ethical approaches to RCTs have not gained universal acceptance and strategies such as
equipoise-stratified randomisation are not widely used.288–291
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Equipoise in individual patients reflects not only the scientific probabilities of particular outcomes (known
to trial clinicians) but also the value that individuals place on particular outcomes or risks (known only to
individual patients). The solution to varying individual patient equipoise is genuine consultation with each
patient about the choices using clear written information; similar approaches can be used with referring
clinicians. It is difficult to ascertain the level of equipoise across the patient community for two reasons.
First, patients hold highly variable views on the impact of and risks from adverse events to drug treatments.
Second, patients also have highly variable views on the severity and ultimate outcome of RA.292,293
Community equipoise is essential for a RCT to be ethical. We considered that there was sufficient
equipoise among rheumatologists on when to use TNFis to justify our proposed RCT. Rheumatologists vary
markedly in prescribing these agents. Discussion with consultant rheumatologists suggests that TNFis are
felt to be highly effective but there is debate on which patients should receive them (in terms of severity
and stage of disease), on their long-term risks and benefits and on their advantages over maximal existing
therapy. There is also uncertainty, especially among public health clinicians, about their cost-effectiveness.
Concerns for patients entering this trial
Apart from general concerns about randomisation, especially for individuals who do not perceive true
equipoise between treatments, there was a specific emotive concern about ‘entitlement’ to anti-TNF
agents. Initially, many UK patients believed that, compared with the USA and continental Europe, they
were deprived of these agents on financial grounds. This was exacerbated by intense pharmaceutical
company involvement with clinicians and some patient organisations and by media presentation of these
agents as ‘miracle cures’. Alternatives such as cDMARDs, which are relatively inexpensive and can be
prescribed generically, have not received the same amount of attention either in the general media or in
information provided to patient groups. As access to TNFis remains variable, patients and clinicians may
perceive the proposed trial as an additional means of inhibiting access. However, a strategy is needed as
biologics cannot be given ‘on demand’ in our resource-limited health system, because of their long-term
costs (reflecting high production costs), the need for indefinite treatment, their uncertain cost-effectiveness
and the many new biologics coming on stream (e.g. abatacept and rituximab).
Public issues and concerns
In the authors’ opinion a national strategy for using TNFis is required, taking into account the extensive
new emerging information about these treatments. The adoption of new agents goes through several
phases. Initially, they are considered safe and effective. Adverse events are underestimated at this stage,
reflecting selective recruitment to clinical trials, careful patient follow-up in trials, the expertise of the
research clinicians and the small numbers of patients treated; efficacy is overestimated for similar reasons.
The next phase of drug adoption involves a reaction against the agent precipitated by unexpected side
effects and the recognition that the agent does not fulfil all of its initial promise. TNFis are leaving the
initial phase as many patients do not respond, those who do respond require continual treatment and
large studies have been published describing more accurately rare, serious complications such as infection
and cancer. They now need to enter the final stage of drug adoption, in which their advantages and
disadvantages are seen in a balanced light. We believe that the TACIT trial is therefore timely from the
perspective of both patients and recruiting clinicians.
Informing potential participants of benefits and risks
Potential participants were identified by rheumatologists and specialist nurses in routine clinics at
participating centres. They received a brief summary of relevant information about the trial including
information on the key risks and benefits. Those patients who were interested received a full
patient information sheet explaining in plain English the purpose of the study and the actual and
potential risks and benefits of DMARD combination therapy compared with the risks and benefits of
treatment with TNFis. The patient information sheet was drawn up by the investigators and patient
representatives based on the analysis of risks and benefits in this application. Advice was sought from
the full trial patient representatives group and the Trial Steering Committee before submission to the
relevant research ethics committee.
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Clinical implications
General implications
Tumour necrosis factor inhibitors and other biological treatments have revolutionised the treatment of RA
and other inflammatory immune disorders. The TACIT trial underlines the need for patients to have
ongoing access to these treatments. There is no evidence in the TACIT trial to indicate that TNFis do not
have a crucial role in the treatment of RA.
Clinical implications
A range of leading experts helped devise existing NICE guidance for the use of TNFis in active RA,81 which
was based on extensive reviews of RCTs and associated observational studies. The rationale for using TNFis
is mainly derived from extrapolating the results of these placebo-controlled trials using modelling studies
that examine the health economic benefits of TNFis, with the help of historical data from observational
studies. Before the TACIT trial there have been no head-to-head trials comparing TNFis with effective
alternative treatments in established RA.
There have been three head-to-head trials of cDMARDs compared with TNFis in early RA. These trials
all show that treatment strategies starting with cDMARDs or with TNFis give equivalent results over
12–24 months. As a consequence, there is no strong indication to start TNFis in preference to cDMARDs in
early RA patients. Current NICE guidance, in our view, correctly recommends that cDMARDs are used
in active early RA.72
The balance of current evidence suggests that the key role of TNFis in RA is in active disease that is not
fully controlled by DMARDs. Placebo-controlled trials have established the efficacy of TNFis. Observational
studies in registries have confirmed their safety. However, neither approach has identified how best to use
them. We consider that defining their optimal use requires undertaking head-to-head trials of different
treatment strategies. Although more than a decade has passed since their introduction, we still do not
know their value as short-term tapered treatments or whether they should be given to selected subsets
of patients.
If TNFis were low-cost treatments there would be little concern about their optimal use. However, they are
among the most expensive of those treatments that are used for relatively common diseases. As a
consequence, the payers for health care wish to ensure that their use delivers true ‘value for money’.
If TNFis ensured that most patients with active RA who received them entered a period of sustained
remission, there would be relatively little difficulty defending their widespread use. However, the TACIT
trial and all other trials and observational studies show that only a minority of patients with active RA who
receive TNFis achieve sustained remission.
Tumour necrosis factor inhibitors are usually simple for patients to take, adverse events are relatively
uncommon and the onset of their effect is usually fairly rapid. Therefore, if cost was not an issue most
patients would probably prefer to take TNFis rather than try cDMARDs.294 However, this is probably
the wrong question to ask. As neither strategy in the TACIT trial ensured that most patients with active RA
enter remission, the real need is to identify more effective and more cost-effective treatment strategies.
The TACIT trial therefore shows that the current approach to using TNFis in established RA, encapsulated
within current NICE guidance, does not necessarily result in cost-effective outcomes in all patients.
We do not consider that using cDMARDs followed by TNFis represents an ideal approach. Instead, further
research is needed to identify more effective treatment strategies. For the present it appears preferable
to ensure that patients with active established RA receive the most clinically effective and cost-effective
treatment possible. From this perspective offering cDMARDs before TNFis appears to be appropriate
and sensible.
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The model of care used in the TACIT trial assumed that all patients with active established RA should be
offered similar treatment. Using this approach some patients achieved a very good response with TNFis,
a slightly small number of patients achieved a very good response with cDMARDs, a few patients
achieved a very good response when they received TNFis after failing to respond to cDMARDs and most
patients had a relatively poor response to all treatments. Universal treatment strategies do not appear
to be very effective. The most sensible approach would be to individualise care.295,296
Research implications
Most clinicians consider that TNFis are highly effective treatments for active RA. However, we have found
them to be no better than intensive cDMARDs for many patients. One reason for clinicians favouring them
is their rapid onset of action. Another reason is that patients enrolled in early trials of biologics had more
severe RA than is normally seen in current routine practice.297 As a consequence, the benefits of biologics
in these trials may have appeared greater that the benefit that would be likely to occur when they are
used in routine practice settings. In addition, there is extensive evidence, at least in some countries, that
patients starting biologics in clinical practice have far milder disease than patients in clinical trials,298–301
making the translation of research findings into practice recommendations particularly challenging.
The TACIT trial was a strategy trial that required patients to attend outpatient clinics for monthly review
and involved substantial efforts from both patients and the rheumatologists and specialist nurses in the
collaborating centres. Before the start of the trial there were concerns about the ethics of asking patients
to wait for biological treatments and whether or not patients would wish to participate. One important
conclusion from the TACIT trial is that comparative trials of high-cost treatments are feasible in long-term
disorders such as RA. Patients and clinicians are willing to take part in such trials and when they are
undertaken in routine clinic settings they can deliver results of potential clinical relevance.
The TACIT trial involved giving patients intensive cDMARD treatments that were organised by specialist
nurses and supervised by rheumatologists. Although some training was provided in the specific
organisation of the trial, this did not include detailed training about how to deliver intensive DMARD
combinations. Nevertheless, specialist nurses achieved this without any difficulties being encountered.
A second general conclusion therefore is that rheumatology specialist nurses have sufficiently high levels of
clinical skills to deliver more intensive DMARD combination therapy. It would therefore be possible to
deliver this management strategy within existing specialist centres using currently available staff.
Finally, the costs of undertaking the TACIT trial merit consideration. The trial was funded by a substantial
grant from the National Institute for Health Research Health Technology Assessment programme and
without this grant it could not have been undertaken. However, the savings from not prescribing TNFis
within the TACIT trial to patients who met the criteria for receiving theses biologics but who received
cheaper DMARDs meant that the overall cost of the TACIT trial to the NHS was relatively small. Therefore,
we consider that it is possible to undertake further strategy trials of high-cost treatments such as TNFis
for minimal additional costs to the NHS as a whole. Many NHS patients receiving high-cost biologics for
arthritis could be enrolled in strategy trials such as the TACIT trial to help the NHS identify the most
effective and cost-effective ways to use high-cost treatments.
The TNFis used in the TACIT trial and a number of other biological agents in RA are licensed within Europe
and North America for treating active RA. The Phase II and Phase III development programmes for these
agents have all been funded by their manufacturers and have used broadly similar trial methods, focusing
on patients who have failed to respond to treatments such as methotrexate either remaining on this
treatment or taking an additional biologic. Such trial designs are efficient in establishing whether or not
the biologics are effective. However, the regulatory process does not involve head-to-head comparisons of
biologics with effective standard treatments. It is likely that the widespread adoption of the current
approach by regulatory agencies might have overemphasised the benefits of biologics compared with
other less expensive forms of treatment. Clearly this a complex issue as there is a balance between
the complexity and duration of the regulatory process and the need to obtain full information about the
DISCUSSION
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relative value of new treatments. In our view there are advantages in placing head-to-head trials with
effective comparators at some point in the regulatory pathway, an assessment that has been made
by others.302,303
Tumour necrosis factor inhibitors achieve rapid improvements in the ESR and other measures of disease
activity compared with conventional DMARDs. Indeed, some licensed DMARDs, such as ciclosporin, have
little impact on the ESR. The use of composite measures to assess treatment response in RA, such as
the DAS28 and ACR response, is likely, in our opinion, to unduly favour TNFis. The impact of TNFis on
measures such as the HAQ and EQ-5D, which are more reflective of patients’ overall status, is less marked.
We are unconvinced that the disproportionate impact of TNFis on laboratory measures such as the ESR is
of clinical consequence, and it may lead to an overemphasis on improving laboratory as opposed to
clinical measures. In the TACIT trial we found that this rapid improvement in ESR was not immediately
related to decreases in clinical measures of direct importance to patients, such as falls in tender and
swollen joint counts. The development of the current assessment methods in clinical trials in RA, which
date back to the 1990s, is based on expert opinion rather than direct evidence. Although the approach is
likely to reduce sample sizes in trials, it may favour some forms of treatment over others. One way of
minimising this risk is to ensure that trials use a wide range of measures. Using changes in some measures,
such as the DAS28, to model changes in other measures, such as the HAQ and EQ-5D, seems
particularly inappropriate.
The economic case for using biologics such as TNFis in RA depends on extrapolating the results of
placebo-controlled trials and using historical data from observational cohorts of previously treated patients.
This approach involves two challenges. First, it is difficult to be certain how non-biological treatments
would affect RA patients over time. Many of the models assume that they would not do well but there is
limited evidence to support this view. Second, the data used for modelling are often historical and changes
in the severity and natural history of treated RA may mean that these historical data have limited relevance
to current patients. We consider that the economic rationale for using biological treatments should involve
more emphasis on directly collected information from clinical trials and give less emphasis to theoretical
modelling over long time frames.
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Chapter 5 Conclusions
Key finding
The TACIT trial showed that RA patients who have failed to respond to methotrexate and another DMARD
show clinically important improvements over 12 months if initially treated with cDMARDs, reserving TNFis
for non-responders to these combinations. These improvements were equivalent to those achieved by
starting all patients on TNFis with methotrexate or another DMARD monotherapy. The cost of the
approach focused on using cDMARDs initially is approximately half the cost of using TNFis during the first
12 months of treatment. The equivalence of cDMARDs and TNFis is confirmed in systematic reviews of
published trials in both early and established RA.
Health-care implications
The results from the TACIT trial, together with the results of the systematic reviews of previous trials of
intensive cDMARDs and TNFis in active early and established RA, suggest that the following points could
be considered when deciding how best to treat patients with active established RA who have not
responded to methotrexate:
1. There is an extensive body of direct and indirect evidence which shows that giving such patients
intensive cDMARD therapy and reserving TNFis for 6-month non-responders is clinically effective. Both
EQ-5D- and SF-36-based QALY assessments suggest that cDMARDs are also cost-effective. A 6-month
period of cDMARD therapy is sufficient to assess its effectiveness and there is no evidence that patients
have any long-term disadvantages in terms of future disability, quality of life or joint damage from
taking DMARD combinations for 6 months, even if they fail to respond.
2. In active established RA, starting treatment with either cDMARDs or TNFis results in equivalent clinically
relevant improvements in disability and quality of life over 12 months. Immediately starting TNFis gives
rapid early reductions in disease activity compared with starting cDMARDs but these improvements do
not result in larger reductions in disability. There is no evidence that either strategy is associated with
substantial erosive damage; radiological progression was minimal with both cDMARDs and TNFis.
3. Only a minority of patients achieve sustained remission with cDMARDs or TNFis. This suggests that
neither approach should be considered an ideal long-term treatment strategy for all RA patients.
Instead, they appear to be therapeutic options that decrease disability and reduce disease activity in
some patients with active established RA.
Research implications
The TACIT trial raises many questions as well as providing some answers. There are a number of research
areas that need to be taken forward. The following issues appear to be particularly important:
1. Identifying predictors of response to cDMARDs and TNFis will enable a move towards individualised
treatment. This is of crucial importance as some patients respond well to cDMARDs whereas others respond
well to TNFis, and prospectively identifying potential good responders should optimise treatment outcomes.
In essence, there is a need to move away from the conventional ‘one size fits all’ approach to a more
personalised clinical care approach. Research needs to focus on identifying predictors of response to these
different treatment approaches. One possible implication is that national guidance on treatment decisions
for specific interventions given to individual patients may not represent the most effective way of planning
the delivery of care. Guidance might be most appropriate if it is moved from the general to the specific.
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2. We need to define the most effective ways of using current treatments, including undertaking more
strategy trials to examine novel ways of using high-cost treatments. Examples include identifying the
benefits of short courses of biologics in early RA, in which the rapid effects of biologics may be
beneficial, and redefining the optimal duration of TNFi treatment in established RA. Currently, once
started, TNFis are continued if patients respond. However, this approach is based on custom and
practice and has not been tested in clinical trials. The TACIT trial suggests that TNFis have dramatic
immediate benefits but that, as currently used, these major improvements are present by 2 or 3 months
and patients do not generally improve further. It is possible that short-term ‘induction therapy’ might be
particularly useful with these treatments. Such an approach would change the cost base of using
biological treatments.
3. There should be a greater emphasis on head-to-head trials when defining the overall benefits of
high-cost treatments in RA. Extrapolating the results of short-term placebo-controlled trials and using
observational studies to model economic benefits are less helpful in determining treatment pathways.
Only head-to-head trials of treatment strategies including economic analyses can help drive forward
innovative, cost-effective treatment approaches involving biologics. The results of the TACIT trial do not
indicate that there should be less overall use of TNFis but that they are not being used in a highly
effective manner.
4. A range of new non-biological treatments, particularly kinase inhibitors, is being developed for RA
and some of these agents may soon be introduced into clinical practice. It is too early to judge the
potential impact of these new treatments but it is likely that the treatment paradigm will change as a
result. The TACIT trial highlights the limitations of our current treatment paradigm and therefore
strengthens the case for developing new approaches to disease management.
The biologics revolution following the introduction of TNFis into routine clinical practice has changed RA
care and, in our view, has benefited patients substantially. Clinicians and patients were keen to have
access to these treatments when they first became available. As with all new treatments this is likely to
have resulted in a relative overestimation of their clinical and economic benefits. Time and experience
usually temper the initial enthusiasm for new treatments and this is likely to be the case with biologics
for RA during the next decade. Trials such as the TACIT trial should help modify previous potential
overenthusiasm for biologics in RA. However, the development of new agents is more likely to have a
major impact, as novelty is a potent driver for changing behaviour. In our view it does not matter so much
what drives change; the crucial point is to realise that some changes are needed.
CONCLUSIONS
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Appendix 1 Types of protocol deviations and
permitted flexibilities
Deviation
type number Protocol deviation Protocol criteria
Data Monitoring and Ethics
Committee flexibility
1 Multiple DMARDs
(while on TNFi)
Patients randomised to the TNFi arm are
permitted to take one DMARD only
(methotrexate unless contraindicated)
No flexibility
2 High-dose steroids Not on high-dose steroids (in excess of
10mg of prednisolone or equivalent
per day at trial entry)
No flexibility
3 Trial medication given
before baseline
Not expressly stated, but trial medication
should commence immediately after the
baseline outcome data are collected
No flexibility
4 Baseline outcome data
(questionnaires)
collected 3 months
after starting trial
medication
Not expressly stated, but trial medication
should commence immediately after the
baseline outcome data are collected
No flexibility
5 > 8 weeks off
trial medication
A temporary interruption in trial medication
of up to 8 weeks (consecutive) will be
permitted if an adverse event or other
unforeseen circumstance, deemed by the
principal investigator to require stoppage
of trial medication, has occurred
No flexibility
6 Ineligible – history of
serious illness
No serious intercurrent illness No flexibility
7 Changed treatment at
6 months despite
improvement in DAS
of > 1.2
At 6 months: no change in treatment if
good response (≥ 1.2 fall in DAS)
No flexibility
8 Steroid injections given
between screening
and baseline
If a steroid injection is given before
baseline, the baseline assessment should be
delayed for 1 month after the date of
the injection
Include in the ITT analysis and
the per-protocol analysis but
baseline screening assessment
should be used rather than the
one immediately following
the steroid injection
9 Milestone assessments
performed outside the
visit window
Milestone assessments (6 and 12 months)
must be performed within ±14 days of the
estimated date of assessment; this was not
defined in the protocol but as part of the
TACIT Working Practice
Milestone assessments must
be performed within ±31 days
of the estimated date of
assessment
10 Insufficient medication
at baseline
At baseline, patients must be started on
cDMARDs if in the DMARD arm and
on a TNFi with accompanying DMARD
if in the TNFi arm
Allow up to 1 month from
baseline for the introduction of
the second trial medication
11 Chest radiography not
carried out prior
to randomisation
Negative screen for tuberculosis (including
chest radiography)
Local methods can be used
12 Patient not switched at
6 months
Patients assessed at 6 months: no change if
good response (≥ 1.2 fall in DAS); change
treatment from 6-month assessment if
< 1.2 fall in DAS (change to second TNFi
if in TNFi arm; change to first TNFi if in
cDMARD arm)
Switch permitted at up to
9 months; however, the
decision to switch is still based
on the 6-month time point
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Appendix 2 Health economic costs
This appendix contains the source data for costs used in the economic analysis.
TABLE 48 Unit costs for the health economic analysis
Item Unit
Unit cost (£)
(2010/11 prices) Assumptions
GP
At surgerya Consultation 30 Per surgery consultation lasting 11.7 minutes. Includes
direct care staff costs; excludes qualification costs
At homea Home visit 99 Per home visit lasting 23.4 minutes. Includes direct
care staff costs; excludes qualification costs
Telephone calla Call 18 Per telephone consultation lasting 7.1 minutes.
Includes direct care staff costs; excludes
qualification costs
Repeat prescription
request without
GP contacta
Prescription 19 Assuming 5 minutes of GP time. Includes direct care
staff costs; excludes qualification costs
Nurse
At surgerya Visit 11 Based on cost per hour of face-to-face contact.
Excludes qualifications and assumes that each
consultation lasts 15.5 minutes
Telephone calla Call 7 Assumes that ratio of time spent on telephone
consultation to time spent on face-to-face consultation
is same as for GP (60.68%)
Physiotherapist
At hospitalb Attendance 38 Physiotherapy Total Attendances – Adult (19 and Over) –
service code 650A – Total OPATT table
At homea,c Visit 58 Based on 2010/11 prices but with time estimates from
2009/10. Excludes qualification costs
At GP surgerya,c Visit 27 Based on 2010/11 prices but with time estimates from
2009/10. Excludes qualification costs
Elsewherea Visit 27 Assumes same cost as physiotherapist at GP surgery as
conservative estimate
Occupational therapist
At hospitalb Attendance 56 Occupational Therapy Total Attendances – Adult
(19 and Over) – service code 651A – Total OPATT table
At homea,c Visit 57 Based on 2010/11 prices but with time estimates from
2009/10. Excludes qualification costs
At GP surgerya,c Visit 20 Based on 2010/11 prices but with time estimates from
2009/10. Excludes qualification costs
Elsewherea Visit 20 Assumes same cost as occupational therapist at
GP surgery as conservative estimate
continued
DOI: 10.3310/hta18660 HEALTH TECHNOLOGY ASSESSMENT 2014 VOL. 18 NO. 66
© Queen’s Printer and Controller of HMSO 2014. This work was produced by Scott et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
137
TABLE 48 Unit costs for the health economic analysis (continued )
Item Unit
Unit cost (£)
(2010/11 prices) Assumptions
Hospital services
A&Eb Attendance 108 Accident and Emergency Services: Not leading to
Admitted – Index table
Hospital stay
1 nightb
Bed-day 568 Non-Elective Inpatient (Short Stay) HRG
Data – Index table (per 1 night)
Hospital stay
> 1 nightb
Bed-day 426 Weighted average of all Non-Elective Inpatient
(Long Stay) HRG Data
Outpatient
appointmentb
Attendance 105 Total – Outpatient Attendances – Index table
Social services
Meals on Wheelsa Meal 6 Average cost per local authority meal on wheels
Home helpa Visit 12 Assumes 30-minute visits. Based on cost per hour of
face-to-face contact. Weighted average accounting for
different rates for day/evening/weekday/weekends
Social workera Hour 152 Adult services – cost per hour of face-to-face contact.
Excludes qualifications
Social worker
telephone calla
Call 38 Assumes face-to-face consultation lasting 15 minutes
Other health or social service
Community and
outreach nurseb
Contact 50 Community and Outreach Nursing Services: Specialist
Nursing – Index table – TCSCNSN
Dentistb Attendance 78 TOCS tab: Community Dental Services – CN20
District nursea Contact 64 Assumes home visit lasting 1 hour
Orthoticsa Contact 16 Assumes podiatrist
Osteopathd Contact 43 Assumes mid-point cost per session from range of
£35–50 per 30- to 40-minute contact
Paramedicb Contact 119 TPARO – Index table
Podiatrista Contact 16 Assumes 30-minute appointment
Medicatione Milligrams Range < 0.01
to 296
Social security benefits
Attendance
Allowancef
Benefit 60 Based on mean of high and low attendance allowance
Disability Living
Allowancef
Benefit 41 Based on mean of care and mobility component
Council Tax
Benefitf
Benefit 65 Based on single person aged 25+ years
Housing Benefitf Benefit 65 Based on single person aged 25+ years
Incapacity Benefitf Benefit 75 Based on the mean of lower and higher rates of
short-term incapacity benefit under state pension age
Income Supportf Benefit 65 Based on single person aged 25+ years
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
TABLE 48 Unit costs for the health economic analysis (continued )
Item Unit
Unit cost (£)
(2010/11 prices) Assumptions
Jobseeker’s
Allowancef
Benefit 65 Based on contribution-based jobseeker’s allowance
personal rates, aged 25+ years
Severe Disablement
Allowancef
Benefit 59 Basic rate only
Statutory Sick Payf Benefit 79
Working Tax
Creditg
Benefit 37 Based on basic element only, £1920 per year divided
by 52 weeks
Carer Allowancef Benefit 54
Child Benefitg Benefit 20 Assumes one child only
Child Tax Creditg Benefit 10 Based on basic element only, £545 per year divided by
52 weeks
Disability Working
Allowanceg
Benefit 51 Disabled person’s tax credit replaced disability working
allowance (see www.hmrc.gov.uk/dptctables/index.
htm), £2650 per year divided by 52 weeks
Family Tax Creditg Benefit 10 Child tax credit family element
Pensionf Benefit 98 Category A or B pension
Pension Creditf Benefit 10 The maximum for a single person is £20.52 so divide
by 2 for an arbitrary figure
Tax Creditg Benefit 37 Assumes working tax credit
A&E, accident and emergency.
a Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: Personal Social Services Research Unit,
University of Kent; 2011.
b Department of Health. NHS Reference Costs 2010/11. URL: www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/
documents/digitalasset/dh_131145.xls (accessed 20 March 2012).
c Curtis L. Unit Costs of Health and Social Care 2010. Canterbury: Personal Social Services Research Unit,
University of Kent; 2010.
d NHS Choices. Osteopathy. URL: www.nhs.uk/conditions/Osteopathy/Pages/Introduction.aspx (accessed 9 October 2012).
e British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 60,
September 2010. London: BMA and RPS; 2010.
f Department for Work and Pensions. Work and Pensions – Social Security Benefit Up-rating. URL: www.dwp.gov.uk/docs/
benefitrates2010.pdf (accessed 26 March 2012).
g Institute of Fiscal Studies. Tax and benefit tables by the Institute of Fiscal Studies. URL: www.ifs.org.uk/ff/taxcredits.xls
(accessed 26 March 2012).
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TABLE 49 Trial medication unit costs
Medication Preparation Cost per mg (£)a
Cost per day if
dose missing (£)b
Cost per medication if medication
taken as required (£, assuming
medication used for 1 month)b
Adalimumab Injection 8.94 1399.73 1399.73
Azathioprine Oral 0.01 0.28 8.27
Ciclosporin Oral 0.02 3.09 92.67
Depo-Medrone Injection 0.07 4.76 4.76
Etanercept Injection 3.58 1002.12 1002.12
Folic acid Oral 0.01 0.04 1.06
Gold injections Injection 0.22 27.69 27.69
Hydroxychloroquine Oral < 0.00 0.17 4.95
Infliximab Injection 4.20 419.62 419.62
Kenalog
(Triamcinolone,
Bristol-Myers Squibb)
Injection 0.04 1.92 1.92
Leflunomide Oral 0.17 2.36 70.87
Methotrexate Oral 0.05 5.01 5.01
Methotrexate Injection 1.98 5.01 5.01
Methylprednisolone Injection 0.04 47.64 47.64
Penicillamine Oral < 0.00 1.00 29.94
Prednisolone Oral 0.06 0.09 2.58
Sulfasalazine Oral < 0.00 0.49 14.66
a British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. No. 60,
September 2010. London: BMA and RPS; 2010.
b Department of Health. Prescription Cost Analysis – England, 2011. London: Department of Health. URL: www.hscic.gov.
uk/pubs/prescostanalysis2011 (accessed August 2014).
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Appendix 3 Complete-case population analysis
This appendix contains the tables and figures from the complete-case analysis.
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TABLE 52 Linear regression for the adjusted and unadjusted treatment effect for the primary outcome measure
(HAQ) in the complete-case population
Outcome
Model 1 (unadjusted):
treatment+ region
Model 2 (adjusted): treatment+
demographics+baseline score
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Change in HAQ score
12 months 0.14 (−0.03 to 0.32) 0.108 0.15 (−0.03 to 0.32) 0.094
6 months −0.06 (−0.25 to 0.13) 0.542 −0.08 (−0.271 to 0.10) 0.362
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs.
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FIGURE 28 Changes in mean HAQ and EQ-5D scores (95% CIs) over 12 months in the complete-case population.
(a) HAQ; and (b) EQ-5D.
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TABLE 53 Longitudinal analysis comparing the effect of randomised treatment arm on primary and secondary
outcome measures in the complete-case population using GEEs with unstructured correlation
Outcome
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score+ time
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Larsen score −0.58 (−1.86 to 0.69) 0.370 −0.46 (−1.91 to 0.98) 0.531
SF-36 role physical 1.39 (−10.75 to 13.52) 0.822 2.29 (−8.22 to 12.80) 0.669
SF-36 vitality 3.84 (−2.69 to 10.37) 0.249 3.66 (−1.82 to 9.14) 0.190
SF-36 social functioning 3.55 (−4.95 to 12.05) 0.413 −2.49 (−9.27 to 4.29) 0.472
SF-36 role emotion 1.11 (−15.37 to 17.59) 0.895 −7.00 (−18.40 to 4.39) 0.229
SF-36 mental health −0.08 (−6.78 to 6.63) 0.982 −1.77 (−6.69 to 3.15) 0.480
SF-36 MCS 0.07 (−3.82 to 3.97) 0.971 −1.68 (−4.64 to 1.29) 0.268
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs.
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FIGURE 29 Changes in mean HAQ and EQ-5D scores (95% CIs) over 12 months in the complete-case population
cDMARD arm by treatment status. (a) HAQ; and (b) EQ-5D.
TABLE 55 Adjusted and unadjusted treatment effect using GEEs for the primary outcome measure (HAQ) in the
complete-case population cDMARD arm by treatment status
Outcome
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score+ time
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Change in HAQ score
12 months 0.22 (0.03 to 0.41) 0.025 0.20 (0.01 to 0.39) 0.039
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is no switch.
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FIGURE 30 Complete-case analysis: mean change in DAS28 (95% CI) by treatment group.
TABLE 57 Longitudinal analysis comparing the effect of randomised treatment arm on disease activity score
(DAS28) and its components in the complete-case population using GEEs
Time period Variable
Model 1 (unadjusted):
treatment+ region+ time
Model 2 (adjusted): treatment+
demographics+baseline score+ time
Coefficient (95% CI) p-value Coefficient (95% CI) p-value
Months 1–6 DAS28 −1.06 (−1.41 to −0.71) < 0.001 −1.02 (−1.37 to −0.68) < 0.001
Tender joint count −4.37 (−6.40 to −2.35) < 0.001 −3.14 (−4.99 to −1.29) 0.001
Swollen joint count −3.33 (−4.95 to −1.71) < 0.001 −2.52 (−3.70 to −1.33) < 0.001
ESR (mm/hour) −5.95 (−10.33 to −1.56) 0.008 −9.20 (−13.02 to −5.37) < 0.001
VAS −10.08 (−17.08 to −3.07) 0.005 −9.07 (−15.36 to −2.78) 0.005
Months 6–12 DAS28 −0.69 (−1.11 to −0.27) 0.001 −0.58 (−0.97 to −0.18) 0.004
Tender joint count −3.65 (−5.93 to −1.37) 0.002 −2.12 (−3.92 to −0.32) 0.021
Swollen joint count −2.81 (−4.71 to −0.91) 0.004 −1.71 (−2.84 to −0.57) 0.003
ESR (mm/hour) −2.71 (−7.38 to 1.96) 0.255 −5.01 (−9.06 to −0.95) 0.016
VAS −2.73 (−11.16 to 5.71) 0.527 −1.47 (−8.53 to 5.60) 0.684
Months 1–12 DAS28 −0.92 (−1.29 to −0.55) < 0.001 −0.82 (−1.18 to −0.46) < 0.001
Tender joint count −4.26 (−6.42 to −2.11) < 0.001 −2.71 (−4.50 to −0.92) 0.003
Swollen joint count −3.11(−4.85 to −1.37) < 0.001 −2.05 (−3.13 to −0.97) < 0.001
ESR (mm/hour) −5.20 (−9.52 to −0.88) 0.018 −7.96 (−11.58 to −4.35) < 0.001
VAS −6.55(−14.17 to 1.07) 0.092 −5.55 (−11.90 to 0.81) 0.087
Demographics variables are age, sex, ethnicity, disease duration and region. The reference group is cDMARDs.
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Appendix 4 Adverse events
This appendix contains details of all of the adverse events reported in the trial.
TABLE 58 Adverse events in the cDMARD group
Adverse event Frequency Per cent
Abdominal discomfort 3 0.47
Ache – arms 1 0.16
Ache – back 1 0.16
Ache – ear 1 0.16
Ache – entire body 3 0.47
Ache – foot (left) 1 0.16
Ache – hands 1 0.16
Anaemia 1 0.16
Bilateral lower lobe bronchiectasis 1 0.16
Bladder irritation 2 0.31
Blepharitis – eye (right) 1 0.16
Blurred vision 3 0.47
Blurred vision (right eye) 2 0.31
Breast lump (right) 1 0.16
Breathlessness 4 0.63
Bruising – arm (left) 1 0.16
Bruising – arm (right) 1 0.16
Bruising – flank (left) 1 0.16
Bruising – thigh (left) 1 0.16
Bruising – thigh (right) 1 0.16
Burning on micturition 1 0.16
Burning sensation – arm (right) 1 0.16
Burning sensation – shoulder (right) 1 0.16
Cardiac palpitations 2 0.31
Carpal tunnel syndrome 1 0.16
Cellulitis – shin (right) 1 0.16
Chest infection 19 2.99
Chest tightness 3 0.47
Cold 12 1.89
Cold sore 1 0.16
Collapse 1 0.16
Constipation 4 0.63
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TABLE 58 Adverse events in the cDMARD group (continued )
Adverse event Frequency Per cent
Cough 5 0.79
Cough – dry 4 0.63
Cough – productive 6 0.94
Cramp – legs 3 0.47
Cramp – stomach 2 0.31
Cutaneous vasculitis 1 0.16
Cyst – breast (right) 1 0.16
Cyst – kidney (right) 1 0.16
Depression 2 0.31
Diarrhoea 30 4.72
Diverticular disease 1 0.16
Dizziness 9 1.42
Dry mouth 3 0.47
Dry skin 1 0.16
Ear infection (left) 1 0.16
Eczema – lower legs 1 0.16
Elevated alkaline phosphatase 2 0.31
Elevated alanine aminotransferase 7 1.1
Elevated aspartate aminotransferase 1 0.16
Elevated cholesterol 2 0.31
Elevated creatinine 3 0.47
Elevated CRP 3 0.47
Elevated ESR 2 0.31
Elevated gamma-glutamyl transferase 3 0.47
Elevated globulin 1 0.16
Elevated liver enzyme 3 0.47
Enlarged axillary lymph nodes (left) 1 0.16
Epigastric pain 1 0.16
Exacerbation of hypertension 1 0.16
Exhaustion 1 0.16
Fall 4 0.63
Fatigue 11 1.73
Fever 6 0.94
Fibromyalgia 1 0.16
Flare of RA 17 2.68
Flatulence 1 0.16
Flexor tendonitis 2 0.31
Flu 7 1.1
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TABLE 58 Adverse events in the cDMARD group (continued )
Adverse event Frequency Per cent
Flushed 2 0.31
Funny taste in mouth 1 0.16
Gallstones 1 0.16
Gastroenteritis 1 0.16
Gingivitis 1 0.16
Gum disease 1 0.16
Haematemesis 1 0.16
Haematuria 1 0.16
Haematuria – macroscopic 1 0.16
Haematuria – microscopic 1 0.16
Haemoptysis 1 0.16
Hair loss 1 0.16
Headache 30 4.72
Head cold 3 0.47
Hearing – diminished 1 0.16
Heartburn 4 0.63
Hiatus hernia – moderate size 1 0.16
High blood pressure 7 1.1
Hot flush 4 0.63
Hot flushes 1 0.16
Hypoglycaemia 2 0.31
Increased frequency of defecation 2 0.31
Increased urine frequency 1 0.16
Indigestion 3 0.47
Infected eyes 1 0.16
Infection – foot (left) 1 0.16
Inflamed eye (right) 1 0.16
Injection site reaction 1 0.16
Insomnia 1 0.16
Intermittent visual disturbance – eye 1 0.16
Itchy skin 7 1.1
Joint pain – feet 1 0.16
Joint pain – generalised 3 0.47
Laryngitis 1 0.16
Lesion – spleen 1 0.16
Lethargy 2 0.31
Leucocytes in urine 2 0.31
continued
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TABLE 58 Adverse events in the cDMARD group (continued )
Adverse event Frequency Per cent
Lightheadedness 3 0.47
Loose stools 3 0.47
Loss of appetite 5 0.79
Low blood pressure 1 0.16
Lower back pain 1 0.16
Low creatinine 1 0.16
Low haemoglobin 2 0.31
Low iron level 1 0.16
Low platelet count 3 0.47
Low white cell count 7 1.1
Lymphadenopathy lungs 1 0.16
Lymphopenia 4 0.63
Migraine 4 0.63
Multiple liver cysts 1 0.16
Muscle ache – generalised 1 0.16
Muscle ache – shins 3 0.47
Muscle ache – shoulder 1 0.16
Nausea 26 4.09
Neutropenia 1 0.16
Night sweat 4 0.63
Nitrites in urine 2 0.31
Nosebleed 2 0.31
Oedema – feet 1 0.16
Pain – abdominal 4 0.63
Pain – ankle (left) 2 0.31
Pain – arm (left) 1 0.16
Pain – arm (right) 2 0.31
Pain – back 5 0.79
Pain – entire body 3 0.47
Pain – eye (left) 1 0.16
Pain – feet 4 0.63
Pain – first metatarsophalangeal joint (right) 1 0.16
Pain – foot (left) 3 0.47
Pain – groin (left) 1 0.16
Pain – hand (right) 1 0.16
Pain – hip (left) 1 0.16
Pain – hip (right) 2 0.31
Pain – knee (left) 1 0.16
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TABLE 58 Adverse events in the cDMARD group (continued )
Adverse event Frequency Per cent
Pain – knee (right) 3 0.47
Pain – left side 1 0.16
Pain – leg (right) 1 0.16
Pain – neck 5 0.79
Pain – shoulder (left) 4 0.63
Pain – shoulder (right) 5 0.79
Pain – shoulders 4 0.63
Pain – wrist (left) 1 0.16
Pain – wrist (right) 3 0.47
Parotid enlargement (bilateral) 1 0.16
Peripheral neuropathy 1 0.16
Pins and needles – arms (both) 1 0.16
Pneumonia 2 0.31
Protein in urine 5 0.79
Pruritus – arms 1 0.16
Pulmonary fibrosis 1 0.16
Raised temperature 2 0.31
Rash – arm (left) 2 0.31
Rash – arm (right) 1 0.16
Rash – arms 3 0.47
Rash – back 4 0.63
Rash – cheek (right) 1 0.16
Rash – entire body 6 0.94
Rash – face 3 0.47
Rash – heel (right) 1 0.16
Rash – leg (left) 2 0.31
Rash – leg (right) 2 0.31
Rash – legs 4 0.63
Rash – neck 2 0.31
Rash – torso 4 0.63
Rectal bleeding 2 0.31
Redness – eye (right) 2 0.31
Reduced appetite 2 0.31
Rigours 1 0.16
Runny nose 1 0.16
Shaking 1 0.16
Shingles 3 0.47
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TABLE 58 Adverse events in the cDMARD group (continued )
Adverse event Frequency Per cent
Shortness of breath 1 0.16
Sinusitis 3 0.47
Skin infection – breast (right) 1 0.16
Skin lesions 1 0.16
Sore gums 2 0.31
Sore lips 1 0.16
Sore mouth 4 0.63
Sore throat 15 2.36
Stomach ache 1 0.16
Sweating 1 0.16
Swelling – ankle (both) 2 0.31
Swelling – calf (left) 1 0.16
Swelling – face (right side) 1 0.16
Swelling – upper lip 1 0.16
Swine flu 1 0.16
Swollen gums 4 0.63
Swollen temporomandibular joint 1 0.16
Synovitis – metatarsophalangeal joint 1 0.16
Tachycardia 1 0.16
Taste – metallic 1 0.16
Tendonitis – achilles 1 0.16
Thrush – mouth 2 0.31
Tingling – mouth area 3 0.47
Tonsillitis 1 0.16
Tooth extraction 5 0.79
Tooth infection 2 0.31
Torn muscle – lower back 1 0.16
Transient ischaemic attack 1 0.16
Ulcerative skin lesion – breast (right) 1 0.16
Ulcers – mouth 12 1.89
Urinary incontinence 1 0.16
Urinary tract infection 6 0.94
Verruca 1 0.16
Vomiting 26 4.09
Weight gain 1 0.16
Weight loss 5 0.79
Total 635 100
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TABLE 59 Adverse events in the TNFis group
Adverse event Frequency Per cent
Abnormal vaginal bleeding 1 0.22
Abscess – axilla (left) 2 0.43
Abscess – tooth 2 0.43
Ache – back 2 0.43
Ache – ear 2 0.43
Ache – ear (left) with discharge 1 0.22
Ache – entire body 4 0.86
Ache – hand (right) 1 0.22
Ache – neck 1 0.22
Ache – tooth 3 0.65
Anxiety 1 0.22
Baker’s cyst 2 0.43
Blocked eustachian tube (right) 1 0.22
Blurred vision 1 0.22
Breast lump (right) 1 0.22
Breathlessness 7 1.51
Broken arm (right) 1 0.22
Bruising – limbs 1 0.22
Bruising – thigh (left) 1 0.22
Bruising – thigh (right) 1 0.22
Burning sensation – neck (right hand side) 1 0.22
Cardiac palpitations 2 0.43
Carpal tunnel syndrome 3 0.65
Cellulitis – leg (right) 2 0.43
Chest infection 27 5.81
Chest pain 5 1.08
Choking – on waking up 1 0.22
Cold 16 3.44
Cold hands and feet 1 0.22
Cold sore 7 1.51
Congested ears 1 0.22
Constipation 2 0.43
Cough 4 0.86
Cough – dry 4 0.86
Cough – productive 5 1.08
Cramp – abdominal 1 0.22
Cyst – liver 1 0.22
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TABLE 59 Adverse events in the TNFis group (continued )
Adverse event Frequency Per cent
Deep vein thrombosis 1 0.22
Depression 1 0.22
Diarrhoea 12 2.58
Diverticular disease 1 0.22
Dizziness 4 0.86
Drop in estimated glomerular filtration rate 1 0.22
Dry feet with flaky skin and blotches 1 0.22
Dry throat 3 0.65
Dyspareunia 1 0.22
Ear infection (left) 2 0.43
Eczema – all over body 1 0.22
Elevated alkaline phosphatase 2 0.43
Elevated alanine aminotransferase 16 3.44
Elevated cholesterol 2 0.43
Elevated gamma-glutamyl transferase 1 0.22
Elevated globulin 1 0.22
Elevated liver enzyme 1 0.22
Elevated potassium 2 0.43
Elevated protein (blood) 1 0.22
Exacerbation of bronchiectasis 1 0.22
Exhaustion 1 0.22
Fall 2 0.43
Fatigue 5 1.08
Fatty liver 2 0.43
Fever 2 0.43
Flare of RA 14 3.01
Flexor tendonitis 2 0.43
Flu 4 0.86
Folliculitis 1 0.22
Fracture – foot (left) 1 0.22
Fungal infection – nail (big toes) 1 0.22
Gastroenteritis 1 0.22
Gum infection 1 0.22
Haematuria – macroscopic 2 0.43
Haematuria – microscopic 1 0.22
Haemostatis 1 0.22
Hair loss 1 0.22
Headache 15 3.23
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TABLE 59 Adverse events in the TNFis group (continued )
Adverse event Frequency Per cent
Head cold 1 0.22
Hearing – diminished 1 0.22
Heartburn 3 0.65
Hot flushes 1 0.22
Impaired walking 1 0.22
Increased urine frequency 1 0.22
Indigestion 1 0.22
Infected eyes 2 0.43
Infection – big toe nail (right) 1 0.22
Injection site reaction 5 1.08
Insect bite 3 0.65
Insomnia 1 0.22
Intermittent flashing lights – both eyes 1 0.22
Intermittent headache 1 0.22
Itchy skin 3 0.65
Joint stiffness – generalised 1 0.22
Lethargy 4 0.86
Leucocytes in urine 1 0.22
Loose stools 1 0.22
Lower back pain 2 0.43
Low platelet count 1 0.22
Low white cell count 1 0.22
Malaise 1 0.22
Medial epicondylitis – (left) 1 0.22
Medial epicondylitis – (right) 1 0.22
Muscle ache – shoulder 1 0.22
Nasal congestion 2 0.43
Nausea 8 1.72
Neck – stiff 3 0.65
Neutropenia 3 0.65
Nose – left axillary lymphadenopathy 1 0.22
Numbness – legs 1 0.22
Numbness – lips 1 0.22
Numbness – toes 1 0.22
Oedema – feet 2 0.43
Oedema – foot (right) 2 0.43
Ovarian cyst 1 0.22
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TABLE 59 Adverse events in the TNFis group (continued )
Adverse event Frequency Per cent
Pain – abdominal 3 0.65
Pain and redness – index distal interphalangeal joint (right) 1 0.22
Pain – ankle (left) 3 0.65
Pain – arm (left) 1 0.22
Pain – back 4 0.86
Pain – entire body 2 0.43
Pain – eye (left) 1 0.22
Pain – foot (left) 1 0.22
Pain – foot (right) 4 0.86
Pain – hand (right) 1 0.22
Pain – hip (left) 3 0.65
Pain – hip (right) 3 0.65
Pain – knee (left) 3 0.65
Pain – knee (right) 5 1.08
Pain – leg (left) 1 0.22
Pain – legs 1 0.22
Pain – neck 2 0.43
Pain – ribs (left) 1 0.22
Pain – shoulder (left) 3 0.65
Pain – shoulder (right) 6 1.29
Pain – wrist (left) 1 0.22
Photosensitivity 1 0.22
Pins and needles – feet 1 0.22
Pins and needles – hands (left and right) 1 0.22
Plantar fasciitis 3 0.65
Pleurisy 1 0.22
Pneumonia 2 0.43
Protein in urine 1 0.22
Pruritus 1 0.22
Raised temperature 1 0.22
Raised white blood cell count 1 0.22
Rash – arms 2 0.43
Rash – back 1 0.22
Rash – entire body 1 0.22
Rash – face 2 0.43
Rash – hand (right) 1 0.22
Rash – legs 1 0.22
Rash – torso 4 0.86
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TABLE 59 Adverse events in the TNFis group (continued )
Adverse event Frequency Per cent
Red and sore eyes (both) 1 0.22
Restless legs 2 0.43
Rigours 1 0.22
Runny nose 3 0.65
Scalp rash 2 0.43
Shaking 1 0.22
Shingles 3 0.65
Shortness of breath 1 0.22
Sinusitis 1 0.22
Skin infection – ankle (left) 1 0.22
Skin lesions 2 0.43
Skin nodules – back 1 0.22
Skin nodules – face 1 0.22
Soft tissue nodule – both feet 1 0.22
Sore mouth 1 0.22
Sore throat 13 2.8
Streptococcus A infection – vaginal 1 0.22
Superficial thrombophlebitis 1 0.22
Swelling – ankle (both) 2 0.43
Swelling – ankle (left) 1 0.22
Swelling – knee (left) 2 0.43
Swelling – lower jaw 1 0.22
Swelling – wrist (right) 1 0.22
Thrush – mouth 2 0.43
Thrush – vaginal 5 1.08
Tonsillitis 4 0.86
Tooth extraction 2 0.43
Tooth infection 3 0.65
Trace glucose in urine 1 0.22
Ulcers – mouth 4 0.86
Ulcers – vascular 1 0.22
Upper respiratory tract infection 6 1.29
Urinary incontinence 1 0.22
Urinary tract infection 9 1.94
Uterus fibroid 1 0.22
Vaginal dryness 1 0.22
Vasovagal attack 4 0.86
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TABLE 59 Adverse events in the TNFis group (continued )
Adverse event Frequency Per cent
Vomiting 3 0.65
Weight gain 1 0.22
Whitening of nails 1 0.22
Total 465 100
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Appendix 5 Systematic review search strategies
Search strategy for early rheumatoid arthritis
1. Early Rheumatoid Arthritis.mp
2. Early RA.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
3. infliximab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
4. etanercept.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
5. adalimumab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
6. golimumab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
7. certolizumab [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, sh, tn, dm, mf, dv, kw]
8. anti-TNF.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
9. biological products.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
10. methotrexate.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
11. cyclosporin.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
12. sulphasalazine.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
13. hydroxychloroquine.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
14. prednisolone.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
15. immunosuppressive agents.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
16. combination DMARDs.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
17. combinatin atreatment.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
18. combination anti-rheumatic drugs.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
19. combination therapy.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
20. leflunomide.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
21. 1 or 2
22. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 18 or 19
23. 20 and 21
24. remove duplicates from 23
25. limit 24 to clinical trial
26. limit 25 to english language
Search strategy for established rheumatoid arthritis
1. Rheumatoid Arthritis.mp
2. RA.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
3. infliximab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
4. etanercept.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
5. adalimumab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
6. golimumab.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
7. certolizumab [mp=ti, ab, ot, nm, hw, kf, ps, rs, ui, an, sh, tn, dm, mf, dv, kw]
8. anti-TNF.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
9. biological products.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
10. methotrexate.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
11. cyclosporin.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
12. sulphasalazine.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
13. hydroxychloroquine.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
14. prednisolone.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
15. immunosuppressive agents.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
16. combination DMARDs.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
17. combinatin atreatment.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
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18. combination anti-rheumatic drugs.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
19. combination therapy.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
20. leflunomide.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, ui]
21. 1 or 2
22. 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 18 or 19
23. 20 and 21
24. remove duplicates from 23
25. limit 24 to clinical trial
26. limit 25 to english language
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